Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Autoimmune Disorders

  Free Subscription


Articles published in Mult Scler

Retrieve available abstracts of 927 articles:
HTML format



Single Articles


    July 2021
  1. LONGINETTI E, Frisell T, Englund S, Reutfors J, et al
    Risk of depression in multiple sclerosis across disease-modifying therapies.
    Mult Scler. 2021 Jul 15:13524585211031128. doi: 10.1177/13524585211031128.
    PubMed     Abstract available


  2. BOUMAN PM, Strijbis VI, Jonkman LE, Hulst HE, et al
    Artificial double inversion recovery images for (juxta)cortical lesion visualization in multiple sclerosis.
    Mult Scler. 2021 Jul 14:13524585211029860. doi: 10.1177/13524585211029860.
    PubMed     Abstract available


  3. MONTALBAN X, Graves J, Midaglia L, Mulero P, et al
    A smartphone sensor-based digital outcome assessment of multiple sclerosis.
    Mult Scler. 2021 Jul 14:13524585211028561. doi: 10.1177/13524585211028561.
    PubMed     Abstract available


  4. HOGESTOL EA, Ghezzo S, Nygaard GO, Espeseth T, et al
    Functional connectivity in multiple sclerosis modelled as connectome stability: A 5-year follow-up study.
    Mult Scler. 2021 Jul 14:13524585211030212. doi: 10.1177/13524585211030212.
    PubMed     Abstract available


  5. WIJERATNE T, Carroll W
    World Brain Day 2021: Global campaign to stop multiple sclerosis.
    Mult Scler. 2021 Jul 14:13524585211030147. doi: 10.1177/13524585211030147.
    PubMed    


  6. HARTUNG HP, Derfuss T, Cree BA, Sormani MP, et al
    Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study.
    Mult Scler. 2021 Jul 9:13524585211024997. doi: 10.1177/13524585211024997.
    PubMed     Abstract available


  7. VAN LIEROP ZY, Toorop AA, van Ballegoij WJ, Olde Dubbelink TB, et al
    Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic.
    Mult Scler. 2021 Jul 9:13524585211028833. doi: 10.1177/13524585211028833.
    PubMed     Abstract available


  8. SPELMAN T, Forsberg L, McKay K, Glaser A, et al
    Increased rate of hospitalisation for COVID-19 among rituximab-treated multiple sclerosis patients: A study of the Swedish multiple sclerosis registry.
    Mult Scler. 2021 Jul 2:13524585211026272. doi: 10.1177/13524585211026272.
    PubMed     Abstract available


  9. KALINOWSKA-LYSZCZARZ A, Tillema JM, Tobin WO, Guo Y, et al
    Long-term clinical, MRI, and cognitive follow-up in a large cohort of pathologically confirmed, predominantly tumefactive multiple sclerosis.
    Mult Scler. 2021 Jul 2:13524585211024162. doi: 10.1177/13524585211024162.
    PubMed     Abstract available


  10. NAUTA IM, Bertens D, van Dam M, Huiskamp M, et al
    Performance validity in outpatients with multiple sclerosis and cognitive complaints.
    Mult Scler. 2021 Jul 2:13524585211025780. doi: 10.1177/13524585211025780.
    PubMed     Abstract available


  11. ESHAGHI A
    Towards an objective classification of multiple sclerosis.
    Mult Scler. 2021;27:1151-1152.
    PubMed    


    June 2021
  12. SCHONFELDER K, Schuh H, Pfister F, Kramer J, et al
    Autoimmune glomerulonephritis in a multiple sclerosis patient after cladribine treatment.
    Mult Scler. 2021 Jun 24:13524585211022719. doi: 10.1177/13524585211022719.
    PubMed     Abstract available


  13. MIZELL R, Chen H, Lambe J, Saidha S, et al
    Association of retinal atrophy with cortical lesions and leptomeningeal enhancement in multiple sclerosis on 7T MRI.
    Mult Scler. 2021 Jun 14:13524585211023343. doi: 10.1177/13524585211023343.
    PubMed     Abstract available


  14. BOMMARITO G, Tarun A, Farouj Y, Preti MG, et al
    Altered anterior default mode network dynamics in progressive multiple sclerosis.
    Mult Scler. 2021 Jun 14:13524585211018116. doi: 10.1177/13524585211018116.
    PubMed     Abstract available


  15. HIDALGO DE LA CRUZ M, Valsasina P, Meani A, Gallo A, et al
    Differential association of cortical, subcortical and spinal cord damage with multiple sclerosis disability milestones: A multiparametric MRI study.
    Mult Scler. 2021 Jun 14:13524585211020296. doi: 10.1177/13524585211020296.
    PubMed     Abstract available


  16. WU J, Engdahl E, Gustafsson R, Fogdell-Hahn A, et al
    High antibody levels against human herpesvirus-6A interact with lifestyle factors in multiple sclerosis development.
    Mult Scler. 2021 Jun 14:13524585211022011. doi: 10.1177/13524585211022011.
    PubMed     Abstract available


  17. VERCELLINO M, Marasciulo S, Grifoni S, Vallino-Costassa E, et al
    Acute and chronic synaptic pathology in multiple sclerosis gray matter.
    Mult Scler. 2021 Jun 14:13524585211022174. doi: 10.1177/13524585211022174.
    PubMed     Abstract available


  18. CORTESE R, Battaglini M, Parodi F, Stromillo ML, et al
    Mild gray matter atrophy in patients with long-standing multiple sclerosis and favorable clinical course.
    Mult Scler. 2021 Jun 8:13524585211019650. doi: 10.1177/13524585211019650.
    PubMed     Abstract available


  19. SADOVNICK AD, Yee IM, Criscuoli M, DeLuca GC, et al
    Genes and environment in multiple sclerosis: Impact of temporal changes in the sex ratio on recurrence risks.
    Mult Scler. 2021 Jun 8:13524585211020221. doi: 10.1177/13524585211020221.
    PubMed     Abstract available


  20. KALINOWSKI A, Cutter G, Bozinov N, Hinman JA, et al
    The timed 25-foot walk in a large cohort of multiple sclerosis patients.
    Mult Scler. 2021 Jun 8:13524585211017013. doi: 10.1177/13524585211017013.
    PubMed     Abstract available


  21. GARJANI A, Hunter R, Law GR, Middleton RM, et al
    Mental health of people with multiple sclerosis during the COVID-19 outbreak: A prospective cohort and cross-sectional case-control study of the UK MS Register.
    Mult Scler. 2021 Jun 3:13524585211020435. doi: 10.1177/13524585211020435.
    PubMed     Abstract available


    May 2021
  22. MESSINA S, Mariano R, Roca-Fernandez A, Cavey A, et al
    Contrasting the brain imaging features of MOG-antibody disease, with AQP4-antibody NMOSD and multiple sclerosis.
    Mult Scler. 2021 May 28:13524585211018987. doi: 10.1177/13524585211018987.
    PubMed     Abstract available


  23. SINGH M, Gavidia R, Dunietz GL, Washnock-Schmid E, et al
    Validation of an obstructive sleep apnea symptom inventory in persons with multiple sclerosis.
    Mult Scler. 2021 May 28:13524585211013014. doi: 10.1177/13524585211013014.
    PubMed     Abstract available


  24. ROUX J, Kingwell E, Zhu F, Tremlett H, et al
    Care consumption of people with multiple sclerosis: A multichannel sequence analysis in a population-based setting in British Columbia, Canada.
    Mult Scler. 2021 May 28:13524585211016726. doi: 10.1177/13524585211016726.
    PubMed     Abstract available


  25. MCMURRAN CE
    Correcting gut dysbiosis can ameliorate inflammation and promote remyelination in multiple sclerosis - No.
    Mult Scler. 2021 May 28:13524585211016722. doi: 10.1177/13524585211016722.
    PubMed    


  26. CALVO-BARREIRO L, Clerico M, Espejo C
    Correcting gut dysbiosis can ameliorate inflammation and promote remyelination in multiple sclerosis - Yes.
    Mult Scler. 2021 May 28:13524585211016723. doi: 10.1177/13524585211016723.
    PubMed    


  27. HOHLFELD R
    Correcting gut dysbiosis can ameliorate inflammation and promote remyelination in multiple sclerosis - Commentary.
    Mult Scler. 2021 May 28:13524585211018990. doi: 10.1177/13524585211018990.
    PubMed    


  28. KEVER A, Buyukturkoglu K, Levin SN, Riley CS, et al
    Associations of social network structure with cognition and amygdala volume in multiple sclerosis: An exploratory investigation.
    Mult Scler. 2021 May 26:13524585211018349. doi: 10.1177/13524585211018349.
    PubMed     Abstract available


  29. LAM KH, van Oirschot P, den Teuling B, Hulst HE, et al
    Reliability, construct and concurrent validity of a smartphone-based cognition test in multiple sclerosis.
    Mult Scler. 2021 May 26:13524585211018103. doi: 10.1177/13524585211018103.
    PubMed     Abstract available


  30. DE STEFANO N, Sormani MP, Giovannoni G, Rammohan K, et al
    Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies.
    Mult Scler. 2021 May 10:13524585211010294. doi: 10.1177/13524585211010294.
    PubMed     Abstract available


  31. WOJCIK C, Fuchs TA, Tran H, Dwyer MG, et al
    Staging and stratifying cognitive dysfunction in multiple sclerosis.
    Mult Scler. 2021 May 6:13524585211011390. doi: 10.1177/13524585211011390.
    PubMed     Abstract available


  32. BROWNLEE WJ, Solomon AJ
    Misdiagnosis of multiple sclerosis: Time for action.
    Mult Scler. 2021;27:805-806.
    PubMed    


  33. CORREA DG, de Souza Lima FC, da Cruz Bezerra D, Coutinho AC Junior, et al
    COVID-19 associated with encephalomyeloradiculitis and positive anti-aquaporin-4 antibodies: Cause or coincidence?
    Mult Scler. 2021;27:973-976.
    PubMed     Abstract available


  34. VALENCIA-SANCHEZ C, Flanagan EP
    COVID-19 associated with encephalomyeloradiculitis and positive anti-aquaporin-4 antibodies: Cause or coincidence? - Commentary.
    Mult Scler. 2021;27:976-977.
    PubMed    


    April 2021
  35. HOLLEN C, Rice J, Park M, Yadav V, et al
    Rituximab for treatment of refractory multiple sclerosis relapses during pregnancy.
    Mult Scler. 2021 Apr 30:1352458521998937. doi: 10.1177/1352458521998937.
    PubMed     Abstract available


  36. GUNGOR F, Tarakci E, Ozdemir-Acar Z, Soysal A, et al
    The effects of supervised versus home Pilates-based core stability training on lower extremity muscle strength and postural sway in people with multiple sclerosis.
    Mult Scler. 2021 Apr 28:13524585211012202. doi: 10.1177/13524585211012202.
    PubMed     Abstract available


  37. VAN LIEROP ZY, Wieske L, Koel-Simmelink MJ, Chatterjee M, et al
    Serum contactin-1 as a biomarker of long-term disease progression in natalizumab-treated multiple sclerosis.
    Mult Scler. 2021 Apr 23:13524585211010097. doi: 10.1177/13524585211010097.
    PubMed     Abstract available


  38. KHADADAH S, Kimoff RJ, Duquette P, Jobin V, et al
    Effect of continuous positive airway pressure treatment of obstructive sleep apnea-hypopnea in multiple sclerosis: A randomized, double-blind, placebo-controlled trial (SAMS-PAP study).
    Mult Scler. 2021 Apr 23:13524585211010390. doi: 10.1177/13524585211010390.
    PubMed     Abstract available


  39. HARRISON AM, Safari R, Mercer T, Picariello F, et al
    Which exercise and behavioural interventions show most promise for treating fatigue in multiple sclerosis? A network meta-analysis.
    Mult Scler. 2021 Apr 20:1352458521996002. doi: 10.1177/1352458521996002.
    PubMed     Abstract available


  40. ALLANACH JR, Farrell JW 3rd, Mesidor M, Karimi-Abdolrezaee S, et al
    Current status of neuroprotective and neuroregenerative strategies in multiple sclerosis: A systematic review.
    Mult Scler. 2021 Apr 19:13524585211008760. doi: 10.1177/13524585211008760.
    PubMed     Abstract available


  41. ZHOU Y, Cuellar-Partida G, Simpson Yap S, Lin X, et al
    Utilising multi-large omics data to elucidate biological mechanisms within multiple sclerosis genetic susceptibly loci.
    Mult Scler. 2021 Apr 19:13524585211004422. doi: 10.1177/13524585211004422.
    PubMed     Abstract available


  42. PAPEIX C, Mazoyer J, Maillart E, Bensa C, et al
    Multiple sclerosis: Is there a risk of worsening after yellow fever vaccination?
    Mult Scler. 2021 Apr 19:13524585211006372. doi: 10.1177/13524585211006372.
    PubMed     Abstract available


  43. CHATTERTON S, Withers B, Sutton IJ, Milliken ST, et al
    Pregnancy post autologous stem cell transplant with BEAM conditioning for multiple sclerosis.
    Mult Scler. 2021 Apr 19:13524585211005660. doi: 10.1177/13524585211005660.
    PubMed     Abstract available


  44. CIOTTI JR, Eby NS, Brier MR, Wu GF, et al
    Central vein sign and other radiographic features distinguishing myelin oligodendrocyte glycoprotein antibody disease from multiple sclerosis and aquaporin-4 antibody-positive neuromyelitis optica.
    Mult Scler. 2021 Apr 19:13524585211007086. doi: 10.1177/13524585211007086.
    PubMed     Abstract available


  45. FLEMING KM, Coote SB, Herring MP
    Home-based Pilates for symptoms of anxiety, depression and fatigue among persons with multiple sclerosis: An 8-week randomized controlled trial.
    Mult Scler. 2021 Apr 19:13524585211009216. doi: 10.1177/13524585211009216.
    PubMed     Abstract available


  46. SCHOONHEIM MM, Pinter D, Prouskas SE, Broeders TA, et al
    Disability in multiple sclerosis is related to thalamic connectivity and cortical network atrophy.
    Mult Scler. 2021 Apr 19:13524585211008743. doi: 10.1177/13524585211008743.
    PubMed     Abstract available


  47. D'AMICO E, Zanghi A, Calogero AE, Patti F, et al
    Male fertility in relapsing-remitting multiple sclerosis patients treated with natalizumab and ocrelizumab: A prospective case-control study.
    Mult Scler. 2021 Apr 19:13524585211009208. doi: 10.1177/13524585211009208.
    PubMed     Abstract available


  48. CORTESE M, Bjornevik K, Chitnis T, Ascherio A, et al
    Aging with multiple sclerosis: A longitudinal study of physical function, mental health, and memory in two cohorts of US women.
    Mult Scler. 2021 Apr 16:13524585211007739. doi: 10.1177/13524585211007739.
    PubMed     Abstract available


  49. COOPER G, Chien C, Zimmermann H, Bellmann-Strobl J, et al
    Longitudinal analysis of T1w/T2w ratio in patients with multiple sclerosis from first clinical presentation.
    Mult Scler. 2021 Apr 15:13524585211003479. doi: 10.1177/13524585211003479.
    PubMed     Abstract available


  50. ACHIRON A, Dolev M, Menascu S, Zohar DN, et al
    COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021.
    Mult Scler. 2021 Apr 15:13524585211003476. doi: 10.1177/13524585211003476.
    PubMed     Abstract available


  51. TROJANO M, Ramio-Torrenta L, Grimaldi LM, Lubetzki C, et al
    A randomized study of natalizumab dosing regimens for relapsing-remitting multiple sclerosis.
    Mult Scler. 2021 Apr 6:13524585211003020. doi: 10.1177/13524585211003020.
    PubMed     Abstract available


  52. BESSING B, Honan CA, van der Mei I, Taylor BV, et al
    Development and psychometric properties of the Multiple Sclerosis Knowledge Assessment Scale: Rasch analysis of a novel tool for evaluating MS knowledge.
    Mult Scler. 2021;27:767-777.
    PubMed     Abstract available


  53. VAN DAM M, Hulst HE, Schoonheim MM
    Coupling structure and function in early MS: How a less diverse repertoire of brain function could lead to clinical progression.
    Mult Scler. 2021;27:491-493.
    PubMed    


    March 2021
  54. HOWLETT-PRIETO Q, Feng X, Kramer JF, Kramer KJ, et al
    Anti-CD20 therapy corrects a CD8 regulatory T cell deficit in multiple sclerosis.
    Mult Scler. 2021 Mar 30:13524585211003301. doi: 10.1177/13524585211003301.
    PubMed     Abstract available


  55. THEODORSDOTTIR A, Debrabant B, Magyari M, Kant M, et al
    Alemtuzumab treatment in Denmark: A national study based on the Danish Multiple Sclerosis Registry.
    Mult Scler. 2021 Mar 29:13524585211003291. doi: 10.1177/13524585211003291.
    PubMed     Abstract available


  56. CREE BA, Cohen JA, Reder AT, Tomic D, et al
    Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosis.
    Mult Scler. 2021 Mar 26:13524585211000280. doi: 10.1177/13524585211000280.
    PubMed     Abstract available


  57. PORTACCIO E, Fonderico M, Hemmer B, Derfuss T, et al
    Impact of COVID-19 on multiple sclerosis care and management: Results from the European Committee for Treatment and Research in Multiple Sclerosis survey.
    Mult Scler. 2021 Mar 25:13524585211005339. doi: 10.1177/13524585211005339.
    PubMed     Abstract available


  58. LEE LE, Vavasour IM, Dvorak A, Liu H, et al
    Cervical cord myelin abnormality is associated with clinical disability in multiple sclerosis.
    Mult Scler. 2021 Mar 22:13524585211001780. doi: 10.1177/13524585211001780.
    PubMed     Abstract available


  59. HARROUD A, Mitchell RE, Richardson TG, Morris JA, et al
    Childhood obesity and multiple sclerosis: A Mendelian randomization study.
    Mult Scler. 2021 Mar 22:13524585211001781. doi: 10.1177/13524585211001781.
    PubMed     Abstract available


  60. BRIGGS FB, Krill D, Hill E, Conway DS, et al
    Age of hypertension onset in multiple sclerosis patients.
    Mult Scler. 2021 Mar 18:13524585211003016. doi: 10.1177/13524585211003016.
    PubMed     Abstract available


  61. MASSAROTTI C, Sbragia E, Boffa G, Vercelli C, et al
    Menstrual cycle resumption and female fertility after autologous hematopoietic stem cell transplantation for multiple sclerosis.
    Mult Scler. 2021 Mar 12:13524585211000616. doi: 10.1177/13524585211000616.
    PubMed     Abstract available


  62. SCHOONHEIM MM, Douw L, Broeders TA, Eijlers AJ, et al
    The cerebellum and its network: Disrupted static and dynamic functional connectivity patterns and cognitive impairment in multiple sclerosis.
    Mult Scler. 2021 Mar 8:1352458521999274. doi: 10.1177/1352458521999274.
    PubMed     Abstract available


  63. MACHLANSKA A, Helbig G, Chromik K, Zapala M, et al
    Hemophagocytic lymphohistiocytosis associated with ocrelizumab treatment in a patient with multiple sclerosis.
    Mult Scler. 2021 Mar 5:1352458521993070. doi: 10.1177/1352458521993070.
    PubMed     Abstract available


  64. LORSCHEIDER J
    When does a heap become a heap?
    Mult Scler. 2021;27:329-330.
    PubMed    


    February 2021
  65. SZILASIOVA J, Mikula P, Rosenberger J, Fedicova M, et al
    Plasma neurofilament light chain levels are predictors of disease activity in multiple sclerosis as measured by four-domain NEDA status, including brain volume loss.
    Mult Scler. 2021 Feb 26:1352458521998039. doi: 10.1177/1352458521998039.
    PubMed     Abstract available


  66. FOX RJ, Raska P, Barro C, Karafa M, et al
    Neurofilament light chain in a phase 2 clinical trial of ibudilast in progressive multiple sclerosis.
    Mult Scler. 2021 Feb 26:1352458520986956. doi: 10.1177/1352458520986956.
    PubMed     Abstract available


  67. MHANNA E, Nouchi A, Louapre C, De Paz R, et al
    Human papillomavirus lesions in 16 MS patients treated with fingolimod: Outcomes and vaccination.
    Mult Scler. 2021 Feb 25:1352458521991433. doi: 10.1177/1352458521991433.
    PubMed     Abstract available


  68. COPETTI M, Liu D
    Machine and deep learning in multiple sclerosis research are just powerful statistics - Commentary.
    Mult Scler. 2021 Feb 24:1352458521996699. doi: 10.1177/1352458521996699.
    PubMed    


  69. HARROUD A, Manousaki D, Butler-Laporte G, Mitchell RE, et al
    The relative contributions of obesity, vitamin D, leptin, and adiponectin to multiple sclerosis risk: A Mendelian randomization mediation analysis.
    Mult Scler. 2021 Feb 19:1352458521995484. doi: 10.1177/1352458521995484.
    PubMed     Abstract available


  70. BINZER S, Jiang X, Hillert J, Manouchehrinia A, et al
    Depression and multiple sclerosis: A bidirectional Mendelian randomisation study.
    Mult Scler. 2021 Feb 19:1352458521996601. doi: 10.1177/1352458521996601.
    PubMed     Abstract available


  71. LEMA DOPICO A, Choi S, Hua J, Li X, et al
    Multi-layer analysis of quantitative 7 T magnetic resonance imaging in the cortex of multiple sclerosis patients reveals pathology associated with disability.
    Mult Scler. 2021 Feb 18:1352458521994556. doi: 10.1177/1352458521994556.
    PubMed     Abstract available


  72. HARROUD A, Marrie RA, Fitzgerald KC, Salter A, et al
    Mendelian randomization provides no evidence for a causal role in the bidirectional relationship between depression and multiple sclerosis.
    Mult Scler. 2021 Feb 16:1352458521993075. doi: 10.1177/1352458521993075.
    PubMed     Abstract available


  73. BESSING B, Hussain MA, Claflin SB, Chen J, et al
    Changes in multiple sclerosis symptoms are associated with changes in work productivity of people living with multiple sclerosis.
    Mult Scler. 2021 Feb 16:1352458521994557. doi: 10.1177/1352458521994557.
    PubMed     Abstract available


  74. BELVISI D, Canevelli M, Baione V, Buscarinu MC, et al
    Operationalization of a frailty index in patients with multiple sclerosis: A cross-sectional investigation.
    Mult Scler. 2021 Feb 10:1352458520987541. doi: 10.1177/1352458520987541.
    PubMed     Abstract available


  75. MIDAGLIA L, Sastre-Garriga J, Pappolla A, Quibus L, et al
    The frequency and characteristics of MS misdiagnosis in patients referred to the multiple sclerosis centre of Catalonia.
    Mult Scler. 2021 Feb 10:1352458520988148. doi: 10.1177/1352458520988148.
    PubMed     Abstract available


  76. VELDKAMP R, Kalron A, Baert I, Hamalainen P, et al
    Differential effects and discriminative validity of motor and cognitive tasks varying in difficulty on cognitive-motor interference in persons with multiple sclerosis.
    Mult Scler. 2021 Feb 10:1352458520986960. doi: 10.1177/1352458520986960.
    PubMed     Abstract available


  77. KRASNIUK S, Classen S, Morrow SA, Alvarez L, et al
    Clinical predictors of driving simulator performance in drivers with multiple sclerosis.
    Mult Scler. 2021 Feb 10:1352458521992507. doi: 10.1177/1352458521992507.
    PubMed     Abstract available


  78. DAS J, Snowden JA, Burman J, Freedman MS, et al
    Autologous haematopoietic stem cell transplantation as a first-line disease-modifying therapy in patients with 'aggressive' multiple sclerosis.
    Mult Scler. 2021 Feb 10:1352458520985238. doi: 10.1177/1352458520985238.
    PubMed     Abstract available



  79. Incidence and clinical outcome of Coronavirus disease 2019 in a cohort of 11,560 Brazilian patients with multiple sclerosis.
    Mult Scler. 2021 Feb 2:1352458520978354. doi: 10.1177/1352458520978354.
    PubMed     Abstract available


  80. NYIRENDA MH, Fadda G, Healy LM, Mexhitaj I, et al
    Pro-inflammatory adiponectin in pediatric-onset multiple sclerosis.
    Mult Scler. 2021 Feb 1:1352458521989090. doi: 10.1177/1352458521989090.
    PubMed     Abstract available


  81. YEH EA
    Real-world outcomes in pediatric MS: Psychiatric comorbidities and school performance.
    Mult Scler. 2021;27:165-166.
    PubMed    


  82. TANASESCU R, Gran B
    Uncovering the underhanded: B-cell depletion therapies and severe viral infections - Commentary on 'Fatal underhanded chronic enterovirus infection associated with anti-CD20 monotherapy for central nervous system demyelinating disease'.
    Mult Scler. 2021;27:323-324.
    PubMed    


    January 2021
  83. MANOUCHEHRINIA A, Kingwell E, Zhu F, Tremlett H, et al
    A multiple sclerosis disease progression measure based on cumulative disability.
    Mult Scler. 2021 Jan 25:1352458520988632. doi: 10.1177/1352458520988632.
    PubMed     Abstract available


  84. JALUSIC KO, Ellenberger D, Rommer P, Stahmann A, et al
    Effect of applying inclusion and exclusion criteria of phase III clinical trials to multiple sclerosis patients in routine clinical care.
    Mult Scler. 2021 Jan 20:1352458520985118. doi: 10.1177/1352458520985118.
    PubMed     Abstract available


  85. BLACK LJ, Hetherton S, Forkan M, Gonzales EG, et al
    An exploratory study of diet in childhood and young adulthood and adult-onset multiple sclerosis.
    Mult Scler. 2021 Jan 19:1352458520986964. doi: 10.1177/1352458520986964.
    PubMed     Abstract available


  86. ROOS I, Leray E, Frascoli F, Casey R, et al
    Determinants of therapeutic lag in multiple sclerosis.
    Mult Scler. 2021 Jan 11:1352458520981300. doi: 10.1177/1352458520981300.
    PubMed     Abstract available


  87. FITZGERALD KC, Damian A, Conway D, Mowry EM, et al
    Vascular comorbidity is associated with lower brain volumes and lower neuroperformance in a large multiple sclerosis cohort.
    Mult Scler. 2021 Jan 8:1352458520984746. doi: 10.1177/1352458520984746.
    PubMed     Abstract available


  88. GONZALEZ-ESCAMILLA G, Groppa S
    7 Tesla MRI will soon be helpful to guide clinical practice in multiple sclerosis centres - No.
    Mult Scler. 2021 Jan 6:1352458520969662. doi: 10.1177/1352458520969662.
    PubMed    


  89. SATI P, Reich DS
    7 Tesla MRI will soon be helpful to guide clinical practice in multiple sclerosis centers - Commentary.
    Mult Scler. 2021 Jan 6:1352458520981738. doi: 10.1177/1352458520981738.
    PubMed    


  90. LOUAPRE C, Beigneux Y
    7 Tesla MRI will soon be helpful to guide clinical practice in multiple sclerosis centres - Yes.
    Mult Scler. 2021 Jan 6:1352458520972270. doi: 10.1177/1352458520972270.
    PubMed    


  91. ROLLOT F, Casey R, Leray E, Debouverie M, et al
    Cumulative effects of therapies on disability in relapsing multiple sclerosis.
    Mult Scler. 2021 Jan 6:1352458520980366. doi: 10.1177/1352458520980366.
    PubMed     Abstract available


  92. MARRIE RA, Leung S, Cutter GR, Fox RJ, et al
    Comparative responsiveness of the health utilities index and the RAND-12 for multiple sclerosis.
    Mult Scler. 2021 Jan 5:1352458520981370. doi: 10.1177/1352458520981370.
    PubMed     Abstract available


  93. AMATO MP, Portaccio E, De Meo E
    Understanding the pathophysiology of cognitive changes in MS: A step forward.
    Mult Scler. 2021;27:4-5.
    PubMed    


  94. BISTROM M, Hultdin J, Sundstrom P
    Response to 'Mendelian randomization analysis does not support a role for leptin in multiple sclerosis'.
    Mult Scler. 2021;27:161-162.
    PubMed    


  95. AL-ARAJI S, Ciccarelli O
    A possible case of serum sickness after ocrelizumab infusion - Commentary.
    Mult Scler. 2021;27:158-159.
    PubMed     Abstract available


    December 2020
  96. NIELSEN NM, Gortz S, Hjalgrim H, Rostgaard K, et al
    Maternal diabetes and risk of multiple sclerosis in the offspring: A Danish nationwide register-based cohort study.
    Mult Scler. 2020 Dec 17:1352458520977120. doi: 10.1177/1352458520977120.
    PubMed     Abstract available


  97. GALLO A, Bisecco A
    Psychological resilience explains functional variability across people with multiple sclerosis - Commentary.
    Mult Scler. 2020 Dec 17:1352458520978213. doi: 10.1177/1352458520978213.
    PubMed    


  98. LEAVITT VM, Kever A
    Psychological resilience explains functional variability across people with multiple sclerosis - Yes.
    Mult Scler. 2020 Dec 17:1352458520972263. doi: 10.1177/1352458520972263.
    PubMed    


  99. PLOUGHMAN M
    Psychological resilience explains functional variability across people with multiple sclerosis - No.
    Mult Scler. 2020 Dec 17:1352458520973633. doi: 10.1177/1352458520973633.
    PubMed    


  100. COMABELLA M, Deutschmann C, Midaglia L, Schierack P, et al
    Chitinase 3-like 1 is not a target antigen in patients with multiple sclerosis.
    Mult Scler. 2020 Dec 17:1352458520980141. doi: 10.1177/1352458520980141.
    PubMed     Abstract available


  101. HYLAND MH, Robb JF
    Teleconsultation will replace most face-to-face interactions in the multiple sclerosis clinic - Yes.
    Mult Scler. 2020 Dec 16:1352458520973640. doi: 10.1177/1352458520973640.
    PubMed    


  102. MOCCIA M
    Teleconsultation will replace most face-to-face interactions in the multiple sclerosis clinic - No.
    Mult Scler. 2020 Dec 16:1352458520968815. doi: 10.1177/1352458520968815.
    PubMed    


  103. D'HAESELEER M
    Teleconsultation will replace most face-to-face interactions in the multiple sclerosis clinic - Commentary.
    Mult Scler. 2020 Dec 16:1352458520979303. doi: 10.1177/1352458520979303.
    PubMed    


  104. CALABRESI PA, Arnold DL, Sangurdekar D, Singh CM, et al
    Temporal profile of serum neurofilament light in multiple sclerosis: Implications for patient monitoring.
    Mult Scler. 2020 Dec 14:1352458520972573. doi: 10.1177/1352458520972573.
    PubMed     Abstract available


  105. FILIPPATOU AG, Moniruzzaman M, Sotirchos ES, Fitzgerald KC, et al
    Serum ceramide levels are altered in multiple sclerosis.
    Mult Scler. 2020 Dec 14:1352458520971816. doi: 10.1177/1352458520971816.
    PubMed     Abstract available


  106. CHAN CK, Tian F, Pimentel Maldonado D, Mowry EM, et al
    Depression in multiple sclerosis across the adult lifespan.
    Mult Scler. 2020 Dec 14:1352458520979304. doi: 10.1177/1352458520979304.
    PubMed     Abstract available


  107. TAPIA-MALTOS MA, Trevino-Frenk I, Garcia-Gonzalez HB, Rosetti M, et al
    Identification of regulatory T cell molecules associated with severity of multiple sclerosis.
    Mult Scler. 2020 Dec 10:1352458520977045. doi: 10.1177/1352458520977045.
    PubMed     Abstract available


  108. NAUTA IM, Kulik SD, Breedt LC, Eijlers AJ, et al
    Functional brain network organization measured with magnetoencephalography predicts cognitive decline in multiple sclerosis.
    Mult Scler. 2020 Dec 9:1352458520977160. doi: 10.1177/1352458520977160.
    PubMed     Abstract available


  109. JACOBS BM, Smets I, Giovannoni G, Noyce A, et al
    Regarding: Nicotinic acetylcholine receptors alpha7 and alpha9 modify tobacco smoke risk for multiple sclerosis.
    Mult Scler. 2020 Dec 8:1352458520969941. doi: 10.1177/1352458520969941.
    PubMed    


  110. BRIGGS F
    Response to Jacobs et al, Nicotinic acetylcholine receptors alpha7 and alpha9 modify tobacco smoke risk for multiple sclerosis.
    Mult Scler. 2020 Dec 8:1352458520977027. doi: 10.1177/1352458520977027.
    PubMed    


  111. KOUBIYR I, Deloire M, Brochet B, Besson P, et al
    Structural constraints of functional connectivity drive cognitive impairment in the early stages of multiple sclerosis.
    Mult Scler. 2020 Dec 7:1352458520971807. doi: 10.1177/1352458520971807.
    PubMed     Abstract available


  112. VUKUSIC S, Ionescu I, Cornu C, Bossard N, et al
    Oral nomegestrol acetate and transdermal 17-beta-estradiol for preventing post-partum relapses in multiple sclerosis: The POPARTMUS study.
    Mult Scler. 2020 Dec 3:1352458520978218. doi: 10.1177/1352458520978218.
    PubMed     Abstract available


  113. RAMANUJAM R, Zhu F, Fink K, Karrenbauer VD, et al
    Accurate classification of secondary progression in multiple sclerosis using a decision tree.
    Mult Scler. 2020 Dec 2:1352458520975323. doi: 10.1177/1352458520975323.
    PubMed     Abstract available


  114. SHAH S
    Real-world evidence: One tweet at a time.
    Mult Scler. 2020;26:1965-1966.
    PubMed    


  115. COETZEE T, Thompson AJ
    Atlas of MS 2020: Informing global policy change.
    Mult Scler. 2020;26:1807-1808.
    PubMed    


  116. PILUTTI LA, Fakolade A
    Rehabilitation should be prescribed acutely in motor relapses - Commentary.
    Mult Scler. 2020;26:1825-1827.
    PubMed    


  117. YONG KP, Kim HJ
    Smelling the danger.
    Mult Scler. 2020;26:1960-1961.
    PubMed    


    November 2020
  118. STEPHENS S, Berenbaum T, Finlayson M, Motl RW, et al
    Youth with multiple sclerosis have low levels of fitness.
    Mult Scler. 2020 Nov 27:1352458520974360. doi: 10.1177/1352458520974360.
    PubMed     Abstract available


  119. ROMEO AR, Rowles WM, Schleimer ES, Barba P, et al
    An electronic, unsupervised patient-reported Expanded Disability Status Scale for multiple sclerosis.
    Mult Scler. 2020 Nov 25:1352458520968814. doi: 10.1177/1352458520968814.
    PubMed     Abstract available


  120. LANGESKOV-CHRISTENSEN M, Hvid LG, Jensen HB, Nielsen HH, et al
    Efficacy of high-intensity aerobic exercise on cognitive performance in people with multiple sclerosis: A randomized controlled trial.
    Mult Scler. 2020 Nov 24:1352458520973619. doi: 10.1177/1352458520973619.
    PubMed     Abstract available


  121. KLISTORNER S, Barnett MH, Yiannikas C, Barton J, et al
    Expansion of chronic lesions is linked to disease progression in relapsing-remitting multiple sclerosis patients.
    Mult Scler. 2020 Nov 20:1352458520974357. doi: 10.1177/1352458520974357.
    PubMed     Abstract available


  122. IAFFALDANO P, Lucisano G, Patti F, Brescia Morra V, et al
    Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors.
    Mult Scler. 2020 Nov 19:1352458520974366. doi: 10.1177/1352458520974366.
    PubMed     Abstract available


  123. LARONI A, Schiavetti I, Sormani MP, Uccelli A, et al
    COVID-19 in patients with multiple sclerosis undergoing disease-modifying treatments.
    Mult Scler. 2020 Nov 18:1352458520971817. doi: 10.1177/1352458520971817.
    PubMed     Abstract available


  124. CREE BA, Magnusson B, Rouyrre N, Fox RJ, et al
    Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis.
    Mult Scler. 2020 Nov 18:1352458520971819. doi: 10.1177/1352458520971819.
    PubMed     Abstract available


  125. GLUKHOVSKY L, Kurz D, Brandstadter R, Leavitt VM, et al
    Depression and cognitive function in early multiple sclerosis: Multitasking is more sensitive than traditional assessments.
    Mult Scler. 2020 Nov 16:1352458520958359. doi: 10.1177/1352458520958359.
    PubMed     Abstract available


  126. PREZIOSA P, Pagani E, Moiola L, Rodegher M, et al
    Occurrence and microstructural features of slowly expanding lesions on fingolimod or natalizumab treatment in multiple sclerosis.
    Mult Scler. 2020 Nov 13:1352458520969105. doi: 10.1177/1352458520969105.
    PubMed     Abstract available


  127. HEITMANN H, Andlauer TFM, Korn T, Muhlau M, et al
    Fatigue, depression, and pain in multiple sclerosis: How neuroinflammation translates into dysfunctional reward processing and anhedonic symptoms.
    Mult Scler. 2020 Nov 12:1352458520972279. doi: 10.1177/1352458520972279.
    PubMed     Abstract available


  128. SACCO R, Braga A, Disanto G, Digesu GA, et al
    Effectiveness of percutaneous posterior tibial nerve stimulation for the management of bowel dysfunction in multiple sclerosis patients.
    Mult Scler. 2020 Nov 12:1352458520972267. doi: 10.1177/1352458520972267.
    PubMed     Abstract available


  129. KARIM ME, Pellegrini F, Platt RW, Simoneau G, et al
    The use and quality of reporting of propensity score methods in multiple sclerosis literature: A review.
    Mult Scler. 2020 Nov 12:1352458520972557. doi: 10.1177/1352458520972557.
    PubMed     Abstract available


  130. AVILA M, Okai A, Thakolwiboon S, O'Bryan C, et al
    The effect of tonsillectomy on John Cunningham virus serological status in multiple sclerosis patients: A retrospective case-control study.
    Mult Scler. 2020 Nov 12:1352458520971822. doi: 10.1177/1352458520971822.
    PubMed     Abstract available


  131. WALTON C, King R, Rechtman L, Kaye W, et al
    Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition.
    Mult Scler. 2020 Nov 11:1352458520970841. doi: 10.1177/1352458520970841.
    PubMed     Abstract available


  132. HEDSTROM AK, Olsson T, Alfredsson L
    Cotinine as a measure of smoking in observational studies of multiple sclerosis.
    Mult Scler. 2020 Nov 10:1352458520968803. doi: 10.1177/1352458520968803.
    PubMed     Abstract available


  133. LAM KH, Meijer KA, Loonstra FC, Coerver E, et al
    Real-world keystroke dynamics are a potentially valid biomarker for clinical disability in multiple sclerosis.
    Mult Scler. 2020 Nov 5:1352458520968797. doi: 10.1177/1352458520968797.
    PubMed     Abstract available


  134. BUYUKTURKOGLU K, Zeng D, Bharadwaj S, Tozlu C, et al
    Classifying multiple sclerosis patients on the basis of SDMT performance using machine learning.
    Mult Scler. 2020 Nov 4:1352458520958362. doi: 10.1177/1352458520958362.
    PubMed     Abstract available


    October 2020
  135. LOZINSKI BM, Yong VW
    Exercise and the brain in multiple sclerosis.
    Mult Scler. 2020 Oct 30:1352458520969099. doi: 10.1177/1352458520969099.
    PubMed     Abstract available


  136. AFZAL HMR, Luo S, Ramadan S, Lechner-Scott J, et al
    The emerging role of artificial intelligence in multiple sclerosis imaging.
    Mult Scler. 2020 Oct 28:1352458520966298. doi: 10.1177/1352458520966298.
    PubMed     Abstract available


  137. PROSPERINI L, Haggiag S, Tortorella C, Galgani S, et al
    Age-related adverse events of disease-modifying treatments for multiple sclerosis: A meta-regression.
    Mult Scler. 2020 Oct 26:1352458520964778. doi: 10.1177/1352458520964778.
    PubMed     Abstract available


  138. STRIK M, Chard DT, Dekker I, Meijer KA, et al
    Increased functional sensorimotor network efficiency relates to disability in multiple sclerosis.
    Mult Scler. 2020 Oct 26:1352458520966292. doi: 10.1177/1352458520966292.
    PubMed     Abstract available


  139. KOSCH R, Schiffmann I, Daumer M, Lederer C, et al
    Long-term prognostic counselling in people with multiple sclerosis using an online analytical processing tool.
    Mult Scler. 2020 Oct 26:1352458520964774. doi: 10.1177/1352458520964774.
    PubMed     Abstract available


  140. TECCHIO F, Bertoli M, Gianni E, L'Abbate T, et al
    Parietal dysfunctional connectivity in depression in multiple sclerosis.
    Mult Scler. 2020 Oct 21:1352458520964412. doi: 10.1177/1352458520964412.
    PubMed    


  141. JAEGER S, Paul F, Finke C
    Functional connectivity alterations of striato-cortical circuits in multiple sclerosis.
    Mult Scler. 2020 Oct 21:1352458520966303. doi: 10.1177/1352458520966303.
    PubMed    


  142. BERMEL RA, Fedler JK, Kaiser P, Novalis C, et al
    Optical coherence tomography outcomes from SPRINT-MS, a multicenter, randomized, double-blind trial of ibudilast in progressive multiple sclerosis.
    Mult Scler. 2020 Oct 15:1352458520964409. doi: 10.1177/1352458520964409.
    PubMed     Abstract available


  143. SIDORE C, Orru V, Cocco E, Steri M, et al
    PRF1 mutation alters immune system activation, inflammation, and risk of autoimmunity.
    Mult Scler. 2020 Oct 14:1352458520963937. doi: 10.1177/1352458520963937.
    PubMed     Abstract available


  144. MARRIE RA, Walld R, Bolton JM, Sareen J, et al
    Effect of mood and anxiety disorders on health care utilization in multiple sclerosis.
    Mult Scler. 2020 Oct 13:1352458520963880. doi: 10.1177/1352458520963880.
    PubMed     Abstract available


  145. CASTELLI L, Quartuccio ME, Ruggieri S, De Giglio L, et al
    'Posture second' strategy predicts disability progression in multiple sclerosis.
    Mult Scler. 2020 Oct 13:1352458520963926. doi: 10.1177/1352458520963926.
    PubMed     Abstract available


  146. VEREB D, Toth E, Bozsik B, Kiraly A, et al
    Altered brain network function during attention-modulated visual processing in multiple sclerosis.
    Mult Scler. 2020 Oct 5:1352458520958360. doi: 10.1177/1352458520958360.
    PubMed     Abstract available


  147. LANGER-GOULD A, Black LJ, Waubant E, Smith JB, et al
    Seafood, fatty acid biosynthesis genes, and multiple sclerosis susceptibility.
    Mult Scler. 2020;26:1476-1485.
    PubMed     Abstract available


  148. CHEN J, Taylor B, Winzenberg T, Palmer AJ, et al
    Comorbidities are prevalent and detrimental for employment outcomes in people of working age with multiple sclerosis.
    Mult Scler. 2020;26:1550-1559.
    PubMed     Abstract available


  149. HULST HE, Penner IK
    Cognition and its relation to brain health in patients with MS.
    Mult Scler. 2020;26:1611-1613.
    PubMed    


  150. HOBART J, Giovannoni G
    Cognition and its relation to brain health in patients with MS: Response to letter.
    Mult Scler. 2020;26:1613-1614.
    PubMed    


  151. AZEVEDO CJ, Zamvil SS
    New cases of vasculitis after alemtuzumab.
    Mult Scler. 2020;26:1606-1608.
    PubMed    


    September 2020
  152. PISA M, Chieffo R, Congiu M, Dalla Costa G, et al
    Intracortical motor conduction is associated with hand dexterity in progressive multiple sclerosis.
    Mult Scler. 2020 Sep 25:1352458520960374. doi: 10.1177/1352458520960374.
    PubMed     Abstract available


  153. FERRE L, Mogavero A, Clarelli F, Moiola L, et al
    Early evidence of disease activity during fingolimod predicts medium-term inefficacy in relapsing-remitting multiple sclerosis.
    Mult Scler. 2020 Sep 25:1352458520961690. doi: 10.1177/1352458520961690.
    PubMed     Abstract available


  154. BOESEN MS, Blinkenberg M, Thygesen LC, Eriksson F, et al
    School performance, psychiatric comorbidity, and healthcare utilization in pediatric multiple sclerosis: A nationwide population-based observational study.
    Mult Scler. 2020 Sep 25:1352458520959673. doi: 10.1177/1352458520959673.
    PubMed     Abstract available


  155. CALVI A, Haider L, Prados F, Tur C, et al
    In vivo imaging of chronic active lesions in multiple sclerosis.
    Mult Scler. 2020 Sep 23:1352458520958589. doi: 10.1177/1352458520958589.
    PubMed     Abstract available


  156. RIVA A, Barcella V, Benatti SV, Capobianco M, et al
    Vaccinations in patients with multiple sclerosis: A Delphi consensus statement.
    Mult Scler. 2020 Sep 17:1352458520952310. doi: 10.1177/1352458520952310.
    PubMed     Abstract available


  157. MOIOLA L, Barcella V, Benatti S, Capobianco M, et al
    The risk of infection in patients with multiple sclerosis treated with disease-modifying therapies: A Delphi consensus statement.
    Mult Scler. 2020 Sep 17:1352458520952311. doi: 10.1177/1352458520952311.
    PubMed     Abstract available


  158. FEYS P, Swinnen E
    Powered exoskeletons for walking in multiple sclerosis.
    Mult Scler. 2020 Sep 15:1352458520958351. doi: 10.1177/1352458520958351.
    PubMed    


  159. WEE SK, Ho CY, Tan SL, Ong CH, et al
    Enhancing quality of life in progressive multiple sclerosis with powered robotic exoskeleton.
    Mult Scler. 2020 Sep 15:1352458520943080. doi: 10.1177/1352458520943080.
    PubMed     Abstract available


  160. CORDANI C, Hidalgo de la Cruz M, Meani A, Valsasina P, et al
    MRI correlates of clinical disability and hand-motor performance in multiple sclerosis phenotypes.
    Mult Scler. 2020 Sep 14:1352458520958356. doi: 10.1177/1352458520958356.
    PubMed     Abstract available


  161. ZHANG Y, Taylor BV, Simpson S Jr, Blizzard L, et al
    Feelings of depression, pain and walking difficulties have the largest impact on the quality of life of people with multiple sclerosis, irrespective of clinical phenotype.
    Mult Scler. 2020 Sep 14:1352458520958369. doi: 10.1177/1352458520958369.
    PubMed     Abstract available


  162. BRIGGS FB
    Nicotinic acetylcholine receptors alpha7 and alpha9 modifies tobacco smoke risk for multiple sclerosis.
    Mult Scler. 2020 Sep 14:1352458520958361. doi: 10.1177/1352458520958361.
    PubMed     Abstract available


  163. KUNCHOK A, Flanagan EP, Krecke KN, Chen JJ, et al
    MOG-IgG1 and co-existence of neuronal autoantibodies.
    Mult Scler. 2020 Sep 10:1352458520951046. doi: 10.1177/1352458520951046.
    PubMed     Abstract available


  164. MARTINO M, Magioncalda P, El Mendili MM, Droby A, et al
    Depression is associated with disconnection of neurotransmitter-related nuclei in multiple sclerosis.
    Mult Scler. 2020 Sep 10:1352458520948214. doi: 10.1177/1352458520948214.
    PubMed     Abstract available


  165. CHEN J, Taylor B, Blizzard L, Simpson-Yap S, et al
    Risk factors for leaving employment due to multiple sclerosis and changes in risk over the past decades: Using competing risk survival analysis.
    Mult Scler. 2020 Sep 3:1352458520954167. doi: 10.1177/1352458520954167.
    PubMed     Abstract available


  166. YILMAZER C, Lamers I, Solaro C, Feys P, et al
    Clinical perspective on pain in multiple sclerosis.
    Mult Scler. 2020 Sep 3:1352458520952015. doi: 10.1177/1352458520952015.
    PubMed     Abstract available


  167. HAWTON A, Goodwin E, Boddy K, Freeman J, et al
    Measuring the cost-effectiveness of treatments for people with multiple sclerosis: Beyond quality-adjusted life-years.
    Mult Scler. 2020 Sep 3:1352458520954172. doi: 10.1177/1352458520954172.
    PubMed     Abstract available


  168. JOISTEN N, Proschinger S, Rademacher A, Schenk A, et al
    High-intensity interval training reduces neutrophil-to-lymphocyte ratio in persons with multiple sclerosis during inpatient rehabilitation.
    Mult Scler. 2020 Sep 3:1352458520951382. doi: 10.1177/1352458520951382.
    PubMed     Abstract available


  169. CICCARELLI O, Cohen JA, Thompson A
    Response of the multiple sclerosis community to COVID-19.
    Mult Scler. 2020;26:1134-1136.
    PubMed    


  170. YAM C, Jokubaitis V, Hellwig K, Dobson R, et al
    MS, pregnancy and COVID-19.
    Mult Scler. 2020;26:1137-1146.
    PubMed     Abstract available


  171. MECA-LALLANA V
    COVID-19 will change MS care forever - Yes.
    Mult Scler. 2020;26:1147-1148.
    PubMed    


  172. PREZIOSA P, Rocca MA, Filippi M
    COVID-19 will change MS care forever - No.
    Mult Scler. 2020;26:1149-1151.
    PubMed    


    August 2020
  173. MIDAGLIA L, Otero S, Baro F, Montalban X, et al
    Menopause and multiple sclerosis: Influence on prognosis and role of disease-modifying drugs and hormonal replacement therapy.
    Mult Scler. 2020 Aug 28:1352458520952022. doi: 10.1177/1352458520952022.
    PubMed     Abstract available


  174. DISANTO G, Ripellino P, Riccitelli GC, Sacco R, et al
    De-escalating rituximab dose results in stability of clinical, radiological, and serum neurofilament levels in multiple sclerosis.
    Mult Scler. 2020 Aug 25:1352458520952036. doi: 10.1177/1352458520952036.
    PubMed     Abstract available


  175. BOFFA G, Sbragia E, Raiola AM, Varaldo R, et al
    Autologous hematopoietic stem cell transplantation following alemtuzumab therapy in aggressive multiple sclerosis: A report of three cases.
    Mult Scler. 2020 Aug 25:1352458520914818. doi: 10.1177/1352458520914818.
    PubMed     Abstract available


  176. SMITH AD, Prokopiusova T, Jones R, Burge T, et al
    Functional electrical stimulation for foot drop in people with multiple sclerosis: The relevance and importance of addressing quality of movement.
    Mult Scler. 2020 Aug 24:1352458520923958. doi: 10.1177/1352458520923958.
    PubMed     Abstract available


  177. SADIGH G, Lava N, Switchenko J, Duszak R Jr, et al
    Patient-reported financial toxicity in multiple sclerosis: Predictors and association with care non-adherence.
    Mult Scler. 2020 Aug 18:1352458520913977. doi: 10.1177/1352458520913977.
    PubMed     Abstract available


  178. JORDAN AL, Yang J, Fisher CJ, Racke MK, et al
    Progressive multifocal leukoencephalopathy in dimethyl fumarate-treated multiple sclerosis patients.
    Mult Scler. 2020 Aug 18:1352458520949158. doi: 10.1177/1352458520949158.
    PubMed     Abstract available


  179. SEYMAN E, Jones A, Guenette M, Vosoughi R, et al
    Clinical and MRI characteristics of multiple sclerosis in patients of Middle Eastern and North African ancestry residing in Ontario, Canada.
    Mult Scler. 2020 Aug 11:1352458520948212. doi: 10.1177/1352458520948212.
    PubMed     Abstract available


  180. MOSS BP, Mahajan KR, Bermel RA, Hellisz K, et al
    Multiple sclerosis management during the COVID-19 pandemic.
    Mult Scler. 2020 Aug 10:1352458520948231. doi: 10.1177/1352458520948231.
    PubMed     Abstract available


  181. BROWNLEE WJ
    COVID-19 and high-efficacy multiple sclerosis therapies: Time for business as usual?
    Mult Scler. 2020 Aug 7:1352458520948211. doi: 10.1177/1352458520948211.
    PubMed    


  182. WURM H, Attfield K, Iversen AK, Gold R, et al
    Recovery from COVID-19 in a B-cell-depleted multiple sclerosis patient.
    Mult Scler. 2020 Aug 7:1352458520943791. doi: 10.1177/1352458520943791.
    PubMed     Abstract available


  183. DERSCH R, Wehrum T, Fahndrich S, Engelhardt M, et al
    COVID-19 pneumonia in a multiple sclerosis patient with severe lymphopenia due to recent cladribine treatment.
    Mult Scler. 2020 Aug 7:1352458520943783. doi: 10.1177/1352458520943783.
    PubMed     Abstract available


  184. JAWORSKI MG 3RD, Fuchs TA, Dwyer MG, Wojcik C, et al
    Conscientiousness and deterioration in employment status in multiple sclerosis over 3 years.
    Mult Scler. 2020 Aug 6:1352458520946019. doi: 10.1177/1352458520946019.
    PubMed     Abstract available


  185. GERALDES R, Jurynczyk M, Dos Passos GR, Pichler A, et al
    The role of pontine lesion location in differentiating multiple sclerosis from vascular risk factor-related small vessel disease.
    Mult Scler. 2020 Aug 6:1352458520943777. doi: 10.1177/1352458520943777.
    PubMed     Abstract available


  186. GUISSET F, Lolli V, Bugli C, Perrotta G, et al
    The central vein sign in multiple sclerosis patients with vascular comorbidities.
    Mult Scler. 2020 Aug 4:1352458520943785. doi: 10.1177/1352458520943785.
    PubMed     Abstract available


  187. ALEXANDER S, Peryer G, Gray E, Barkhof F, et al
    Wearable technologies to measure clinical outcomes in multiple sclerosis: A scoping review.
    Mult Scler. 2020 Aug 4:1352458520946005. doi: 10.1177/1352458520946005.
    PubMed     Abstract available


  188. LIPP I, Foster C, Stickland R, Sgarlata E, et al
    Predictors of training-related improvement in visuomotor performance in patients with multiple sclerosis: A behavioural and MRI study.
    Mult Scler. 2020 Aug 4:1352458520943788. doi: 10.1177/1352458520943788.
    PubMed     Abstract available


  189. ABBOUD H
    Iatrogenic demyelinating disorders: New insights, new culprits.
    Mult Scler. 2020;26:1129-1130.
    PubMed    


    July 2020
  190. RINGH MV, Hagemann-Jensen M, Needhamsen M, Kullberg S, et al
    Methylome and transcriptome signature of bronchoalveolar cells from multiple sclerosis patients in relation to smoking.
    Mult Scler. 2020 Jul 30:1352458520943768. doi: 10.1177/1352458520943768.
    PubMed     Abstract available



  191. CORRIGENDUM to "Effectiveness of the transcutaneous tibial nerve stimulation and pelvic floor muscle training with biofeedback in women with multiple sclerosis for the management of overactive bladder".
    Mult Scler. 2020 Jul 24:1352458520945512. doi: 10.1177/1352458520945512.
    PubMed    


  192. SIMPSON-YAP S, Oddy WH, Taylor B, Lucas RM, et al
    High Prudent diet factor score predicts lower relapse hazard in early multiple sclerosis.
    Mult Scler. 2020 Jul 23:1352458520943087. doi: 10.1177/1352458520943087.
    PubMed     Abstract available


  193. INOJOSA H, Ziemssen T
    How to reduce the delay of diagnosing secondary progression in multiple sclerosis.
    Mult Scler. 2020 Jul 22:1352458520943799. doi: 10.1177/1352458520943799.
    PubMed    


  194. CONWAY DS, Thompson NR, Meng X, Johnson K, et al
    Patient reported outcomes and performance metrics at diagnosis of secondary progressive multiple sclerosis.
    Mult Scler. 2020 Jul 16:1352458520936214. doi: 10.1177/1352458520936214.
    PubMed     Abstract available


  195. HUBBARD AL, Golla H, Lausberg H
    What's in a name? That which we call Multiple Sclerosis Fatigue.
    Mult Scler. 2020 Jul 16:1352458520941481. doi: 10.1177/1352458520941481.
    PubMed     Abstract available


  196. PEETERS LM, Parciak T, Walton C, Geys L, et al
    COVID-19 in people with multiple sclerosis: A global data sharing initiative.
    Mult Scler. 2020 Jul 14:1352458520941485. doi: 10.1177/1352458520941485.
    PubMed     Abstract available


  197. HIDALGO DE LA CRUZ M, Valsasina P, Gobbi C, Gallo A, et al
    Longitudinal cortical thinning progression differs across multiple sclerosis phenotypes and is clinically relevant: A multicentre study.
    Mult Scler. 2020 Jul 14:1352458520940548. doi: 10.1177/1352458520940548.
    PubMed     Abstract available


  198. BARCELLOS LF, Horton M, Shao X, Bellesis KH, et al
    A validation study for remote testing of cognitive function in multiple sclerosis.
    Mult Scler. 2020 Jul 14:1352458520937385. doi: 10.1177/1352458520937385.
    PubMed     Abstract available


  199. LOONSTRA FC, Hoitsma E, van Kempen ZL, Killestein J, et al
    COVID-19 in multiple sclerosis: The Dutch experience.
    Mult Scler. 2020 Jul 14:1352458520942198. doi: 10.1177/1352458520942198.
    PubMed     Abstract available


  200. STORELLI L, Pagani E, Preziosa P, Filippi M, et al
    Measurement of white matter fiber-bundle cross-section in multiple sclerosis using diffusion-weighted imaging.
    Mult Scler. 2020 Jul 14:1352458520938999. doi: 10.1177/1352458520938999.
    PubMed     Abstract available


  201. ABBATEMARCO JR, Griffin A, Jones NG, Hartman J, et al
    Long-term outcomes of intrathecal baclofen in ambulatory multiple sclerosis patients: A single-center experience.
    Mult Scler. 2020 Jul 14:1352458520936912. doi: 10.1177/1352458520936912.
    PubMed     Abstract available


  202. WU P, Li R, Zhang W, Lu H, et al
    Mendelian randomization analysis does not support a role for leptin in multiple sclerosis.
    Mult Scler. 2020 Jul 14:1352458520938990. doi: 10.1177/1352458520938990.
    PubMed    


  203. PINTER D, Khalil M, Pirpamer L, Damulina A, et al
    Long-term course and morphological MRI correlates of cognitive function in multiple sclerosis.
    Mult Scler. 2020 Jul 14:1352458520941474. doi: 10.1177/1352458520941474.
    PubMed     Abstract available


  204. CROTEAU D, Tobenkin A, Brinker A, Kortepeter CM, et al
    Tumefactive multiple sclerosis in association with fingolimod initiation and discontinuation.
    Mult Scler. 2020 Jul 14:1352458520938354. doi: 10.1177/1352458520938354.
    PubMed     Abstract available


  205. GERALDES R
    Two-armed active comparator trials are unethical in pediatric multiple sclerosis - No.
    Mult Scler. 2020 Jul 10:1352458520931784. doi: 10.1177/1352458520931784.
    PubMed    


  206. WAUBANT E
    Two-armed active comparator trials are unethical in paediatric multiple sclerosis - Commentary.
    Mult Scler. 2020 Jul 10:1352458520936243. doi: 10.1177/1352458520936243.
    PubMed    


  207. KRUPP LB, Charvet LE
    Two-armed active comparator trials are unethical in pediatric multiple sclerosis - Yes.
    Mult Scler. 2020 Jul 10:1352458520931796. doi: 10.1177/1352458520931796.
    PubMed    


  208. CHITNIS T, Banwell B, Krupp L, Arnold DL, et al
    Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy in paediatric patients with multiple sclerosis: Results from the PARADIGMS study.
    Mult Scler. 2020 Jul 7:1352458520936934. doi: 10.1177/1352458520936934.
    PubMed     Abstract available


  209. FITZGERALD KC, Morris B, Soroosh A, Balshi A, et al
    Pilot randomized active-placebo-controlled trial of low-dose ketamine for the treatment of multiple sclerosis-related fatigue.
    Mult Scler. 2020 Jul 7:1352458520936226. doi: 10.1177/1352458520936226.
    PubMed     Abstract available


  210. HACOHEN Y, Banwell B, Ciccarelli O
    What does first-line therapy mean for paediatric multiple sclerosis in the current era?
    Mult Scler. 2020 Jul 7:1352458520937644. doi: 10.1177/1352458520937644.
    PubMed     Abstract available


  211. KUNCHOK A, Flanagan EP, Snyder M, Saadeh R, et al
    Coexisting systemic and organ-specific autoimmunity in MOG-IgG1-associated disorders versus AQP4-IgG+ NMOSD.
    Mult Scler. 2020 Jul 7:1352458520933884. doi: 10.1177/1352458520933884.
    PubMed     Abstract available


  212. BSTEH G, Berek K, Hegen H, Altmann P, et al
    Macular ganglion cell-inner plexiform layer thinning as a biomarker of disability progression in relapsing multiple sclerosis.
    Mult Scler. 2020 Jul 2:1352458520935724. doi: 10.1177/1352458520935724.
    PubMed     Abstract available


  213. THRUE C, Riemenschneider M, Hvid LG, Stenager E, et al
    Time matters: Early-phase multiple sclerosis is accompanied by considerable impairments across multiple domains.
    Mult Scler. 2020 Jul 2:1352458520936231. doi: 10.1177/1352458520936231.
    PubMed     Abstract available


  214. ARRAMBIDE G
    MOG-antibody-associated disease-getting the whole picture.
    Mult Scler. 2020;26:1000-1001.
    PubMed    


    June 2020
  215. FEINSTEIN A, Meza C, Stefan C, Staines WR, et al
    Discontinuing cannabis improves depression in people with multiple sclerosis: A short report.
    Mult Scler. 2020 Jun 26:1352458520934070. doi: 10.1177/1352458520934070.
    PubMed     Abstract available


  216. SIGNORI A, Boffa G, Bovis F, Mariottini A, et al
    Prevalence of disability improvement as a potential outcome for multiple sclerosis trials.
    Mult Scler. 2020 Jun 26:1352458520936236. doi: 10.1177/1352458520936236.
    PubMed     Abstract available



  217. Household paired design reduces variance and increases power in multi-city gut microbiome study in multiple sclerosis.
    Mult Scler. 2020 Jun 26:1352458520924594. doi: 10.1177/1352458520924594.
    PubMed     Abstract available


  218. MEHNDIRATTA A, Treaba CA, Barletta V, Herranz E, et al
    Characterization of thalamic lesions and their correlates in multiple sclerosis by ultra-high-field MRI.
    Mult Scler. 2020 Jun 25:1352458520932804. doi: 10.1177/1352458520932804.
    PubMed     Abstract available


  219. BOVE R, Rowles W, Zhao C, Anderson A, et al
    A novel in-home digital treatment to improve processing speed in people with multiple sclerosis: A pilot study.
    Mult Scler. 2020 Jun 25:1352458520930371. doi: 10.1177/1352458520930371.
    PubMed     Abstract available


  220. WIENDL H, Spelman T, Butzkueven H, Kappos L, et al
    Real-world disability improvement in patients with relapsing-remitting multiple sclerosis treated with natalizumab in the Tysabri Observational Program.
    Mult Scler. 2020 Jun 24:1352458520926869. doi: 10.1177/1352458520926869.
    PubMed     Abstract available


  221. GLUKHOVSKY L, Brandstadter R, Leavitt VM, Krieger S, et al
    Hippocampal volume is more related to patient-reported memory than objective memory performance in early multiple sclerosis.
    Mult Scler. 2020 Jun 22:1352458520922830. doi: 10.1177/1352458520922830.
    PubMed     Abstract available


  222. SASTRE-GARRIGA J, Tintore M, Montalban X
    Keeping standards of multiple sclerosis care through the COVID-19 pandemic.
    Mult Scler. 2020 Jun 19:1352458520931785. doi: 10.1177/1352458520931785.
    PubMed    


  223. LEVIN SN, Ezuma C, Levine L, Vargas WS, et al
    Switching from natalizumab to ocrelizumab in patients with multiple sclerosis.
    Mult Scler. 2020 Jun 19:1352458520927631. doi: 10.1177/1352458520927631.
    PubMed    


  224. GHEZZI A, Banwell B, Bar-Or A, Chitnis T, et al
    Rituximab in patients with pediatric multiple sclerosis and other demyelinating disorders of the CNS: Practical considerations.
    Mult Scler. 2020 Jun 19:1352458520932798. doi: 10.1177/1352458520932798.
    PubMed     Abstract available


  225. BHARGAVA P, Nogueras-Ortiz C, Kim S, Delgado-Peraza F, et al
    Synaptic and complement markers in extracellular vesicles in multiple sclerosis.
    Mult Scler. 2020 Jun 17:1352458520924590. doi: 10.1177/1352458520924590.
    PubMed     Abstract available


  226. RICIGLIANO VA, Tonietto M, Palladino R, Poirion E, et al
    Thalamic energy dysfunction is associated with thalamo-cortical tract damage in multiple sclerosis: A diffusion spectroscopy study.
    Mult Scler. 2020 Jun 17:1352458520921362. doi: 10.1177/1352458520921362.
    PubMed     Abstract available


  227. YAVARPOUR-BALI H, Ghasemi-Kasman M
    The role of inflammasomes in multiple sclerosis.
    Mult Scler. 2020 Jun 16:1352458520932776. doi: 10.1177/1352458520932776.
    PubMed     Abstract available


  228. GHEZZI A, Amato MP, Edan G, Hartung HP, et al
    The introduction of new medications in pediatric multiple sclerosis: Open issues and challenges.
    Mult Scler. 2020 Jun 16:1352458520930620. doi: 10.1177/1352458520930620.
    PubMed     Abstract available


  229. LE M, Malpas C, Sharmin S, Horakova D, et al
    Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis.
    Mult Scler. 2020 Jun 15:1352458520926955. doi: 10.1177/1352458520926955.
    PubMed     Abstract available


  230. IACOBAEUS E, Arrambide G, Pia Amato M, Derfuss T, et al
    Aggressive multiple sclerosis (1): Towards a definition of the phenotype.
    Mult Scler. 2020 Jun 12:1352458520925369. doi: 10.1177/1352458520925369.
    PubMed     Abstract available


  231. ARRAMBIDE G, Iacobaeus E, Amato MP, Derfuss T, et al
    Aggressive multiple sclerosis (2): Treatment.
    Mult Scler. 2020 Jun 12:1352458520924595. doi: 10.1177/1352458520924595.
    PubMed     Abstract available


  232. LIZAK N, Hodgkinson S, Butler E, Lechner-Scott J, et al
    Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: An MSBase registry substudy.
    Mult Scler. 2020 Jun 12:1352458520921087. doi: 10.1177/1352458520921087.
    PubMed     Abstract available


  233. POLAT DUNYA C, Tulek Z, Kurtuncu M, Panicker JN, et al
    Effectiveness of the transcutaneous tibial nerve stimulation and pelvic floor muscle training with biofeedback in women with multiple sclerosis for the management of overactive bladder.
    Mult Scler. 2020 Jun 9:1352458520926666. doi: 10.1177/1352458520926666.
    PubMed     Abstract available


  234. SOLARI A, Oliver D
    Palliative care in multiple sclerosis: European guideline.
    Mult Scler. 2020 Jun 9:1352458520926467. doi: 10.1177/1352458520926467.
    PubMed    


  235. XU Y, Hiyoshi A, Brand JS, Smith KA, et al
    Higher body mass index at ages 16 to 20 years is associated with increased risk of a multiple sclerosis diagnosis in subsequent adulthood among men.
    Mult Scler. 2020 Jun 8:1352458520928061. doi: 10.1177/1352458520928061.
    PubMed     Abstract available


  236. BROWN J, Quattrochi B, Everett C, Hong BY, et al
    Gut commensals, dysbiosis, and immune response imbalance in the pathogenesis of multiple sclerosis.
    Mult Scler. 2020 Jun 8:1352458520928301. doi: 10.1177/1352458520928301.
    PubMed     Abstract available


  237. CELIUS EG
    Breastfeeding and treatment of multiple sclerosis.
    Mult Scler. 2020 Jun 8:1352458520931786. doi: 10.1177/1352458520931786.
    PubMed    


  238. PIHL-JENSEN G, Wanscher B, Frederiksen JL
    Predictive value of optical coherence tomography, multifocal visual evoked potentials, and full-field visual evoked potentials of the fellow, non-symptomatic eye for subsequent multiple sclerosis development in patients with acute optic neuritis.
    Mult Scler. 2020 Jun 8:1352458520917924. doi: 10.1177/1352458520917924.
    PubMed     Abstract available


  239. ROJAS JI, Patrucco L, Alonso R, Garcea O, et al
    Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis: Multicenter study in Argentina.
    Mult Scler. 2020 Jun 2:1352458520924586. doi: 10.1177/1352458520924586.
    PubMed     Abstract available


  240. OH J, Chen M, Cybulsky K, Suthiphosuwan S, et al
    Five-year longitudinal changes in quantitative spinal cord MRI in multiple sclerosis.
    Mult Scler. 2020 Jun 1:1352458520923970. doi: 10.1177/1352458520923970.
    PubMed     Abstract available


  241. COSTELLO F, Petzold A
    Weighting evidence in MS: Obesity and neurodegeneration.
    Mult Scler. 2020;26:748-750.
    PubMed    


  242. BOYKO A
    Radiologically isolated syndrome with oligoclonal bands in CSF (RIS + OCB) can be classified as high MS risk group.
    Mult Scler. 2020;26:869-870.
    PubMed    


  243. DE STEFANO N
    Response to Dr Boyko's letter: 'Radiologically isolated syndrome with oligoclonal bands in CSF (RIS + OCB) can be classified as highly MS-risk group'.
    Mult Scler. 2020;26:871.
    PubMed    


  244. VAN DER WALT A
    Addressing the treatment gap in MS-associated tremor: A new door opens.
    Mult Scler. 2020;26:858.
    PubMed    


    May 2020
  245. VARGAS WS, Noble KG, Banwell B, De Jager P, et al
    The educational impact of childhood-onset multiple sclerosis: Why assessing academic achievement is imperative.
    Mult Scler. 2020 May 28:1352458520923946. doi: 10.1177/1352458520923946.
    PubMed     Abstract available


  246. VON WYL V, Benkert P, Moser A, Lorscheider J, et al
    Disability progression in relapse-free multiple sclerosis patients on fingolimod versus interferon-beta/glatiramer acetate.
    Mult Scler. 2020 May 28:1352458520918489. doi: 10.1177/1352458520918489.
    PubMed     Abstract available


  247. CARANDINI T, Pietroboni AM, Sacchi L, De Riz MA, et al
    Alemtuzumab in multiple sclerosis during the COVID-19 pandemic: A mild uncomplicated infection despite intense immunosuppression.
    Mult Scler. 2020 May 28:1352458520926459. doi: 10.1177/1352458520926459.
    PubMed    


  248. PASQUA G, Tommasin S, Bharti K, Ruggieri S, et al
    Resting-state functional connectivity of anterior and posterior cerebellar lobes is altered in multiple sclerosis.
    Mult Scler. 2020 May 28:1352458520922770. doi: 10.1177/1352458520922770.
    PubMed     Abstract available


  249. AYRIGNAC X, Larochelle C, Keezer M, Roger E, et al
    Frailty in ageing persons with multiple sclerosis.
    Mult Scler. 2020 May 27:1352458520923945. doi: 10.1177/1352458520923945.
    PubMed     Abstract available


  250. CORONADO I, Gabr RE, Narayana PA
    Deep learning segmentation of gadolinium-enhancing lesions in multiple sclerosis.
    Mult Scler. 2020 May 22:1352458520921364. doi: 10.1177/1352458520921364.
    PubMed     Abstract available


  251. WANG FM, Davis MF, Briggs FB
    Predicting self-reported depression after the onset of multiple sclerosis using genetic and non-genetic factors.
    Mult Scler. 2020 May 18:1352458520921073. doi: 10.1177/1352458520921073.
    PubMed     Abstract available


  252. BRUIJSTENS AL, Blok KM, Smolders J, Wokke BH, et al
    Pediatric MS patients with a primary progressive-like disease may still have relevant inflammatory activity and may benefit from regular MS treatment.
    Mult Scler. 2020 May 14:1352458520921367. doi: 10.1177/1352458520921367.
    PubMed    


  253. VALBURG C, Sonti A, Stern JN, Najjar S, et al
    Dietary factors in experimental autoimmune encephalomyelitis and multiple sclerosis: A comprehensive review.
    Mult Scler. 2020 May 14:1352458520923955. doi: 10.1177/1352458520923955.
    PubMed     Abstract available


  254. KILJAN S, Preziosa P, Jonkman LE, van de Berg WD, et al
    Cortical axonal loss is associated with both gray matter demyelination and white matter tract pathology in progressive multiple sclerosis: Evidence from a combined MRI-histopathology study.
    Mult Scler. 2020 May 11:1352458520918978. doi: 10.1177/1352458520918978.
    PubMed     Abstract available


  255. GHARAKHANLOU R, Wesselmann L, Rademacher A, Lampit A, et al
    Exercise training and cognitive performance in persons with multiple sclerosis: A systematic review and multilevel meta-analysis of clinical trials.
    Mult Scler. 2020 May 11:1352458520917935. doi: 10.1177/1352458520917935.
    PubMed     Abstract available


  256. LUNEMANN JD, Diaz-Diaz J, Stankoff B, Young C, et al
    Highlights from the 2019 European Congress on Treatment and Research in Multiple Sclerosis (ECTRIMS 2019).
    Mult Scler. 2020 May 4:1352458520918377. doi: 10.1177/1352458520918377.
    PubMed     Abstract available


  257. BOSE G, Thebault S, Rush CA, Atkins HL, et al
    Autologous hematopoietic stem cell transplantation for multiple sclerosis: A current perspective.
    Mult Scler. 2020 May 4:1352458520917936. doi: 10.1177/1352458520917936.
    PubMed     Abstract available


  258. LAMBE J, Saidha S, Bermel RA
    Optical coherence tomography and multiple sclerosis: Update on clinical application and role in clinical trials.
    Mult Scler. 2020;26:624-639.
    PubMed     Abstract available


  259. HARTUNG HP, Mares J, Barnett MH
    Alemtuzumab: Rare serious adverse events of a high-efficacy drug.
    Mult Scler. 2020;26:737-740.
    PubMed    


  260. KRIEGER SC, Sumowski JF
    Toward biologically meaningful categories of MS-related fatigue.
    Mult Scler. 2020;26:620-621.
    PubMed    


  261. PROSCHMANN U, Sehr T, Akgun K, Ziemssen T, et al
    Letter to the editor regarding "Therapeutic drug monitoring of natalizumab".
    Mult Scler. 2020;26:741-742.
    PubMed    


    April 2020
  262. FOX E, Lovett-Racke AE, Gormley M, Liu Y, et al
    A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis.
    Mult Scler. 2020 Apr 30:1352458520918375. doi: 10.1177/1352458520918375.
    PubMed     Abstract available


  263. KALB R, Brown TR, Coote S, Costello K, et al
    Exercise and lifestyle physical activity recommendations for people with multiple sclerosis throughout the disease course.
    Mult Scler. 2020 Apr 23:1352458520915629. doi: 10.1177/1352458520915629.
    PubMed     Abstract available


  264. AHRABIAN D, Neill L, Bell R, Leary SM, et al
    Acute cardiotoxicity associated with alemtuzumab infusion for multiple sclerosis.
    Mult Scler. 2020 Apr 16:1352458519855725. doi: 10.1177/1352458519855725.
    PubMed     Abstract available


  265. FILIPPATOU AG, Lambe J, Sotirchos ES, Fitzgerald KC, et al
    Association of body mass index with longitudinal rates of retinal atrophy in multiple sclerosis.
    Mult Scler. 2020 Apr 16:1352458519900942. doi: 10.1177/1352458519900942.
    PubMed     Abstract available


  266. UHER T, McComb M, Galkin S, Srpova B, et al
    Neurofilament levels are associated with blood-brain barrier integrity, lymphocyte extravasation, and risk factors following the first demyelinating event in multiple sclerosis.
    Mult Scler. 2020 Apr 7:1352458520912379. doi: 10.1177/1352458520912379.
    PubMed     Abstract available


  267. YUSUF F, Wijnands JM, Kingwell E, Zhu F, et al
    Fatigue, sleep disorders, anaemia and pain in the multiple sclerosis prodrome.
    Mult Scler. 2020 Apr 6:1352458520908163. doi: 10.1177/1352458520908163.
    PubMed     Abstract available


  268. BELBASIS L, Bellou V, Evangelou E, Tzoulaki I, et al
    Environmental factors and risk of multiple sclerosis: Findings from meta-analyses and Mendelian randomization studies.
    Mult Scler. 2020;26:397-404.
    PubMed     Abstract available


  269. SOLOMON AJ
    Progress towards a diagnostic biomarker for MS: Central vein sign.
    Mult Scler. 2020;26:394-396.
    PubMed    


  270. LEVY M
    Expanding the spectrum of MOG antibody disease.
    Mult Scler. 2020;26:515-516.
    PubMed    


    March 2020
  271. HEALY BC, Barker L, Bakshi R, Benedict RHB, et al
    Trajectories of Symbol Digit Modalities Test performance in individuals with multiple sclerosis.
    Mult Scler. 2020 Mar 31:1352458520913439. doi: 10.1177/1352458520913439.
    PubMed     Abstract available


  272. TREMLETT H, Marrie RA
    The multiple sclerosis prodrome: Emerging evidence, challenges, and opportunities.
    Mult Scler. 2020 Mar 31:1352458520914844. doi: 10.1177/1352458520914844.
    PubMed     Abstract available


  273. MOTL RW, Sandroff BM, Benedict RH, Hubbard EM, et al
    Do subcortical gray matter volumes and aerobic capacity account for cognitive-motor coupling in multiple sclerosis?
    Mult Scler. 2020 Mar 31:1352458520914822. doi: 10.1177/1352458520914822.
    PubMed     Abstract available


  274. DEMORTIERE S, Rico A, Maarouf A, Boutiere C, et al
    Maintenance of natalizumab during the first trimester of pregnancy in active multiple sclerosis.
    Mult Scler. 2020 Mar 23:1352458520912637. doi: 10.1177/1352458520912637.
    PubMed     Abstract available


  275. JACOBS BM, Giovannoni G, Cuzick J, Dobson R, et al
    Systematic review and meta-analysis of the association between Epstein-Barr virus, multiple sclerosis and other risk factors.
    Mult Scler. 2020 Mar 23:1352458520907901. doi: 10.1177/1352458520907901.
    PubMed     Abstract available


  276. DADAR M, Narayanan S, Arnold DL, Collins DL, et al
    Conversion of diffusely abnormal white matter to focal lesions is linked to progression in secondary progressive multiple sclerosis.
    Mult Scler. 2020 Mar 23:1352458520912172. doi: 10.1177/1352458520912172.
    PubMed     Abstract available


  277. OTURAI DB, Bach Sondergaard H, Koch-Henriksen N, Andersen C, et al
    Exposure to passive smoking during adolescence is associated with an increased risk of developing multiple sclerosis.
    Mult Scler. 2020 Mar 23:1352458520912500. doi: 10.1177/1352458520912500.
    PubMed     Abstract available


  278. PEREZ T, Rico A, Boutiere C, Maarouf A, et al
    Comparison of rituximab originator (MabThera((R))) to biosimilar (Truxima((R))) in patients with multiple sclerosis.
    Mult Scler. 2020 Mar 17:1352458520912170. doi: 10.1177/1352458520912170.
    PubMed     Abstract available


  279. SOLOMON AJ, Pettigrew R, Naismith RT, Chahin S, et al
    Challenges in multiple sclerosis diagnosis: Misunderstanding and misapplication of the McDonald criteria.
    Mult Scler. 2020 Mar 12:1352458520910496. doi: 10.1177/1352458520910496.
    PubMed     Abstract available


  280. SMITH KA, Burkill S, Hiyoshi A, Olsson T, et al
    Comorbid disease burden among MS patients 1968-2012: A Swedish register-based cohort study.
    Mult Scler. 2020 Mar 12:1352458520910497. doi: 10.1177/1352458520910497.
    PubMed     Abstract available


  281. BERTOLI M, Tecchio F
    Fatigue in multiple sclerosis: Does the functional or structural damage prevail?
    Mult Scler. 2020 Mar 12:1352458520912175. doi: 10.1177/1352458520912175.
    PubMed     Abstract available


  282. DALGAS U, Hvid LG, Kwakkel G, Motl RW, et al
    Moving exercise research in multiple sclerosis forward (the MoXFo initiative): Developing consensus statements for research.
    Mult Scler. 2020 Mar 12:1352458520910360. doi: 10.1177/1352458520910360.
    PubMed     Abstract available


  283. NG HS, Kingwell E, Zhu F, Zhang T, et al
    Adherence to laboratory monitoring among people taking oral drugs for multiple sclerosis: A Canadian population-based study.
    Mult Scler. 2020 Mar 6:1352458520910500. doi: 10.1177/1352458520910500.
    PubMed     Abstract available


  284. ABDEL-MANNAN O, Cortese R, Wassmer E, Hemingway C, et al
    Primary progressive multiple sclerosis presenting under the age of 18 years: Fact or fiction?
    Mult Scler. 2020 Mar 3:1352458520910361. doi: 10.1177/1352458520910361.
    PubMed     Abstract available


  285. FUJIHARA K
    MOG-antibody-associated disease is different from MS and NMOSD and should be classified as a distinct disease entity - Commentary.
    Mult Scler. 2020;26:276-278.
    PubMed    


  286. LEITE MI, Sato DK
    MOG-antibody-associated disease is different from MS and NMOSD and should be considered as a distinct disease entity - Yes.
    Mult Scler. 2020;26:272-274.
    PubMed    


  287. COBO-CALVO A, Marignier R
    MOG-antibody-associated disease is different from MS and NMO and should be considered as a distinct disease entity - No.
    Mult Scler. 2020;26:274-276.
    PubMed    


  288. DURAND-DUBIEF F, Marignier R, Berthezene Y, Cottin J, et al
    Spontaneous multiple cervical artery dissections after alemtuzumab.
    Mult Scler. 2020;26:381-383.
    PubMed     Abstract available


  289. CHIARAVALLOTI ND, Moore NB, DeLuca J
    The efficacy of the modified Story Memory Technique in progressive MS.
    Mult Scler. 2020;26:354-362.
    PubMed     Abstract available


  290. ROSSOR T, Benetou C, Wright S, Duignan S, et al
    Early predictors of epilepsy and subsequent relapse in children with acute disseminated encephalomyelitis.
    Mult Scler. 2020;26:333-342.
    PubMed     Abstract available


    February 2020
  291. SECHI E, Krecke KN, Pittock SJ, Dubey D, et al
    Frequency and characteristics of MRI-negative myelitis associated with MOG autoantibodies.
    Mult Scler. 2020 Feb 27:1352458520907900. doi: 10.1177/1352458520907900.
    PubMed     Abstract available


  292. POVOLO CA, Reid JN, Shariff SZ, Welk B, et al
    Concussion in adolescence and the risk of multiple sclerosis: A retrospective cohort study.
    Mult Scler. 2020 Feb 24:1352458520908037. doi: 10.1177/1352458520908037.
    PubMed     Abstract available


  293. FONDERICO M, Biagioli T, Lanzilao L, Bellinvia A, et al
    Prognostic role of intrathecal IgM synthesis in multiple sclerosis: Results from a clinical series.
    Mult Scler. 2020 Feb 24:1352458520907913. doi: 10.1177/1352458520907913.
    PubMed     Abstract available


  294. HORISBERGER A, Pantazou V, Cuendet G, Ribi C, et al
    ANCA-associated life-threatening systemic vasculitis after alemtuzumab treatment for multiple sclerosis.
    Mult Scler. 2020 Feb 21:1352458519895449. doi: 10.1177/1352458519895449.
    PubMed     Abstract available


  295. BIGAUT K, Lambert C, Kremer L, Lebrun C, et al
    Atypical myelitis in patients with multiple sclerosis: Characterization and comparison with typical multiple sclerosis and neuromyelitis optica spectrum disorders.
    Mult Scler. 2020 Feb 20:1352458520906995. doi: 10.1177/1352458520906995.
    PubMed     Abstract available


  296. MAHLANZA TD, Manieri MC, Klawiter EC, Solomon AJ, et al
    Prospective growth and developmental outcomes in infants born to mothers with multiple sclerosis.
    Mult Scler. 2020 Feb 17:1352458520904545. doi: 10.1177/1352458520904545.
    PubMed     Abstract available


  297. MCKEON A, Zekeridou A
    Autoimmune encephalitis management: MS centers and beyond.
    Mult Scler. 2020 Feb 13:1352458520905485. doi: 10.1177/1352458520905485.
    PubMed     Abstract available


  298. SERRA A, Petzold A
    Can stability of visual fixation be a measure for disability in multiple sclerosis?
    Mult Scler. 2020 Feb 7:1352458520903296. doi: 10.1177/1352458520903296.
    PubMed    


  299. SHEEHY CK, Bensinger ES, Romeo A, Rani L, et al
    Fixational microsaccades: A quantitative and objective measure of disability in multiple sclerosis.
    Mult Scler. 2020 Feb 7:1352458519894712. doi: 10.1177/1352458519894712.
    PubMed     Abstract available


  300. BSTEH G, Berger T
    Commentary on "Lymphocytic colitis in the setting of teriflunomide use for relapsing multiple sclerosis".
    Mult Scler. 2020 Feb 7:1352458520904546. doi: 10.1177/1352458520904546.
    PubMed    


  301. SON M, McEwan L, Ubaidat M, Bovell K, et al
    Lymphocytic colitis in the setting of teriflunomide use for relapsing multiple sclerosis.
    Mult Scler. 2020 Feb 7:1352458519900961. doi: 10.1177/1352458519900961.
    PubMed     Abstract available


  302. BISTROM M, Hultdin J, Andersen O, Alonso-Magdalena L, et al
    Leptin levels are associated with multiple sclerosis risk.
    Mult Scler. 2020 Feb 7:1352458520905033. doi: 10.1177/1352458520905033.
    PubMed     Abstract available


  303. BOUVET L, Chassard D
    Is neuraxial anesthesia not associated with increased risk of post-partum relapses in multiple sclerosis? More precise assessment is required.
    Mult Scler. 2020 Feb 5:1352458519898344. doi: 10.1177/1352458519898344.
    PubMed    


  304. MARIOTTINI A, Filippini S, Innocenti C, Forci B, et al
    Impact of autologous haematopoietic stem cell transplantation on disability and brain atrophy in secondary progressive multiple sclerosis.
    Mult Scler. 2020 Feb 3:1352458520902392. doi: 10.1177/1352458520902392.
    PubMed     Abstract available


  305. ABSINTA M, Ontaneda D
    Controversial association between leptomeningeal enhancement and demyelinated cortical lesions in multiple sclerosis.
    Mult Scler. 2020;26:135-136.
    PubMed    


  306. THOMPSON AJ, Cohen JA, Kim HJ, Geurts J, et al
    MSJ 2020 - Editorial comment.
    Mult Scler. 2020;26:134.
    PubMed    


  307. LUBLIN F
    Real-world studies provide reliable comparisons of disease modifying therapies in MS - Commentary.
    Mult Scler. 2020;26:163-164.
    PubMed    


  308. SORMANI MP
    Real-world studies provide reliable comparisons of disease modifying therapies in MS - No.
    Mult Scler. 2020;26:161-162.
    PubMed    


  309. KALINCIK T
    Real-world studies provide reliable comparisons of disease modifying therapies in MS - Yes.
    Mult Scler. 2020;26:159-161.
    PubMed    


    January 2020
  310. CHARABATI M, Donkers SJ, Kirkland MC, Osborne LC, et al
    A critical analysis of helminth immunotherapy in multiple sclerosis.
    Mult Scler. 2020 Jan 23:1352458519899040. doi: 10.1177/1352458519899040.
    PubMed     Abstract available


  311. PALOTAI M, Cavallari M, Healy BC, Guttmann CR, et al
    A novel classification of fatigue in multiple sclerosis based on longitudinal assessments.
    Mult Scler. 2020 Jan 23:1352458519898112. doi: 10.1177/1352458519898112.
    PubMed     Abstract available


  312. BENEDICT RH, Pol J, Yasin F, Hojnacki D, et al
    Recovery of cognitive function after relapse in multiple sclerosis.
    Mult Scler. 2020 Jan 23:1352458519898108. doi: 10.1177/1352458519898108.
    PubMed     Abstract available


  313. CHITNIS T, Prat A
    A roadmap to precision medicine for multiple sclerosis.
    Mult Scler. 2020 Jan 22:1352458519881558. doi: 10.1177/1352458519881558.
    PubMed     Abstract available


  314. BOSE G, Freedman MS
    Precision medicine in the multiple sclerosis clinic: Selecting the right patient for the right treatment.
    Mult Scler. 2020 Jan 22:1352458519887324. doi: 10.1177/1352458519887324.
    PubMed     Abstract available


  315. MYCKO MP, Baranzini SE
    microRNA and exosome profiling in multiple sclerosis.
    Mult Scler. 2020 Jan 22:1352458519879303. doi: 10.1177/1352458519879303.
    PubMed     Abstract available


  316. VOSKUHL RR
    The effect of sex on multiple sclerosis risk and disease progression.
    Mult Scler. 2020 Jan 22:1352458519892491. doi: 10.1177/1352458519892491.
    PubMed     Abstract available


  317. PATSOPOULOS NA, De Jager PL
    Genetic and gene expression signatures in multiple sclerosis.
    Mult Scler. 2020 Jan 22:1352458519898332. doi: 10.1177/1352458519898332.
    PubMed     Abstract available


  318. BHARGAVA P, Anthony D
    Metabolomics in multiple sclerosis disease course and progression.
    Mult Scler. 2020 Jan 22:1352458519876020. doi: 10.1177/1352458519876020.
    PubMed     Abstract available


  319. KISTER I, Kantarci OH
    Multiple Sclerosis Severity Score: Concept and applications.
    Mult Scler. 2020 Jan 22:1352458519880125. doi: 10.1177/1352458519880125.
    PubMed     Abstract available


  320. CARNERO CONTENTTI E, Giachello S, Correale J
    Barriers to access and utilization of multiple sclerosis care services in a large cohort of Latin American patients.
    Mult Scler. 2020 Jan 21:1352458519898590. doi: 10.1177/1352458519898590.
    PubMed     Abstract available


  321. SRPOVA B, Uher T, Hrnciarova T, Barro C, et al
    Serum neurofilament light chain reflects inflammation-driven neurodegeneration and predicts delayed brain volume loss in early stage of multiple sclerosis.
    Mult Scler. 2020 Jan 21:1352458519901272. doi: 10.1177/1352458519901272.
    PubMed     Abstract available


  322. CORTESE R, Tur C, Prados F, Schneider T, et al
    Ongoing microstructural changes in the cervical cord underpin disability progression in early primary progressive multiple sclerosis.
    Mult Scler. 2020 Jan 21:1352458519900971. doi: 10.1177/1352458519900971.
    PubMed     Abstract available


  323. MCDONELL J, Costello K, Laurson-Doube J, Rijke N, et al
    World Health Organization Essential Medicines List: Multiple sclerosis disease-modifying therapies application.
    Mult Scler. 2020 Jan 16:1352458519898340. doi: 10.1177/1352458519898340.
    PubMed     Abstract available


  324. SALTER A, Fox RJ, Tyry T, Cutter G, et al
    New applications for independent activities of daily living in measuring disability in multiple sclerosis.
    Mult Scler. 2020 Jan 14:1352458519898591. doi: 10.1177/1352458519898591.
    PubMed     Abstract available


  325. WARNKE C, Hartung HP
    Big data in MS-What can we learn from large international observational studies such as MSBase?
    Mult Scler. 2020;26:4-5.
    PubMed    


  326. REDDEL SW
    Clinical commentary on 'Post-mortem diagnosis of invasive pulmonary aspergillosis after alemtuzumab treatment for multiple sclerosis'.
    Mult Scler. 2020;26:126-127.
    PubMed    


  327. VUKUSIC S, Casey R, Rollot F, Brochet B, et al
    Observatoire Francais de la Sclerose en Plaques (OFSEP): A unique multimodal nationwide MS registry in France.
    Mult Scler. 2020;26:118-122.
    PubMed     Abstract available


  328. MELI R, Roccatagliata L, Capello E, Bruschi N, et al
    Ecological impact of isolated cognitive relapses in MS.
    Mult Scler. 2020;26:114-117.
    PubMed     Abstract available


  329. AOYAMA S, Mori M, Uzawa A, Uchida T, et al
    Serum anti-John Cunningham virus antibody seroprevalence and index among Japanese patients with neuromyelitis optica spectrum disorders.
    Mult Scler. 2020;26:128-129.
    PubMed    


    December 2019
  330. CROUSE DL, Foroughi I, Gupta N
    Neighbourhood environments and the risk of hospital admission for cardiometabolic and mental health comorbidities in multiple sclerosis: A population cohort analysis using linked administrative data.
    Mult Scler. 2019 Dec 20:1352458519895985. doi: 10.1177/1352458519895985.
    PubMed     Abstract available


  331. COULOUME L, Barbin L, Leray E, Wiertlewski S, et al
    High-dose biotin in progressive multiple sclerosis: A prospective study of 178 patients in routine clinical practice.
    Mult Scler. 2019 Dec 17:1352458519894713. doi: 10.1177/1352458519894713.
    PubMed     Abstract available


  332. KALKERS NF, Galan I, Kerbrat A, Tacchino A, et al
    Differential item functioning of the Arm function in Multiple Sclerosis Questionnaire (AMSQ) by language, a study in six countries.
    Mult Scler. 2019 Dec 17:1352458519895450. doi: 10.1177/1352458519895450.
    PubMed     Abstract available


  333. KVISTAD SAS, Lehmann AK, Trovik LH, Kristoffersen EK, et al
    Safety and efficacy of autologous hematopoietic stem cell transplantation for multiple sclerosis in Norway.
    Mult Scler. 2019 Dec 13:1352458519893926. doi: 10.1177/1352458519893926.
    PubMed     Abstract available


  334. HOLTON KF, Kirkland AE
    Moving past antioxidant supplementation for the dietary treatment of multiple sclerosis.
    Mult Scler. 2019 Dec 11:1352458519893925. doi: 10.1177/1352458519893925.
    PubMed     Abstract available


  335. RAHNAMA'I MS
    Neuromodulation for functional bladder disorders in patients with multiple sclerosis.
    Mult Scler. 2019 Dec 9:1352458519894714. doi: 10.1177/1352458519894714.
    PubMed     Abstract available


  336. BISECCO A, Capuano R, Caiazzo G, d'Ambrosio A, et al
    Regional changes in thalamic shape and volume are related to cognitive performance in multiple sclerosis.
    Mult Scler. 2019 Dec 3:1352458519892552. doi: 10.1177/1352458519892552.
    PubMed     Abstract available


  337. HARDY TA
    Regulatory B cells: The key to post-alemtuzumab rebound phenomena in multiple sclerosis?
    Mult Scler. 2019;25:1945-1946.
    PubMed    


    November 2019
  338. GONZALEZ CAMPO C, Salamone PC, Rodriguez-Arriagada N, Richter F, et al
    Fatigue in multiple sclerosis is associated with multimodal interoceptive abnormalities.
    Mult Scler. 2019 Nov 28:1352458519888881. doi: 10.1177/1352458519888881.
    PubMed     Abstract available


  339. COHEN JA, Trojano M, Mowry EM, Uitdehaag BM, et al
    Leveraging real-world data to investigate multiple sclerosis disease behavior, prognosis, and treatment.
    Mult Scler. 2019 Nov 28:1352458519892555. doi: 10.1177/1352458519892555.
    PubMed     Abstract available


  340. WALLACH AI, Waltz M, Casper TC, Aaen G, et al
    Cognitive processing speed in pediatric-onset multiple sclerosis: Baseline characteristics of impairment and prediction of decline.
    Mult Scler. 2019 Nov 28:1352458519891984. doi: 10.1177/1352458519891984.
    PubMed     Abstract available


  341. LI CMF, Hung PS, Chu PP, Tohyama S, et al
    Trigeminal neuralgia associated with multiple sclerosis: A multimodal assessment of brainstem plaques and response to Gamma Knife radiosurgery.
    Mult Scler. 2019 Nov 26:1352458519886070. doi: 10.1177/1352458519886070.
    PubMed     Abstract available


  342. COMI G, Alroughani R, Boster AL, Bass AD, et al
    Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies.
    Mult Scler. 2019 Nov 25:1352458519888610. doi: 10.1177/1352458519888610.
    PubMed     Abstract available


  343. KIM JE, Park SH, Han K, Kim HJ, et al
    Prevalence and incidence of neuromyelitis optica spectrum disorder and multiple sclerosis in Korea.
    Mult Scler. 2019 Nov 21:1352458519888609. doi: 10.1177/1352458519888609.
    PubMed     Abstract available


  344. BRANDSTADTER R, Fabian M, Leavitt VM, Krieger S, et al
    Word-finding difficulty is a prevalent disease-related deficit in early multiple sclerosis.
    Mult Scler. 2019 Nov 19:1352458519881760. doi: 10.1177/1352458519881760.
    PubMed     Abstract available


  345. BAETGE SJ, Filser M, Renner A, Ullrich S, et al
    On the validity of single tests, two-test combinations and the full Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) in detecting patients with cognitive impairment.
    Mult Scler. 2019 Nov 19:1352458519887897. doi: 10.1177/1352458519887897.
    PubMed     Abstract available


  346. ZURAWSKI J, Tauhid S, Chu R, Khalid F, et al
    7T MRI cerebral leptomeningeal enhancement is common in relapsing-remitting multiple sclerosis and is associated with cortical and thalamic lesions.
    Mult Scler. 2019 Nov 12:1352458519885106. doi: 10.1177/1352458519885106.
    PubMed     Abstract available


  347. BOESEN F, Norgaard M, Skjerbaek AG, Rasmussen PV, et al
    Can inpatient multidisciplinary rehabilitation improve health-related quality of life in MS patients on the long term - The Danish MS Hospitals Rehabilitation Study.
    Mult Scler. 2019 Nov 5:1352458519884244. doi: 10.1177/1352458519884244.
    PubMed     Abstract available


  348. PELLEGRINI F, Copetti M, Sormani MP, Bovis F, et al
    Predicting disability progression in multiple sclerosis: Insights from advanced statistical modeling.
    Mult Scler. 2019 Nov 5:1352458519887343. doi: 10.1177/1352458519887343.
    PubMed     Abstract available


  349. CORDANI C, Valsasina P, Preziosa P, Meani A, et al
    Action observation training promotes motor improvement and modulates functional network dynamic connectivity in multiple sclerosis.
    Mult Scler. 2019 Nov 5:1352458519887332. doi: 10.1177/1352458519887332.
    PubMed     Abstract available


  350. COLLORONE S, Cawley N, Grussu F, Prados F, et al
    Reduced neurite density in the brain and cervical spinal cord in relapsing-remitting multiple sclerosis: A NODDI study.
    Mult Scler. 2019 Nov 4:1352458519885107. doi: 10.1177/1352458519885107.
    PubMed     Abstract available


  351. MILO R, Korczyn AD, Manouchehri N, Stuve O, et al
    The temporal and causal relationship between inflammation and neurodegeneration in multiple sclerosis.
    Mult Scler. 2019 Nov 4:1352458519886943. doi: 10.1177/1352458519886943.
    PubMed     Abstract available


  352. NAISMITH RT, Wolinsky JS, Wundes A, LaGanke C, et al
    Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study.
    Mult Scler. 2019 Nov 4:1352458519881761. doi: 10.1177/1352458519881761.
    PubMed     Abstract available


  353. KUHLE J, Plavina T, Barro C, Disanto G, et al
    Neurofilament light levels are associated with long-term outcomes in multiple sclerosis.
    Mult Scler. 2019 Nov 4:1352458519885613. doi: 10.1177/1352458519885613.
    PubMed     Abstract available


  354. VAN WIJMEERSCH B, Singer BA, Boster A, Broadley S, et al
    Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies.
    Mult Scler. 2019 Nov 1:1352458519881759. doi: 10.1177/1352458519881759.
    PubMed     Abstract available


  355. MOSTERT JP, De Keyser J
    Response to Grech et al.: FLOUX-PMS study sample considerations.
    Mult Scler. 2019;25:1820-1821.
    PubMed    


  356. GRECH LB, Butler E, Stuckey S, Hester R, et al
    Letter to the editor: FLOUX-PMS study sample considerations.
    Mult Scler. 2019;25:1819-1820.
    PubMed    


    October 2019
  357. RYAN JM, Fortune J, Stennett A, Kilbride C, et al
    Safety, feasibility, acceptability and effects of a behaviour-change intervention to change physical activity behaviour among people with multiple sclerosis: Results from the iStep-MS randomised controlled trial.
    Mult Scler. 2019 Oct 31:1352458519886231. doi: 10.1177/1352458519886231.
    PubMed     Abstract available


  358. LEAVITT VM, Riley CS, De Jager PL, Bloom S, et al
    eSupport: Feasibility trial of telehealth support group participation to reduce loneliness in multiple sclerosis.
    Mult Scler. 2019 Oct 31:1352458519884241. doi: 10.1177/1352458519884241.
    PubMed     Abstract available


  359. ZHOU Y, Claflin SB, Stankovich J, van der Mei I, et al
    Redefining the Multiple Sclerosis Severity Score (MSSS): The effect of sex and onset phenotype.
    Mult Scler. 2019 Oct 31:1352458519881994. doi: 10.1177/1352458519881994.
    PubMed     Abstract available


  360. CLARKE MA, Samaraweera AP, Falah Y, Pitiot A, et al
    Single Test to ARrive at Multiple Sclerosis (STAR-MS) diagnosis: A prospective pilot study assessing the accuracy of the central vein sign in predicting multiple sclerosis in cases of diagnostic uncertainty.
    Mult Scler. 2019 Oct 31:1352458519882282. doi: 10.1177/1352458519882282.
    PubMed     Abstract available


  361. BSTEH G, Berek K, Hegen H, Teuchner B, et al
    Serum neurofilament levels correlate with retinal nerve fiber layer thinning in multiple sclerosis.
    Mult Scler. 2019 Oct 31:1352458519882279. doi: 10.1177/1352458519882279.
    PubMed     Abstract available


  362. WOJCIK CM, Beier M, Costello K, DeLuca J, et al
    Computerized neuropsychological assessment devices in multiple sclerosis: A systematic review.
    Mult Scler. 2019 Oct 22:1352458519879094. doi: 10.1177/1352458519879094.
    PubMed     Abstract available


  363. CHITNIS T
    Serum NFL levels should be used to monitor multiple sclerosis evolution - Commentary.
    Mult Scler. 2019 Oct 18:1352458519880471. doi: 10.1177/1352458519880471.
    PubMed    


  364. MYHR KM, Torkildsen O
    Serum NFL levels should be used to monitor multiple sclerosis evolution - No.
    Mult Scler. 2019 Oct 18:1352458519872891. doi: 10.1177/1352458519872891.
    PubMed    


  365. LEPPERT D, Kuhle J
    Serum NfL levels should be used to monitor multiple sclerosis evolution - Yes.
    Mult Scler. 2019 Oct 18:1352458519872921. doi: 10.1177/1352458519872921.
    PubMed    


  366. JOHANSSON S, Ytterberg C, Gottberg K, Holmqvist LW, et al
    Participation in social/lifestyle activities in people with multiple sclerosis: Changes across 10 years and predictors of sustained participation.
    Mult Scler. 2019 Oct 17:1352458519881991. doi: 10.1177/1352458519881991.
    PubMed     Abstract available


  367. BILODEAU PA, Kumar V, Rodriguez AE, Li CT, et al
    MOG-IgG myelitis coexisting with systemic lupus erythematosus in the post-partum setting.
    Mult Scler. 2019 Oct 17:1352458519872895. doi: 10.1177/1352458519872895.
    PubMed     Abstract available


  368. MANEZ-MIRO JU, Martinez-Fernandez R, Del Alamo M, Pineda-Pardo JA, et al
    Focused ultrasound thalamotomy for multiple sclerosis-associated tremor.
    Mult Scler. 2019 Oct 16:1352458519861597. doi: 10.1177/1352458519861597.
    PubMed     Abstract available


  369. JAKIMOVSKI D, Zivadinov R, Ramanthan M, Hagemeier J, et al
    Serum neurofilament light chain level associations with clinical and cognitive performance in multiple sclerosis: A longitudinal retrospective 5-year study.
    Mult Scler. 2019 Oct 15:1352458519881428. doi: 10.1177/1352458519881428.
    PubMed     Abstract available


  370. DAMASCENO A, Pimentel-Silva LR, Damasceno BP, Cendes F, et al
    Cognitive trajectories in relapsing-remitting multiple sclerosis: A longitudinal 6-year study.
    Mult Scler. 2019 Oct 11:1352458519878685. doi: 10.1177/1352458519878685.
    PubMed     Abstract available


  371. BIANCHI A, Ciccarelli O
    Daclizumab-induced encephalitis in multiple sclerosis.
    Mult Scler. 2019;25:1557-1559.
    PubMed    


  372. IGHANI M, Jonas S, Izbudak I, Choi S, et al
    No association between cortical lesions and leptomeningeal enhancement on 7-Tesla MRI in multiple sclerosis.
    Mult Scler. 2019 Oct 1:1352458519876037. doi: 10.1177/1352458519876037.
    PubMed     Abstract available


  373. GRYTTEN N, Myhr KM, Celius EG, Benjaminsen E, et al
    Risk of cancer among multiple sclerosis patients, siblings, and population controls: A prospective cohort study.
    Mult Scler. 2019 Oct 1:1352458519877244. doi: 10.1177/1352458519877244.
    PubMed     Abstract available


  374. ZECCA C, Bovis F, Novi G, Capobianco M, et al
    Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience.
    Mult Scler. 2019 Oct 1:1352458519872889. doi: 10.1177/1352458519872889.
    PubMed     Abstract available


  375. MACARON G, Ontaneda D
    Clinical commentary on "Warts and all: Fingolimod and unusual HPV associated lesions".
    Mult Scler. 2019;25:1550-1552.
    PubMed    


  376. BERGER JR
    PML with dimethyl fumarate-No role for natalizumab?
    Mult Scler. 2019;25:1686-1687.
    PubMed    


    September 2019
  377. PALOTAI M, Guttmann CR
    Brain anatomical correlates of fatigue in multiple sclerosis.
    Mult Scler. 2019 Sep 19:1352458519876032. doi: 10.1177/1352458519876032.
    PubMed     Abstract available


  378. MAGGI P, Absinta M, Sati P, Perrotta G, et al
    The "central vein sign" in patients with diagnostic "red flags" for multiple sclerosis: A prospective multicenter 3T study.
    Mult Scler. 2019 Sep 19:1352458519876031. doi: 10.1177/1352458519876031.
    PubMed     Abstract available


  379. MARRIE RA, Tremlett H, Kingwell E, Schaffer SA, et al
    Disparities in management and outcomes of myocardial infarction in multiple sclerosis: A matched cohort study.
    Mult Scler. 2019 Sep 13:1352458519876038. doi: 10.1177/1352458519876038.
    PubMed     Abstract available


  380. VAN GEEL F, Veldkamp R, Severijns D, Dalgas U, et al
    Day-to-day reliability, agreement and discriminative validity of measuring walking-related performance fatigability in persons with multiple sclerosis.
    Mult Scler. 2019 Sep 9:1352458519872465. doi: 10.1177/1352458519872465.
    PubMed     Abstract available


  381. BRANDSTADTER R, Katz Sand I, Sumowski JF
    Beyond rehabilitation: A prevention model of reserve and brain maintenance in multiple sclerosis.
    Mult Scler. 2019;25:1372-1378.
    PubMed     Abstract available


  382. WEBER E, Goverover Y, DeLuca J
    Beyond cognitive dysfunction: Relevance of ecological validity of neuropsychological tests in multiple sclerosis.
    Mult Scler. 2019;25:1412-1419.
    PubMed     Abstract available


    August 2019
  383. PALOTAI M, Cavallari M, Koubiyr I, Morales Pinzon A, et al
    Microstructural fronto-striatal and temporo-insular alterations are associated with fatigue in patients with multiple sclerosis independent of white matter lesion load and depression.
    Mult Scler. 2019 Aug 16:1352458519869185. doi: 10.1177/1352458519869185.
    PubMed     Abstract available


  384. FAMBIATOS A, Jokubaitis V, Horakova D, Kubala Havrdova E, et al
    Risk of secondary progressive multiple sclerosis: A longitudinal study.
    Mult Scler. 2019 Aug 9:1352458519868990. doi: 10.1177/1352458519868990.
    PubMed     Abstract available


  385. PISA M, Ratti F, Vabanesi M, Radaelli M, et al
    Subclinical neurodegeneration in multiple sclerosis and neuromyelitis optica spectrum disorder revealed by optical coherence tomography.
    Mult Scler. 2019 Aug 8:1352458519861603. doi: 10.1177/1352458519861603.
    PubMed     Abstract available


  386. SIVAKOLUNDU DK, West KL, Maruthy GB, Zuppichini M, et al
    Reduced arterial compliance along the cerebrovascular tree predicts cognitive slowing in multiple sclerosis: Evidence for a neurovascular uncoupling hypothesis.
    Mult Scler. 2019 Aug 2:1352458519866605. doi: 10.1177/1352458519866605.
    PubMed     Abstract available


  387. KILLESTEIN J, van Oosten B
    Emerging safety issues in alemtuzumab-treated MS patients.
    Mult Scler. 2019;25:1206-1208.
    PubMed    


  388. HERRANZ E, Louapre C, Treaba CA, Govindarajan ST, et al
    Profiles of cortical inflammation in multiple sclerosis by (11)C-PBR28 MR-PET and 7 Tesla imaging.
    Mult Scler. 2019 Aug 1:1352458519867320. doi: 10.1177/1352458519867320.
    PubMed     Abstract available


  389. MCGINLEY MP, Cola PA, Fox RJ, Cohen JA, et al
    Perspectives of individuals with multiple sclerosis on discontinuation of disease-modifying therapies.
    Mult Scler. 2019 Aug 1:1352458519867314. doi: 10.1177/1352458519867314.
    PubMed     Abstract available


  390. BOVE R, Rankin K, Lin C, Zhao C, et al
    Effect of assisted reproductive technology on multiple sclerosis relapses: Case series and meta-analysis.
    Mult Scler. 2019 Aug 1:1352458519865118. doi: 10.1177/1352458519865118.
    PubMed     Abstract available


  391. BEECHAM AH, Amezcua L, Chinea A, Manrique CP, et al
    The genetic diversity of multiple sclerosis risk among Hispanic and African American populations living in the United States.
    Mult Scler. 2019 Aug 1:1352458519863764. doi: 10.1177/1352458519863764.
    PubMed     Abstract available


    July 2019
  392. SOTIRCHOS ES, Filippatou A, Fitzgerald KC, Salama S, et al
    Aquaporin-4 IgG seropositivity is associated with worse visual outcomes after optic neuritis than MOG-IgG seropositivity and multiple sclerosis, independent of macular ganglion cell layer thinning.
    Mult Scler. 2019 Jul 31:1352458519864928. doi: 10.1177/1352458519864928.
    PubMed     Abstract available


  393. SCHWEHR NA, Kuntz KM, Butler M, Enns EA, et al
    Age-related decreases in relapses among adults with relapsing-onset multiple sclerosis.
    Mult Scler. 2019 Jul 29:1352458519866613. doi: 10.1177/1352458519866613.
    PubMed     Abstract available


  394. CAMPBELL JA, Simpson S Jr, Ahmad H, Taylor BV, et al
    Change in multiple sclerosis prevalence over time in Australia 2010-2017 utilising disease-modifying therapy prescription data.
    Mult Scler. 2019 Jul 26:1352458519861270. doi: 10.1177/1352458519861270.
    PubMed     Abstract available


  395. LARSSON D, Akerfeldt T, Carlson K, Burman J, et al
    Intrathecal immunoglobulins and neurofilament light after autologous haematopoietic stem cell transplantation for multiple sclerosis.
    Mult Scler. 2019 Jul 26:1352458519863983. doi: 10.1177/1352458519863983.
    PubMed     Abstract available


  396. PRAVATA E, Valsasina P, Gobbi C, Zecca C, et al
    Influence of CNS T2-focal lesions on cervical cord atrophy and disability in multiple sclerosis.
    Mult Scler. 2019 Jul 26:1352458519865989. doi: 10.1177/1352458519865989.
    PubMed     Abstract available


  397. CALLESEN J, Cattaneo D, Brincks J, Kjeldgaard Jorgensen ML, et al
    How do resistance training and balance and motor control training affect gait performance and fatigue impact in people with multiple sclerosis? A randomized controlled multi-center study.
    Mult Scler. 2019 Jul 24:1352458519865740. doi: 10.1177/1352458519865740.
    PubMed     Abstract available


  398. BRIGGS FB, Hill E
    Estimating the prevalence of multiple sclerosis using 56.6 million electronic health records from the United States.
    Mult Scler. 2019 Jul 24:1352458519864681. doi: 10.1177/1352458519864681.
    PubMed     Abstract available


  399. HACOHEN Y, Brownlee W, Mankad K, Chong WK', et al
    Improved performance of the 2017 McDonald criteria for diagnosis of multiple sclerosis in children in a real-life cohort.
    Mult Scler. 2019 Jul 18:1352458519863781. doi: 10.1177/1352458519863781.
    PubMed     Abstract available


  400. CAMARA-LEMARROY CR, Silva C, Greenfield J, Liu WQ, et al
    Biomarkers of intestinal barrier function in multiple sclerosis are associated with disease activity.
    Mult Scler. 2019 Jul 18:1352458519863133. doi: 10.1177/1352458519863133.
    PubMed     Abstract available


  401. WARNKE C, Hartung HP
    Challenging a concept: Pulsed treatment regimen-No risk of PML?
    Mult Scler. 2019;25:1076-1078.
    PubMed    


  402. GEREVINI S, Capra R, Bertoli D, Sottini A, et al
    Immune profiling of a patient with alemtuzumab-associated progressive multifocal leukoencephalopathy.
    Mult Scler. 2019;25:1196-1201.
    PubMed     Abstract available


  403. PREZIOSA P, Rocca MA, Filippi M
    PET is necessary to make the next step forward in understanding MS pathophysiology - No.
    Mult Scler. 2019;25:1088-1090.
    PubMed    


  404. BODINI B, Stankoff B
    PET is necessary to make the next step forward in understanding MS pathophysiology - Yes.
    Mult Scler. 2019;25:1086-1087.
    PubMed    


  405. KUMAR N, Abboud H
    Iatrogenic CNS demyelination in the era of modern biologics.
    Mult Scler. 2019;25:1079-1085.
    PubMed     Abstract available


  406. COMBES B, Kerbrat A, Ferre JC, Callot V, et al
    Focal and diffuse cervical spinal cord damage in patients with early relapsing-remitting MS: A multicentre magnetisation transfer ratio study.
    Mult Scler. 2019;25:1113-1123.
    PubMed     Abstract available


  407. BICHUETTI DB, Perin MMM, Souza NA, Oliveira EML, et al
    Treating neuromyelitis optica with azathioprine: 20-year clinical practice.
    Mult Scler. 2019;25:1150-1161.
    PubMed     Abstract available


  408. KANG Y, Gauthier SA
    PET is necessary to make the next step forward in understanding MS pathophysiology - Commentary.
    Mult Scler. 2019;25:1090-1091.
    PubMed    


    June 2019
  409. DE LOTT LB, Zerafa S, Shedden K, Dunietz GL, et al
    Multiple sclerosis relapse risk in the postoperative period: Effects of invasive surgery and anesthesia.
    Mult Scler. 2019 Jun 25:1352458519860304. doi: 10.1177/1352458519860304.
    PubMed     Abstract available


  410. INEICHEN BV, Moridi T, Granberg T, Piehl F, et al
    Rituximab treatment for multiple sclerosis.
    Mult Scler. 2019 Jun 25:1352458519858604. doi: 10.1177/1352458519858604.
    PubMed     Abstract available


  411. GHEZZI L, Cantoni C, Cignarella F, Bollman B, et al
    T cells producing GM-CSF and IL-13 are enriched in the cerebrospinal fluid of relapsing MS patients.
    Mult Scler. 2019 Jun 25:1352458519852092. doi: 10.1177/1352458519852092.
    PubMed     Abstract available


  412. LEAVITT VM, Brandstadter R, Fabian M, Katz Sand I, et al
    Dissociable cognitive patterns related to depression and anxiety in multiple sclerosis.
    Mult Scler. 2019 Jun 24:1352458519860319. doi: 10.1177/1352458519860319.
    PubMed     Abstract available


  413. PERONI S, Sorosina M, Malhotra S, Clarelli F, et al
    A pharmacogenetic study implicates NINJ2 in the response to Interferon-beta in multiple sclerosis.
    Mult Scler. 2019 Jun 21:1352458519851428. doi: 10.1177/1352458519851428.
    PubMed     Abstract available


  414. MARCK CH, das Nair R, Grech LB, Borland R, et al
    Modifiable risk factors for poor health outcomes in multiple sclerosis: The urgent need for research to maximise smoking cessation success.
    Mult Scler. 2019 Jun 20:1352458519858730. doi: 10.1177/1352458519858730.
    PubMed     Abstract available


  415. FUCHS TA, Benedict RH, Wilding G, Wojcik C, et al
    Trait Conscientiousness predicts rate of brain atrophy in multiple sclerosis.
    Mult Scler. 2019 Jun 20:1352458519858605. doi: 10.1177/1352458519858605.
    PubMed     Abstract available


  416. CHATAWAY J, Weir CJ, Fox RJ
    The FLUOX-PMS trial: Underestimating the challenge in progressive multiple sclerosis trials.
    Mult Scler. 2019 Jun 20:1352458519856985. doi: 10.1177/1352458519856985.
    PubMed    


  417. CAMBRON M, Mostert J, D'Hooghe M, Nagels G, et al
    Fluoxetine in progressive multiple sclerosis: The FLUOX-PMS trial.
    Mult Scler. 2019 Jun 20:1352458519843051. doi: 10.1177/1352458519843051.
    PubMed     Abstract available


  418. SPRENGER T, Kappos L, Radue EW, Gaetano L, et al
    Association of brain volume loss and long-term disability outcomes in patients with multiple sclerosis treated with teriflunomide.
    Mult Scler. 2019 Jun 14:1352458519855722. doi: 10.1177/1352458519855722.
    PubMed     Abstract available


  419. GABR RE, Coronado I, Robinson M, Sujit SJ, et al
    Brain and lesion segmentation in multiple sclerosis using fully convolutional neural networks: A large-scale study.
    Mult Scler. 2019 Jun 13:1352458519856843. doi: 10.1177/1352458519856843.
    PubMed     Abstract available


  420. KLINEOVA S, Brandstadter R, Fabian MT, Sand IK, et al
    Psychological resilience is linked to motor strength and gait endurance in early multiple sclerosis.
    Mult Scler. 2019 Jun 7:1352458519852725. doi: 10.1177/1352458519852725.
    PubMed     Abstract available


  421. BROWN JWL, Prados Carrasco F, Eshaghi A, Sudre CH, et al
    Periventricular magnetisation transfer ratio abnormalities in multiple sclerosis improve after alemtuzumab.
    Mult Scler. 2019 Jun 6:1352458519852093. doi: 10.1177/1352458519852093.
    PubMed     Abstract available


  422. MARRIE RA, Dufault B, Tyry T, Cutter GR, et al
    Developing a crosswalk between the RAND-12 and the health utilities index for multiple sclerosis.
    Mult Scler. 2019 Jun 4:1352458519852722. doi: 10.1177/1352458519852722.
    PubMed     Abstract available


  423. STAMPANONI BASSI M, Iezzi E, Buttari F, Gilio L, et al
    Obesity worsens central inflammation and disability in multiple sclerosis.
    Mult Scler. 2019 Jun 4:1352458519853473. doi: 10.1177/1352458519853473.
    PubMed     Abstract available


  424. MESCHERIAKOVA JY, Verkerk J, Amin N, Uitterlinden AG, et al
    Response to Vilarino-Guell et al.
    Mult Scler. 2019;25:1013-1015.
    PubMed    


  425. SCALFARI A
    MS progression is predominantly driven by age-related mechanisms - YES.
    Mult Scler. 2019;25:902-904.
    PubMed    


  426. MCGINLEY M, Ontaneda D
    MS progression is predominantly driven by age-related mechanisms - NO.
    Mult Scler. 2019;25:904-906.
    PubMed    


  427. ROCCA MA, Savoldi F, Valsasina P, Radaelli M, et al
    Cross-modal plasticity among sensory networks in neuromyelitis optica spectrum disorders.
    Mult Scler. 2019;25:968-979.
    PubMed     Abstract available


  428. ZEYDAN B, Kantarci OH
    MS progression is predominantly driven by age-related mechanisms - Commentary.
    Mult Scler. 2019;25:906-908.
    PubMed    


    May 2019
  429. SCARPAZZA C, Signori A, Cosottini M, Sormani MP, et al
    Should frequent MRI monitoring be performed in natalizumab-treated MS patients? A contribution to a recent debate.
    Mult Scler. 2019 May 30:1352458519854162. doi: 10.1177/1352458519854162.
    PubMed     Abstract available


  430. AKGUN K, Ziemssen T
    Response to Hyun J.W. et al. "Longitudinal analysis of serum neurofilament light chain: A potential therapeutic monitoring biomarker for multiple sclerosis".
    Mult Scler. 2019 May 30:1352458519854263. doi: 10.1177/1352458519854263.
    PubMed    


  431. PELLEGRINI F, Copetti M, Bovis F, Cheng D, et al
    A proof-of-concept application of a novel scoring approach for personalized medicine in multiple sclerosis.
    Mult Scler. 2019 May 30:1352458519849513. doi: 10.1177/1352458519849513.
    PubMed     Abstract available


  432. ARROYO R, Bury DP, Guo JD, Margolin DH, et al
    Impact of alemtuzumab on health-related quality of life over 6 years in CARE-MS II trial extension patients with relapsing-remitting multiple sclerosis.
    Mult Scler. 2019 May 30:1352458519849796. doi: 10.1177/1352458519849796.
    PubMed     Abstract available


  433. MOBERG JY, Laursen B, Thygesen LC, Magyari M, et al
    Reproductive history of the Danish multiple sclerosis population: A register-based study.
    Mult Scler. 2019 May 30:1352458519851245. doi: 10.1177/1352458519851245.
    PubMed     Abstract available


  434. CAPONE F, Collorone S, Cortese R, Di Lazzaro V, et al
    Fatigue in multiple sclerosis: The role of thalamus.
    Mult Scler. 2019 May 29:1352458519851247. doi: 10.1177/1352458519851247.
    PubMed     Abstract available


  435. MCCOMBE PA
    Women who contributed to past research in multiple sclerosis.
    Mult Scler. 2019 May 28:1352458519846101. doi: 10.1177/1352458519846101.
    PubMed     Abstract available


  436. MARRIE RA
    Recognizing the diversity gap in multiple sclerosis.
    Mult Scler. 2019 May 28:1352458519850070. doi: 10.1177/1352458519850070.
    PubMed    


  437. AHRWEILLER K, Rousseau C, Le Page E, Bajeux E, et al
    Decreasing impact of late relapses on disability worsening in secondary progressive multiple sclerosis.
    Mult Scler. 2019 May 16:1352458519848090. doi: 10.1177/1352458519848090.
    PubMed     Abstract available


  438. MURPHY OC, Kwakyi O, Iftikhar M, Zafar S, et al
    Alterations in the retinal vasculature occur in multiple sclerosis and exhibit novel correlations with disability and visual function measures.
    Mult Scler. 2019 May 16:1352458519845116. doi: 10.1177/1352458519845116.
    PubMed     Abstract available


  439. PUGLIATTI M
    Changes in the sex ratio are a good indicator of changes in multiple sclerosis incidence - Commentary.
    Mult Scler. 2019 May 15:1352458519845114. doi: 10.1177/1352458519845114.
    PubMed    


  440. KOPP TI, Blinkenberg M, Chalmer TA, Petersen T, et al
    Predictors of treatment outcome in patients with paediatric onset multiple sclerosis.
    Mult Scler. 2019 May 13:1352458519846100. doi: 10.1177/1352458519846100.
    PubMed     Abstract available


  441. CONTE A, Gianni C, Belvisi D, Cortese A, et al
    Deep grey matter involvement and altered sensory gating in multiple sclerosis.
    Mult Scler. 2019 May 13:1352458519845287. doi: 10.1177/1352458519845287.
    PubMed     Abstract available


  442. FITZGERALD KC, Salter A, Tyry T, Fox RJ, et al
    Measures of general and abdominal obesity and disability severity in a large population of people with multiple sclerosis.
    Mult Scler. 2019 May 13:1352458519845836. doi: 10.1177/1352458519845836.
    PubMed     Abstract available


  443. MOSS BP, Cohen JA
    The emergence of follow-on disease-modifying therapies for multiple sclerosis.
    Mult Scler. 2019 May 10:1352458519845106. doi: 10.1177/1352458519845106.
    PubMed     Abstract available


  444. TUR C, Grussu F, Prados F, Charalambous T, et al
    A multi-shell multi-tissue diffusion study of brain connectivity in early multiple sclerosis.
    Mult Scler. 2019 May 10:1352458519845105. doi: 10.1177/1352458519845105.
    PubMed     Abstract available


  445. FALET JR, Deshmukh S, Al-Jassim A, Sigler G, et al
    The neurologist's role in disabling multiple sclerosis: A qualitative study of patient and care provider perspectives.
    Mult Scler. 2019 May 10:1352458519845107. doi: 10.1177/1352458519845107.
    PubMed     Abstract available


  446. FAZEKAS F
    Instead of tweaking the diagnostic criteria for MS in those with CIS, we should develop diagnostic criteria that distinguish MS from other conditions - Commentary.
    Mult Scler. 2019;25:770-771.
    PubMed    


  447. SOLOMON AJ
    Instead of tweaking the diagnostic criteria for MS in those with CIS, we should develop diagnostic criteria that distinguish MS from other conditions - Yes.
    Mult Scler. 2019;25:766-768.
    PubMed    


  448. BROWNLEE WJ
    Instead of tweaking the diagnostic criteria for MS in those with CIS, we should develop diagnostic criteria that distinguish MS from other conditions - No.
    Mult Scler. 2019;25:768-770.
    PubMed    


  449. TRIPLETT J, Vijayan S, Prince R, Kermode A, et al
    Dimethyl fumarate-associated transient bone marrow oedema syndrome.
    Mult Scler. 2019;25:876-879.
    PubMed     Abstract available


  450. ROSATO R, Testa S, Bertolotto A, Scavelli F, et al
    eMSQOL-29: Prospective validation of the abbreviated, electronic version of MSQOL-54.
    Mult Scler. 2019;25:856-866.
    PubMed     Abstract available


  451. GOODIN DS, Reder AT, Traboulsee AL, Li DK, et al
    Predictive validity of NEDA in the 16- and 21-year follow-up from the pivotal trial of interferon beta-1b.
    Mult Scler. 2019;25:837-847.
    PubMed     Abstract available


  452. DUROZARD P, Maarouf A, Boutiere C, Ruet A, et al
    Efficacy of rituximab in refractory RRMS.
    Mult Scler. 2019;25:828-836.
    PubMed     Abstract available


    April 2019
  453. PHELPS R, Winston JA, Wynn D, Habek M, et al
    Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis.
    Mult Scler. 2019 Apr 15:1352458519841829. doi: 10.1177/1352458519841829.
    PubMed     Abstract available


  454. BARLETTA VT, Herranz E, Treaba CA, Ouellette R, et al
    Evidence of diffuse cerebellar neuroinflammation in multiple sclerosis by (11)C-PBR28 MR-PET.
    Mult Scler. 2019 Apr 11:1352458519843048. doi: 10.1177/1352458519843048.
    PubMed     Abstract available


  455. VUKUSIC S, Coyle PK, Jurgensen S, Truffinet P, et al
    Pregnancy outcomes in patients with multiple sclerosis treated with teriflunomide: Clinical study data and 5 years of post-marketing experience.
    Mult Scler. 2019 Apr 10:1352458519843055. doi: 10.1177/1352458519843055.
    PubMed     Abstract available


  456. BROWN JWL, Chowdhury A, Kanber B, Prados Carrasco F, et al
    Magnetisation transfer ratio abnormalities in primary and secondary progressive multiple sclerosis.
    Mult Scler. 2019 Apr 8:1352458519841810. doi: 10.1177/1352458519841810.
    PubMed     Abstract available


  457. BANWELL B
    Are children with multiple sclerosis really "old" adults.
    Mult Scler. 2019 Apr 4:1352458519841505. doi: 10.1177/1352458519841505.
    PubMed    


  458. BARTELS F, Nobis K, Cooper G, Wendel E, et al
    Childhood multiple sclerosis is associated with reduced brain volumes at first clinical presentation and brain growth failure.
    Mult Scler. 2019 Apr 4:1352458519829698. doi: 10.1177/1352458519829698.
    PubMed     Abstract available


  459. LAVIE C, Rollot F, Durand-Dubief F, Marignier R, et al
    Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS.
    Mult Scler. 2019;25:591-600.
    PubMed     Abstract available


  460. BUCK D, Andlauer TF, Igl W, Wicklein EM, et al
    Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials.
    Mult Scler. 2019;25:565-573.
    PubMed     Abstract available


  461. HYUN JW, Huh SY, Shin HJ, Woodhall M, et al
    Evaluation of brain lesion distribution criteria at disease onset in differentiating MS from NMOSD and MOG-IgG-associated encephalomyelitis.
    Mult Scler. 2019;25:585-590.
    PubMed     Abstract available


  462. ZELEK WM, Watkins LM, Howell OW, Evans R, et al
    Measurement of soluble CD59 in CSF in demyelinating disease: Evidence for an intrathecal source of soluble CD59.
    Mult Scler. 2019;25:523-531.
    PubMed     Abstract available


  463. MANOUSAKI D, Richards JB
    Vitamin D deficiency is an etiological factor for MS - Yes.
    Mult Scler. 2019;25:637-639.
    PubMed    


  464. LANGER-GOULD A, Lucas RM
    Vitamin D deficiency is an etiological factor for MS - No.
    Mult Scler. 2019;25:639-641.
    PubMed    


  465. WILLIAMS T, Chataway J
    Immune-mediated encephalitis with daclizumab: The final nail.
    Mult Scler. 2019;25:753-754.
    PubMed     Abstract available


  466. THOUVENOT E, Hinsinger G, Demattei C, Uygunoglu U, et al
    Cerebrospinal fluid chitinase-3-like protein 1 level is not an independent predictive factor for the risk of clinical conversion in radiologically isolated syndrome.
    Mult Scler. 2019;25:669-677.
    PubMed     Abstract available


    March 2019
  467. HYUN JW, Kim Y, Kim G, Kim SH, et al
    Longitudinal analysis of serum neurofilament light chain: A potential therapeutic monitoring biomarker for multiple sclerosis.
    Mult Scler. 2019 Mar 26:1352458519840757. doi: 10.1177/1352458519840757.
    PubMed     Abstract available


  468. BOONSTRA FM, Noffs G, Perera T, Jokubaitis VG, et al
    Functional neuroplasticity in response to cerebello-thalamic injury underpins the clinical presentation of tremor in multiple sclerosis.
    Mult Scler. 2019 Mar 25:1352458519837706. doi: 10.1177/1352458519837706.
    PubMed     Abstract available


  469. BAGNATO F, Franco G, Ye F, Fan R, et al
    Selective inversion recovery quantitative magnetization transfer imaging: Toward a 3 T clinical application in multiple sclerosis.
    Mult Scler. 2019 Mar 25:1352458519833018. doi: 10.1177/1352458519833018.
    PubMed     Abstract available


  470. D'AMBROSIO A, Valsasina P, Gallo A, De Stefano N, et al
    Reduced dynamics of functional connectivity and cognitive impairment in multiple sclerosis.
    Mult Scler. 2019 Mar 19:1352458519837707. doi: 10.1177/1352458519837707.
    PubMed     Abstract available


  471. RUSSO CV, Sacca F, Paternoster M, Buonomo AR, et al
    Post-mortem diagnosis of invasive pulmonary aspergillosis after alemtuzumab treatment for multiple sclerosis.
    Mult Scler. 2019 Mar 18:1352458518813110. doi: 10.1177/1352458518813110.
    PubMed    


  472. MEYER CE, Gao JL, Cheng JY, Oberoi MR, et al
    Axonal damage in spinal cord is associated with gray matter atrophy in sensorimotor cortex in experimental autoimmune encephalomyelitis.
    Mult Scler. 2019 Mar 7:1352458519830614. doi: 10.1177/1352458519830614.
    PubMed     Abstract available


  473. STRAUDI S, Manfredini F, Lamberti N, Martinuzzi C, et al
    Robot-assisted gait training is not superior to intensive overground walking in multiple sclerosis with severe disability (the RAGTIME study): A randomized controlled trial.
    Mult Scler. 2019 Mar 4:1352458519833901. doi: 10.1177/1352458519833901.
    PubMed     Abstract available


  474. BARANZINI SE
    Insights into microbiome research 6: The role of consortia in studying the role of microbes in health and disease.
    Mult Scler. 2019;25:336-337.
    PubMed     Abstract available


  475. CAMARA-LEMARROY CR, Burton JM
    Area postrema syndrome: A short history of a pearl in demyelinating diseases.
    Mult Scler. 2019;25:325-329.
    PubMed     Abstract available


  476. WATTJES MP, Killestein J
    Imaging of meningeal inflammation should become part of the routine MRI protocol - No.
    Mult Scler. 2019;25:331-333.
    PubMed    


  477. ABSINTA M, Reich DS
    Imaging of meningeal inflammation should become part of the routine MRI protocol - Yes.
    Mult Scler. 2019;25:330-331.
    PubMed    


  478. DEISENHAMMER F, Jank M, Lauren A, Sjodin A, et al
    Prediction of natalizumab anti-drug antibodies persistency.
    Mult Scler. 2019;25:392-398.
    PubMed     Abstract available


  479. ROCCA MA, Riccitelli GC, Meani A, Pagani E, et al
    Cognitive reserve, cognition, and regional brain damage in MS: A 2 -year longitudinal study.
    Mult Scler. 2019;25:372-381.
    PubMed     Abstract available


  480. AL-LOUZI O, Sotirchos ES, Vidal-Jordana A, Beh SC, et al
    Characteristics of morphologic macular abnormalities in neuroimmunology practice.
    Mult Scler. 2019;25:361-371.
    PubMed     Abstract available


    February 2019
  481. PALMER AJ, van der Mei I, Taylor BV, Clarke PM, et al
    Modelling the impact of multiple sclerosis on life expectancy, quality-adjusted life years and total lifetime costs: Evidence from Australia.
    Mult Scler. 2019 Feb 26:1352458519831213. doi: 10.1177/1352458519831213.
    PubMed     Abstract available


  482. URRU SA, Antonelli A, Sechi GM
    Prevalence of multiple sclerosis in Sardinia: A systematic cross-sectional multi-source survey.
    Mult Scler. 2019 Feb 22:1352458519828600. doi: 10.1177/1352458519828600.
    PubMed     Abstract available


  483. PORTACCIO E, Amato MP
    Breastfeeding and post-partum relapses in multiple sclerosis patients.
    Mult Scler. 2019 Feb 22:1352458519830588. doi: 10.1177/1352458519830588.
    PubMed     Abstract available


  484. CUKER A, Bass AD, Nadj C, Agius MA, et al
    Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management.
    Mult Scler. 2019 Feb 20:1352458518816612. doi: 10.1177/1352458518816612.
    PubMed     Abstract available


  485. JAKIMOVSKI D, Ramanathan M, Weinstock-Guttman B, Bergsland N, et al
    Higher EBV response is associated with more severe gray matter and lesion pathology in relapsing multiple sclerosis patients: A case-controlled magnetization transfer ratio study.
    Mult Scler. 2019 Feb 13:1352458519828667. doi: 10.1177/1352458519828667.
    PubMed     Abstract available


  486. SOTIRCHOS ES, Gonzalez-Caldito N, Dewey BE, Fitzgerald KC, et al
    Effect of disease-modifying therapies on subcortical gray matter atrophy in multiple sclerosis.
    Mult Scler. 2019 Feb 11:1352458519826364. doi: 10.1177/1352458519826364.
    PubMed     Abstract available


  487. CICERO CE, Patti F, Lo Fermo S, Giuliano L, et al
    Lack of association between Toxocara canis and multiple sclerosis: A population-based case-control study.
    Mult Scler. 2019 Feb 11:1352458518825394. doi: 10.1177/1352458518825394.
    PubMed    


  488. LEFEUVRE JA, Guy JR, Luciano NJ, Ha SK, et al
    The spectrum of spinal cord lesions in a primate model of multiple sclerosis.
    Mult Scler. 2019 Feb 7:1352458518822408. doi: 10.1177/1352458518822408.
    PubMed     Abstract available


  489. NICOLETTI CG, Monteleone F, Marfia GA, Usiello A, et al
    Oral D-Aspartate enhances synaptic plasticity reserve in progressive multiple sclerosis.
    Mult Scler. 2019 Feb 7:1352458519828294. doi: 10.1177/1352458519828294.
    PubMed     Abstract available


  490. RAIMO S, Spitaleri D, Trojano L, Santangelo G, et al
    Apathy as a herald of cognitive changes in multiple sclerosis: A 2-year follow-up study.
    Mult Scler. 2019 Feb 7:1352458519828296. doi: 10.1177/1352458519828296.
    PubMed     Abstract available


  491. PLANCHE V, Su JH, Mournet S, Saranathan M, et al
    White-matter-nulled MPRAGE at 7T reveals thalamic lesions and atrophy of specific thalamic nuclei in multiple sclerosis.
    Mult Scler. 2019 Feb 7:1352458519828297. doi: 10.1177/1352458519828297.
    PubMed     Abstract available


  492. CHARD DT
    Commentary on Al Hussona et al. 'New-onset seizures as a sole clinical presentation of multiple sclerosis'.
    Mult Scler. 2019;25:298-299.
    PubMed     Abstract available


  493. BARANZINI SE
    Insights into microbiome research 5: Mapping is first but function must come next.
    Mult Scler. 2019;25:193-195.
    PubMed     Abstract available


  494. HELLWIG K
    We need to conduct clinical trials of disease-modifying therapy in pregnancy to optimize care of women with MS - No.
    Mult Scler. 2019;25:189-190.
    PubMed    


  495. ALVAREZ E, Mowry EM
    We need to conduct clinical trials of disease-modifying therapy in pregnancy to optimize care of women with MS - Yes.
    Mult Scler. 2019;25:187-188.
    PubMed    


  496. BOVE R
    We need to conduct clinical trials of disease-modifying therapy in pregnancy to optimize care of women with MS - Commentary.
    Mult Scler. 2019;25:190-192.
    PubMed    


  497. HEDSTROM AK
    Smoking and its interaction with genetics in MS etiology.
    Mult Scler. 2019;25:180-186.
    PubMed     Abstract available


  498. BSTEH G, Hegen H, Ladstatter F, Berek K, et al
    Change of olfactory function as a marker of inflammatory activity and disability progression in MS.
    Mult Scler. 2019;25:267-274.
    PubMed     Abstract available


  499. BOVIS F, De Stefano N, Steinerman JR, Knappertz V, et al
    Validating the use of brain volume cutoffs to identify clinically relevant atrophy in RRMS.
    Mult Scler. 2019;25:217-223.
    PubMed     Abstract available


    January 2019
  500. SECHI E, Flanagan EP
    Area postrema syndrome in autoimmune GFAP astrocytopathy.
    Mult Scler. 2019 Jan 21:1352458519826489. doi: 10.1177/1352458519826489.
    PubMed    


  501. STORK L, Bruck W, von Gottberg P, Pulkowski U, et al
    Severe meningo-/encephalitis after daclizumab therapy for multiple sclerosis.
    Mult Scler. 2019 Jan 18:1352458518819098. doi: 10.1177/1352458518819098.
    PubMed     Abstract available


  502. CORDANI C, Meani A, Esposito F, Valsasina P, et al
    Imaging correlates of hand motor performance in multiple sclerosis: A multiparametric structural and functional MRI study.
    Mult Scler. 2019 Jan 18:1352458518822145. doi: 10.1177/1352458518822145.
    PubMed     Abstract available


  503. VALENCIA-SANCHEZ C, Goodman BP, Carter JL, Wingerchuk DM, et al
    The spectrum of acute cardiopulmonary events associated with multiple sclerosis exacerbations.
    Mult Scler. 2019 Jan 18:1352458518823482. doi: 10.1177/1352458518823482.
    PubMed     Abstract available


  504. VAN MUNSTER CE, Kaya L, Obura M, Kalkers NF, et al
    Minimal clinically important difference of improvement on the Arm Function in Multiple Sclerosis Questionnaire (AMSQ).
    Mult Scler. 2019 Jan 18:1352458518823489. doi: 10.1177/1352458518823489.
    PubMed     Abstract available


  505. BARIN L, Kamm CP, Salmen A, Dressel H, et al
    How do patients enter the healthcare system after the first onset of multiple sclerosis symptoms? The influence of setting and physician specialty on speed of diagnosis.
    Mult Scler. 2019 Jan 18:1352458518823955. doi: 10.1177/1352458518823955.
    PubMed     Abstract available


  506. MARRODAN M, Alessandro L, Farez MF, Correale J, et al
    The role of infections in multiple sclerosis.
    Mult Scler. 2019 Jan 14:1352458518823940. doi: 10.1177/1352458518823940.
    PubMed     Abstract available


  507. PAGANI E, Rocca MA, De Meo E, Horsfield MA, et al
    Structural connectivity in multiple sclerosis and modeling of disconnection.
    Mult Scler. 2019 Jan 9:1352458518820759. doi: 10.1177/1352458518820759.
    PubMed     Abstract available


  508. JAKIMOVSKI D, Benedict RH, Marr K, Gandhi S, et al
    Lower total cerebral arterial flow contributes to cognitive performance in multiple sclerosis patients.
    Mult Scler. 2019 Jan 9:1352458518819608. doi: 10.1177/1352458518819608.
    PubMed     Abstract available


  509. FUCHS TA, Wojcik C, Wilding GE, Pol J, et al
    Trait Conscientiousness predicts rate of longitudinal SDMT decline in multiple sclerosis.
    Mult Scler. 2019 Jan 7:1352458518820272. doi: 10.1177/1352458518820272.
    PubMed     Abstract available


  510. BARANZINI SE
    Insights into microbiome research 4: The computational analysis.
    Mult Scler. 2019;25:21-22.
    PubMed     Abstract available


  511. THOMPSON AJ, Antel J, Carroll WB, Geurts J, et al
    MSJ 2019 - Editorial comment.
    Mult Scler. 2019;25:4-5.
    PubMed    


  512. SA M, Thornton R, Chong WK, Kaliakatsos M, et al
    Paediatric MOG antibody-associated ADEM with complex movement disorder: A case report.
    Mult Scler. 2019;25:125-128.
    PubMed     Abstract available


  513. BREZA M, Smyrni N, Koutsis G, Anagnostou E, et al
    Ocular flutter as presenting manifestation of pediatric MOG antibody-associated demyelination: A case report.
    Mult Scler. 2019;25:122-125.
    PubMed     Abstract available


  514. PITT D, Ponath G
    Astrocytes play a crucial role in the formation and evolution of MS lesions - Yes.
    Mult Scler. 2019;25:15-17.
    PubMed    


  515. KERLERO DE ROSBO N
    Astrocytes play a crucial role in the formation and evolution of MS lesions - No.
    Mult Scler. 2019;25:17-19.
    PubMed    


  516. VIJAYASINGHAM L, Viswanathan S
    A call for more research and global collaboration in South-East Asia to address challenges of DMT access and MS management in the region.
    Mult Scler. 2019;25:130-131.
    PubMed    


  517. PATEL VP, Feinstein A
    The link between depression and performance on the Symbol Digit Modalities Test: Mechanisms and clinical significance.
    Mult Scler. 2019;25:118-121.
    PubMed     Abstract available


  518. MAZZOLA MA, Raheja R, Regev K, Beynon V, et al
    Monomethyl fumarate treatment impairs maturation of human myeloid dendritic cells and their ability to activate T cells.
    Mult Scler. 2019;25:63-71.
    PubMed     Abstract available


  519. MARIGNIER R
    Unusual presentations of MOG antibody-associated central nervous system demyelination: Expanding the spectrum.
    Mult Scler. 2019;25:128-129.
    PubMed    


  520. QUINTANA FJ
    Astrocytes play a crucial role in the formation and evolution of MS lesions - Commentary.
    Mult Scler. 2019;25:19-20.
    PubMed    


    December 2018
  521. HOGEL H, Rissanen E, Barro C, Matilainen M, et al
    Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity.
    Mult Scler. 2018 Dec 20:1352458518819380. doi: 10.1177/1352458518819380.
    PubMed     Abstract available


  522. SATCHIDANAND N, Drake A, Smerbeck A, Hojnacki D, et al
    Dalfampridine benefits ambulation but not cognition in multiple sclerosis.
    Mult Scler. 2018 Dec 19:1352458518815795. doi: 10.1177/1352458518815795.
    PubMed     Abstract available


  523. ELLIOTT C, Wolinsky JS, Hauser SL, Kappos L, et al
    Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions.
    Mult Scler. 2018 Dec 19:1352458518814117. doi: 10.1177/1352458518814117.
    PubMed     Abstract available


  524. MATTHEWS L
    Clinical commentary on 'Relapsing remitting multiple sclerosis in progressive external ophthalmoplegia: A report of two cases'.
    Mult Scler. 2018 Dec 17:1352458518816621. doi: 10.1177/1352458518816621.
    PubMed    


  525. PATEL KR, Karaa A, Mateen FJ
    Relapsing remitting multiple sclerosis in progressive external ophthalmoplegia: A report of two cases.
    Mult Scler. 2018 Dec 17:1352458518800794. doi: 10.1177/1352458518800794.
    PubMed     Abstract available


  526. POURCHER V, Todesco E, Dubois C, Pallier C, et al
    False hepatitis B and C viral serologies in patients with multiple sclerosis receiving high-dose biotin.
    Mult Scler. 2018 Dec 11:1352458518818294. doi: 10.1177/1352458518818294.
    PubMed    


  527. BSTEH G, Algrang L, Hegen H, Auer M, et al
    Pregnancy and multiple sclerosis in the DMT era: A cohort study in Western Austria.
    Mult Scler. 2018 Dec 3:1352458518816614. doi: 10.1177/1352458518816614.
    PubMed     Abstract available


  528. VAUGHN CB, Kavak KS, Dwyer MG, Bushra A, et al
    Fatigue at enrollment predicts EDSS worsening in the New York State Multiple Sclerosis Consortium.
    Mult Scler. 2018 Dec 3:1352458518816619. doi: 10.1177/1352458518816619.
    PubMed     Abstract available


    November 2018
  529. CHIEN C, Scheel M, Schmitz-Hubsch T, Borisow N, et al
    Spinal cord lesions and atrophy in NMOSD with AQP4-IgG and MOG-IgG associated autoimmunity.
    Mult Scler. 2018 Nov 26:1352458518815596. doi: 10.1177/1352458518815596.
    PubMed     Abstract available


  530. BSTEH G, Berek K, Hegen H, Teuchner B, et al
    Smelling multiple sclerosis: Different qualities of olfactory function reflect either inflammatory activity or neurodegeneration.
    Mult Scler. 2018 Nov 22:1352458518814113. doi: 10.1177/1352458518814113.
    PubMed     Abstract available


  531. WOJCIK CM, Rao SM, Schembri AJ, Drake AS, et al
    Necessity of technicians for computerized neuropsychological assessment devices in multiple sclerosis.
    Mult Scler. 2018 Nov 22:1352458518813287. doi: 10.1177/1352458518813287.
    PubMed     Abstract available


  532. WALLECZEK NK, Frommlet F, Bsteh G, Eggers C, et al
    Month-of-birth-effect in multiple sclerosis in Austria.
    Mult Scler. 2018 Nov 22:1352458518810924. doi: 10.1177/1352458518810924.
    PubMed     Abstract available


  533. SEGAL BM
    Enhancing natural killer cells is beneficial in multiple sclerosis - Commentary.
    Mult Scler. 2018 Nov 13:1352458518809296. doi: 10.1177/1352458518809296.
    PubMed    


  534. LIU Q, Shi FD
    Enhancing natural killer cells is beneficial in multiple sclerosis - No.
    Mult Scler. 2018 Nov 13:1352458518799591. doi: 10.1177/1352458518799591.
    PubMed    


  535. LARONI A
    Enhancing natural killer cells is beneficial in multiple sclerosis - Yes.
    Mult Scler. 2018 Nov 13:1352458518800776. doi: 10.1177/1352458518800776.
    PubMed    


  536. RAATS J, Lamers I, Baert I, Willekens B, et al
    Cognitive-motor interference in persons with multiple sclerosis during five upper limb motor tasks with different complexity.
    Mult Scler. 2018 Nov 12:1352458518808194. doi: 10.1177/1352458518808194.
    PubMed     Abstract available


  537. FOX EJ, Markowitz C, Applebee A, Montalban X, et al
    Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial.
    Mult Scler. 2018 Nov 12:1352458518808189. doi: 10.1177/1352458518808189.
    PubMed     Abstract available


  538. LUIJTEN MA, Eekhout I, D'Hooghe M, Uitdehaag BM, et al
    Development of the Arm Function in Multiple Sclerosis Questionnaire-Short Form (AMSQ-SF): A static 10-item version.
    Mult Scler. 2018 Nov 9:1352458518808197. doi: 10.1177/1352458518808197.
    PubMed     Abstract available


  539. LAMERS I, Feys P
    Patient reported outcome measures of upper limb function in multiple sclerosis: A critical overview.
    Mult Scler. 2018 Nov 9:1352458518809294. doi: 10.1177/1352458518809294.
    PubMed    


  540. HYUN JW, Kim Y, Kim G, Kim SH, et al
    Severe B cell-mediated disease activation despite two cycles of alemtuzumab in a patient with multiple sclerosis.
    Mult Scler. 2018 Nov 7:1352458518810261. doi: 10.1177/1352458518810261.
    PubMed     Abstract available


  541. ACHIRON A, Sarova-Pinhas I, Magalashvili D, Stern Y, et al
    Residual disability after severe relapse in people with multiple sclerosis treated with disease-modifying therapy.
    Mult Scler. 2018 Nov 1:1352458518809903. doi: 10.1177/1352458518809903.
    PubMed     Abstract available


  542. HOBART J, Bowen A, Pepper G, Crofts H, et al
    International consensus on quality standards for brain health-focused care in multiple sclerosis.
    Mult Scler. 2018 Nov 1:1352458518809326. doi: 10.1177/1352458518809326.
    PubMed     Abstract available


  543. HEALY BC, Zurawski J, Gonzalez CT, Chitnis T, et al
    Assessment of computer adaptive testing version of the Neuro-QOL for people with multiple sclerosis.
    Mult Scler. 2018 Nov 1:1352458518810159. doi: 10.1177/1352458518810159.
    PubMed     Abstract available


  544. PEETERS LM, van Munster CE, Van Wijmeersch B, Bruyndonckx R, et al
    Multidisciplinary data infrastructures in multiple sclerosis: Why they are needed and can be done!
    Mult Scler. 2018 Nov 1:1352458518807076. doi: 10.1177/1352458518807076.
    PubMed     Abstract available


    October 2018
  545. FARRELL R
    Clinical commentary on "De novo convulsive status epilepticus in patients with multiple sclerosis treated with dalfampridine".
    Mult Scler. 2018 Oct 30:1352458518810661. doi: 10.1177/1352458518810661.
    PubMed    


  546. PANICUCCI E, Cohen M, Bourg V, Rocher F, et al
    De novo convulsive status epilepticus in patients with multiple sclerosis treated with dalfampridine.
    Mult Scler. 2018 Oct 30:1352458518790379. doi: 10.1177/1352458518790379.
    PubMed     Abstract available


  547. DOBSON R
    Clinical commentary on 'Life-threatening vitamin D intoxication due to intake of ultra-high doses in multiple sclerosis: a note of caution'.
    Mult Scler. 2018 Oct 25:1352458518807053. doi: 10.1177/1352458518807053.
    PubMed    


  548. FEIGE J, Salmhofer H, Hecker C, Kunz AB, et al
    Life-threatening vitamin D intoxication due to intake of ultra-high doses in multiple sclerosis: A note of caution.
    Mult Scler. 2018 Oct 25:1352458518807059. doi: 10.1177/1352458518807059.
    PubMed     Abstract available


  549. AHMAD H, van der Mei I, Taylor BV, Lucas RM, et al
    Estimation of annual probabilities of changing disability levels in Australians with relapsing-remitting multiple sclerosis.
    Mult Scler. 2018 Oct 23:1352458518806103. doi: 10.1177/1352458518806103.
    PubMed     Abstract available


  550. SOELBERG SORENSEN P, Giovannoni G, Montalban X, Thalheim C, et al
    The Multiple Sclerosis Care Unit.
    Mult Scler. 2018 Oct 23:1352458518807082. doi: 10.1177/1352458518807082.
    PubMed     Abstract available


  551. ROTSTEIN DL, Cortese M, Fung TT, Chitnis T, et al
    Diet quality and risk of multiple sclerosis in two cohorts of US women.
    Mult Scler. 2018 Oct 23:1352458518807061. doi: 10.1177/1352458518807061.
    PubMed     Abstract available


  552. STROBER L, DeLuca J, Benedict RH, Jacobs A, et al
    Symbol Digit Modalities Test: A valid clinical trial endpoint for measuring cognition in multiple sclerosis.
    Mult Scler. 2018 Oct 18:1352458518808204. doi: 10.1177/1352458518808204.
    PubMed     Abstract available


  553. BURROWS DJ, McGown A, Jain SA, De Felice M, et al
    Animal models of multiple sclerosis: From rodents to zebrafish.
    Mult Scler. 2018 Oct 15:1352458518805246. doi: 10.1177/1352458518805246.
    PubMed     Abstract available


  554. DUBUISSON N, Marta M, Gnanapavan S, Turner B, et al
    Inclusion criteria used in trials of people with progressive multiple sclerosis.
    Mult Scler. 2018 Oct 15:1352458518803769. doi: 10.1177/1352458518803769.
    PubMed    


  555. GRAF J, Ringelstein M, Lepka K, Schaller J, et al
    Acute sarcoidosis in a multiple sclerosis patient after alemtuzumab treatment.
    Mult Scler. 2018 Oct 11:1352458518771276. doi: 10.1177/1352458518771276.
    PubMed     Abstract available


  556. WILLIS MD, Hope-Gill B, Flood-Page P, Joseph F, et al
    Sarcoidosis following alemtuzumab treatment for multiple sclerosis.
    Mult Scler. 2018 Oct 11:1352458518790391. doi: 10.1177/1352458518790391.
    PubMed     Abstract available


  557. PFEUFFER S
    Sarcoidosis following alemtuzumab treatment: Autoimmunity mediated by T cells and interferon-gamma.
    Mult Scler. 2018 Oct 11:1352458518804124. doi: 10.1177/1352458518804124.
    PubMed    


  558. CONWAY BL, Zeydan B, Uygunoglu U, Novotna M, et al
    Age is a critical determinant in recovery from multiple sclerosis relapses.
    Mult Scler. 2018 Oct 10:1352458518800815. doi: 10.1177/1352458518800815.
    PubMed     Abstract available


  559. KALB R, Beier M, Benedict RH, Charvet L, et al
    Recommendations for cognitive screening and management in multiple sclerosis care.
    Mult Scler. 2018 Oct 10:1352458518803785. doi: 10.1177/1352458518803785.
    PubMed     Abstract available


  560. VILARINO-GUELL C, Encarnacion M, Bernales CQ, Sadovnick AD, et al
    Analysis of Canadian multiple sclerosis patients does not support a role for FKBP6 in disease.
    Mult Scler. 2018 Oct 9:1352458518803789. doi: 10.1177/1352458518803789.
    PubMed    


  561. KREMER D, Akkermann R, Kury P, Dutta R, et al
    Current advancements in promoting remyelination in multiple sclerosis.
    Mult Scler. 2018 Oct 1:1352458518800827. doi: 10.1177/1352458518800827.
    PubMed     Abstract available


  562. TATEO F, Grassivaro F, Ermani M, Puthenparampil M, et al
    PM2.5 levels strongly associate with multiple sclerosis prevalence in the Province of Padua, Veneto Region, North-East Italy.
    Mult Scler. 2018 Oct 1:1352458518803273. doi: 10.1177/1352458518803273.
    PubMed     Abstract available


    September 2018
  563. BOSE G, Atkins HL, Bowman M, Freedman MS, et al
    Autologous hematopoietic stem cell transplantation improves fatigue in multiple sclerosis.
    Mult Scler. 2018 Sep 25:1352458518802544. doi: 10.1177/1352458518802544.
    PubMed     Abstract available


  564. MIN M, Spelman T, Lugaresi A, Boz C, et al
    Silent lesions on MRI imaging - Shifting goal posts for treatment decisions in multiple sclerosis.
    Mult Scler. 2018 Sep 20:1352458518798147. doi: 10.1177/1352458518798147.
    PubMed     Abstract available


  565. LAVORGNA L, Brigo F, Moccia M, Leocani L, et al
    e-Health and multiple sclerosis: An update.
    Mult Scler. 2018 Sep 19:1352458518799629. doi: 10.1177/1352458518799629.
    PubMed     Abstract available


  566. ANTONAZZO IC, Poluzzi E, Forcesi E, Riise T, et al
    Liver injury with drugs used for multiple sclerosis: A contemporary analysis of the FDA Adverse Event Reporting System.
    Mult Scler. 2018 Sep 19:1352458518799598. doi: 10.1177/1352458518799598.
    PubMed     Abstract available


  567. ROMMER PS, Eichstadt K, Ellenberger D, Flachenecker P, et al
    Symptomatology and symptomatic treatment in multiple sclerosis: Results from a nationwide MS registry.
    Mult Scler. 2018 Sep 19:1352458518799580. doi: 10.1177/1352458518799580.
    PubMed     Abstract available


  568. O'GRADY KP, Dula AN, Lyttle BD, Thompson LM, et al
    Glutamate-sensitive imaging and evaluation of cognitive impairment in multiple sclerosis.
    Mult Scler. 2018 Sep 19:1352458518799583. doi: 10.1177/1352458518799583.
    PubMed     Abstract available


  569. BENJAMIN LA
    A tale of two demyelinating diseases and Zika virus.
    Mult Scler. 2018 Sep 18:1352458518799584. doi: 10.1177/1352458518799584.
    PubMed    


    August 2018
  570. VAN ROSSUM JA, Killestein J, Villar LM, Riskind PN, et al
    gMS-Classifier1 does not predict disability progression in multiple sclerosis.
    Mult Scler. 2018 Aug 31:1352458518798048. doi: 10.1177/1352458518798048.
    PubMed    


  571. VAN MUNSTER CE, D'Souza M, Steinheimer S, Kamm CP, et al
    Tasks of activities of daily living (ADL) are more valuable than the classical neurological examination to assess upper extremity function and mobility in multiple sclerosis.
    Mult Scler. 2018 Aug 31:1352458518796690. doi: 10.1177/1352458518796690.
    PubMed     Abstract available


  572. O'MAHONY J, Marrie RA, Laporte A, Bar-Or A, et al
    Pediatric-onset multiple sclerosis is associated with reduced parental health-related quality of life and family functioning.
    Mult Scler. 2018 Aug 30:1352458518796676. doi: 10.1177/1352458518796676.
    PubMed     Abstract available


  573. BOVE R, Bevan C, Crabtree E, Zhao C, et al
    Toward a low-cost, in-home, telemedicine-enabled assessment of disability in multiple sclerosis.
    Mult Scler. 2018 Aug 24:1352458518793527. doi: 10.1177/1352458518793527.
    PubMed     Abstract available


  574. NICHOLAS RS, Han E, Raffel J, Chataway J, et al
    Over three decades study populations in progressive multiple sclerosis have become older and more disabled, but have lower on-trial progression rates: A systematic review and meta-analysis of 43 randomised placebo-controlled trials.
    Mult Scler. 2018 Aug 24:1352458518794063. doi: 10.1177/1352458518794063.
    PubMed     Abstract available


  575. SKJERBAEK AG, Boesen F, Petersen T, Rasmussen PV, et al
    Can we trust self-reported walking distance when determining EDSS scores in patients with multiple sclerosis? The Danish MS hospitals rehabilitation study.
    Mult Scler. 2018 Aug 20:1352458518795416. doi: 10.1177/1352458518795416.
    PubMed     Abstract available


  576. ANDERSEN C, Sondergaard HB, Bang Oturai D, Laursen JH, et al
    Alcohol consumption in adolescence is associated with a lower risk of multiple sclerosis in a Danish cohort.
    Mult Scler. 2018 Aug 20:1352458518795418. doi: 10.1177/1352458518795418.
    PubMed     Abstract available


  577. GAUZZI MC
    Vitamin D-binding protein and multiple sclerosis: Evidence, controversies, and needs.
    Mult Scler. 2018 Aug 16:1352458518792433. doi: 10.1177/1352458518792433.
    PubMed     Abstract available


  578. SELLEBJERG F, Royen L, Soelberg Sorensen P, Oturai AB, et al
    Prognostic value of cerebrospinal fluid neurofilament light chain and chitinase-3-like-1 in newly diagnosed patients with multiple sclerosis.
    Mult Scler. 2018 Aug 16:1352458518794308. doi: 10.1177/1352458518794308.
    PubMed     Abstract available


  579. VISWANATHAN S, Wah LM
    A nationwide epidemiological study on the prevalence of multiple sclerosis and neuromyelitis optica spectrum disorder with important multi-ethnic differences in Malaysia.
    Mult Scler. 2018 Aug 16:1352458518792430. doi: 10.1177/1352458518792430.
    PubMed     Abstract available


  580. SEEBACHER B, Kuisma R, Glynn A, Berger T, et al
    Effects and mechanisms of differently cued and non-cued motor imagery in people with multiple sclerosis: A randomised controlled trial.
    Mult Scler. 2018 Aug 14:1352458518795332. doi: 10.1177/1352458518795332.
    PubMed     Abstract available


  581. PIETROBONI AM, Caprioli M, Carandini T, Scarioni M, et al
    CSF beta-amyloid predicts prognosis in patients with multiple sclerosis.
    Mult Scler. 2018 Aug 7:1352458518791709. doi: 10.1177/1352458518791709.
    PubMed     Abstract available


  582. ROCCA MA, Meani A, Fumagalli S, Pagani E, et al
    Functional and structural plasticity following action observation training in multiple sclerosis.
    Mult Scler. 2018 Aug 7:1352458518792771. doi: 10.1177/1352458518792771.
    PubMed     Abstract available


  583. KUSPINAR A, Mayo NE
    Validation of the preference-based multiple sclerosis index.
    Mult Scler. 2018 Aug 2:1352458518792423. doi: 10.1177/1352458518792423.
    PubMed     Abstract available


  584. TOMASSINI V, Fanelli F, Prosperini L, Cerqua R, et al
    Predicting the profile of increasing disability in multiple sclerosis.
    Mult Scler. 2018 Aug 2:1352458518790397. doi: 10.1177/1352458518790397.
    PubMed     Abstract available


  585. PETERSEN ER, Sondergaard HB, Laursen JH, Olsson AG, et al
    Smoking is associated with increased disease activity during natalizumab treatment in multiple sclerosis.
    Mult Scler. 2018 Aug 2:1352458518791753. doi: 10.1177/1352458518791753.
    PubMed     Abstract available


  586. DI STADIO A, Ralli M
    Inner ear involvement in multiple sclerosis: An underestimated condition?
    Mult Scler. 2018;24:1264-1265.
    PubMed    


  587. BHAN A, Jacobsen C, Myhr KM, Dalen I, et al
    Neurofilaments and 10-year follow-up in multiple sclerosis.
    Mult Scler. 2018 Aug 1:1352458518782005. doi: 10.1177/1352458518782005.
    PubMed     Abstract available


    July 2018
  588. YANG R, Dunn JF
    Multiple sclerosis disease progression: Contributions from a hypoxia-inflammation cycle.
    Mult Scler. 2018 Jul 27:1352458518791683. doi: 10.1177/1352458518791683.
    PubMed     Abstract available


  589. SACCA F, Lanzillo R, Signori A, Maniscalco GT, et al
    Determinants of therapy switch in multiple sclerosis treatment-naive patients: A real-life study.
    Mult Scler. 2018 Jul 25:1352458518790390. doi: 10.1177/1352458518790390.
    PubMed     Abstract available


  590. HYUN JW, Kim W, Huh SY, Park MS, et al
    Application of the 2017 McDonald diagnostic criteria for multiple sclerosis in Korean patients with clinically isolated syndrome.
    Mult Scler. 2018 Jul 25:1352458518790702. doi: 10.1177/1352458518790702.
    PubMed     Abstract available


  591. HOLM HANSEN R, Hojsgaard Chow H, Sellebjerg F, Rode von Essen M, et al
    Dimethyl fumarate therapy suppresses B cell responses and follicular helper T cells in relapsing-remitting multiple sclerosis.
    Mult Scler. 2018 Jul 25:1352458518790417. doi: 10.1177/1352458518790417.
    PubMed     Abstract available


  592. COHEN JA, Comi G, Arnold DL, Bar-Or A, et al
    Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study.
    Mult Scler. 2018 Jul 25:1352458518789884. doi: 10.1177/1352458518789884.
    PubMed     Abstract available


  593. LIN F, Zivadinov R, Hagemeier J, Weinstock-Guttman B, et al
    Altered nuclei-specific thalamic functional connectivity patterns in multiple sclerosis and their associations with fatigue and cognition.
    Mult Scler. 2018 Jul 1:1352458518788218. doi: 10.1177/1352458518788218.
    PubMed     Abstract available


  594. SENDERS A, Hanes D, Bourdette D, Carson K, et al
    Impact of mindfulness-based stress reduction for people with multiple sclerosis at 8 weeks and 12 months: A randomized clinical trial.
    Mult Scler. 2018 Jul 1:1352458518786650. doi: 10.1177/1352458518786650.
    PubMed     Abstract available


  595. FISSOLO N, Cervera-Carles L, Villar Guimerans LM, Lleo A, et al
    Cerebrospinal fluid mitochondrial DNA levels in patients with multiple sclerosis.
    Mult Scler. 2018 Jul 1:1352458518786055. doi: 10.1177/1352458518786055.
    PubMed     Abstract available


  596. OSHIMA Y, Tanimoto T, Yuji K, Tojo A, et al
    Drug-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients.
    Mult Scler. 2018 Jul 1:1352458518786075. doi: 10.1177/1352458518786075.
    PubMed     Abstract available


  597. WIJNANDS JM, Zhu F, Kingwell E, Zhao Y, et al
    Five years before multiple sclerosis onset: Phenotyping the prodrome.
    Mult Scler. 2018 Jul 1:1352458518783662. doi: 10.1177/1352458518783662.
    PubMed     Abstract available


  598. WONG YYM, van der Vuurst de Vries RM, van Pelt ED, Ketelslegers IA, et al
    T-cell activation marker sCD27 is associated with clinically definite multiple sclerosis in childhood-acquired demyelinating syndromes.
    Mult Scler. 2018 Jul 1:1352458518786655. doi: 10.1177/1352458518786655.
    PubMed     Abstract available


  599. KEARNEY H
    Clinical monitoring of multiple sclerosis should routinely include spinal cord imaging - No.
    Mult Scler. 2018 Jul 1:1352458518770279. doi: 10.1177/1352458518770279.
    PubMed    


  600. SASTRE-GARRIGA J
    Clinical monitoring of multiple sclerosis should routinely include spinal cord imaging - Commentary.
    Mult Scler. 2018 Jul 1:1352458518783362. doi: 10.1177/1352458518783362.
    PubMed    


  601. CORTESE R, Ciccarelli O
    Clinical monitoring of multiple sclerosis should routinely include spinal cord imaging - Yes.
    Mult Scler. 2018 Jul 1:1352458518778010. doi: 10.1177/1352458518778010.
    PubMed    


    June 2018
  602. MESCHERIAKOVA JY, Verkerk AJ, Amin N, Uitterlinden AG, et al
    Linkage analysis and whole exome sequencing identify a novel candidate gene in a Dutch multiple sclerosis family.
    Mult Scler. 2018 Jun 1:1352458518777202. doi: 10.1177/1352458518777202.
    PubMed     Abstract available


  603. PUTHENPARAMPIL M, Zito A, Pantano G, Federle L, et al
    Peripheral imbalanced TFH/TFR ratio correlates with intrathecal IgG synthesis in multiple sclerosis at clinical onset.
    Mult Scler. 2018 Jun 1:1352458518779951. doi: 10.1177/1352458518779951.
    PubMed     Abstract available


  604. AL HUSSONA M, Kearney H, Fisher A, Lynch J, et al
    New onset seizures as a sole clinical presentation of multiple sclerosis.
    Mult Scler. 2018 Jun 1:1352458518781994. doi: 10.1177/1352458518781994.
    PubMed     Abstract available


  605. REDDEL SW, Barnett MH, Riminton S, Dugal T, et al
    Successful implementation of an automated electronic support system for patient safety monitoring: The alemtuzumab in multiple sclerosis safety systems (AMS3) study.
    Mult Scler. 2018 Jun 1:1352458518783673. doi: 10.1177/1352458518783673.
    PubMed     Abstract available


  606. CHEN J, Taylor B, Palmer AJ, Kirk-Brown A, et al
    Estimating MS-related work productivity loss and factors associated with work productivity loss in a representative Australian sample of people with multiple sclerosis.
    Mult Scler. 2018 Jun 1:1352458518781971. doi: 10.1177/1352458518781971.
    PubMed     Abstract available


  607. MANOUCHEHRINIA A, Zhu F, Piani-Meier D, Lange M, et al
    Predicting risk of secondary progression in multiple sclerosis: A nomogram.
    Mult Scler. 2018 Jun 1:1352458518783667. doi: 10.1177/1352458518783667.
    PubMed     Abstract available


  608. GALLAGHER LG, Ilango S, Wundes A, Stobbe GA, et al
    Lifetime exposure to ultraviolet radiation and the risk of multiple sclerosis in the US radiologic technologists cohort study.
    Mult Scler. 2018 Jun 1:1352458518783343. doi: 10.1177/1352458518783343.
    PubMed     Abstract available


  609. MAGALHAES S, Banwell B, Bar-Or A, Fortier I, et al
    A framework for measurement and harmonization of pediatric multiple sclerosis etiologic research studies: The Pediatric MS Tool-Kit.
    Mult Scler. 2018 Jun 1:1352458518783345. doi: 10.1177/1352458518783345.
    PubMed     Abstract available


  610. ALVES-LEON SV, Lima MDR, Nunes PCG, Chimelli LMC, et al
    Zika virus found in brain tissue of a multiple sclerosis patient undergoing an acute disseminated encephalomyelitis-like episode.
    Mult Scler. 2018 Jun 1:1352458518781992. doi: 10.1177/1352458518781992.
    PubMed     Abstract available


    May 2018
  611. FROEHLICH A, Schmidt S, Landsberg J, Bieber T, et al
    Spontaneous regression of tumor-stage cutaneous T-cell lymphoma in a multiple sclerosis patient after discontinuing fingolimod.
    Mult Scler. 2018 May 1:1352458518774444. doi: 10.1177/1352458518774444.
    PubMed    


  612. NAUTA IM, Balk LJ, Sonder JM, Hulst HE, et al
    The clinical value of the patient-reported multiple sclerosis neuropsychological screening questionnaire.
    Mult Scler. 2018 May 1:1352458518777295. doi: 10.1177/1352458518777295.
    PubMed     Abstract available


  613. ROMME CHRISTENSEN J, Komori M, von Essen MR, Ratzer R, et al
    CSF inflammatory biomarkers responsive to treatment in progressive multiple sclerosis capture residual inflammation associated with axonal damage.
    Mult Scler. 2018 May 1:1352458518774880. doi: 10.1177/1352458518774880.
    PubMed     Abstract available


  614. MILLS EA, Mao-Draayer Y
    Aging and lymphocyte changes by immunomodulatory therapies impact PML risk in multiple sclerosis patients.
    Mult Scler. 2018 May 1:1352458518775550. doi: 10.1177/1352458518775550.
    PubMed     Abstract available


  615. VAN DER VUURST DE VRIES RM, Wong YYM, Mescheriakova JY, van Pelt ED, et al
    High neurofilament levels are associated with clinically definite multiple sclerosis in children and adults with clinically isolated syndrome.
    Mult Scler. 2018 May 1:1352458518775303. doi: 10.1177/1352458518775303.
    PubMed     Abstract available


  616. SCHEE JP, Viswanathan S
    Pure spinal multiple sclerosis: A possible novel entity within the multiple sclerosis disease spectrum.
    Mult Scler. 2018 May 1:1352458518775912. doi: 10.1177/1352458518775912.
    PubMed     Abstract available


  617. BOESEN MS, Koch-Henriksen N, Thygesen LC, Eriksson F, et al
    Infections seem to be more frequent before onset of pediatric multiple sclerosis: A Danish nationwide nested case-control study.
    Mult Scler. 2018 May 1:1352458518771871. doi: 10.1177/1352458518771871.
    PubMed     Abstract available


  618. BAKER G, Nair KPS, Baster K, Rosato R, et al
    Reliability and acceptability of the Multiple Sclerosis Quality of Life-29 questionnaire in an English-speaking cohort.
    Mult Scler. 2018 May 1:1352458518776583. doi: 10.1177/1352458518776583.
    PubMed     Abstract available


  619. BEESLEY R, Anderson V, Harding KE, Joseph F, et al
    Impact of the 2017 revisions to McDonald criteria on the diagnosis of multiple sclerosis.
    Mult Scler. 2018 May 1:1352458518778007. doi: 10.1177/1352458518778007.
    PubMed    


  620. HUGOS CL, Cameron MH, Chen Z, Chen Y, et al
    A multicenter randomized controlled trial of two group education programs for fatigue in multiple sclerosis: Long-term (12-month) follow-up at one site.
    Mult Scler. 2018 May 1:1352458518775920. doi: 10.1177/1352458518775920.
    PubMed     Abstract available


  621. TSAGKAS C, Magon S, Gaetano L, Pezold S, et al
    Preferential spinal cord volume loss in primary progressive multiple sclerosis.
    Mult Scler. 2018 May 1:1352458518775006. doi: 10.1177/1352458518775006.
    PubMed     Abstract available


  622. MARANZANO J, Till C, Assemlal HE, Fonov V, et al
    Detection and clinical correlation of leukocortical lesions in pediatric-onset multiple sclerosis on multi-contrast MRI.
    Mult Scler. 2018 May 1:1352458518779952. doi: 10.1177/1352458518779952.
    PubMed     Abstract available


  623. BJORNEVIK K, Myhr KM, Beiske A, Bjerve KS, et al
    alpha-Linolenic acid is associated with MRI activity in a prospective cohort of multiple sclerosis patients.
    Mult Scler. 2018 May 1:1352458518779925. doi: 10.1177/1352458518779925.
    PubMed     Abstract available


    April 2018
  624. ALMEIDA KJ, Barreto-Soares RV, Campos-Sousa RN, Campos-Sousa MG, et al
    Pulmonary paracoccidioidomycosis associated with the use of natalizumab in multiple sclerosis.
    Mult Scler. 2018 Apr 1:1352458518763091. doi: 10.1177/1352458518763091.
    PubMed     Abstract available


  625. MCNICHOLAS N, Lockhart A, Yap SM, O'Connell K, et al
    New versus old: Implications of evolving diagnostic criteria for relapsing-remitting multiple sclerosis.
    Mult Scler. 2018 Apr 1:1352458518770088. doi: 10.1177/1352458518770088.
    PubMed     Abstract available


  626. KREMER D, Kury P, Hartung HP
    ECTRIMS/ACTRIMS 2017: Closing in on neurorepair in progressive multiple sclerosis.
    Mult Scler. 2018 Apr 1:1352458518768770. doi: 10.1177/1352458518768770.
    PubMed     Abstract available


  627. KOBELT G, Langdon D, Jonsson L
    The effect of self-assessed fatigue and subjective cognitive impairment on work capacity: The case of multiple sclerosis.
    Mult Scler. 2018 Apr 1:1352458518769837. doi: 10.1177/1352458518769837.
    PubMed     Abstract available


  628. VAVASOUR IM, Tam R, Li DK, Laule C, et al
    A 24-month advanced magnetic resonance imaging study of multiple sclerosis patients treated with alemtuzumab.
    Mult Scler. 2018 Apr 1:1352458518770085. doi: 10.1177/1352458518770085.
    PubMed     Abstract available


  629. MARRIE RA, Montalban X
    Disease-modifying therapy in multiple sclerosis: Two guidelines (almost) passing in the night.
    Mult Scler. 2018;24:558-562.
    PubMed    


  630. LORSCHEIDER J, Benkert P, Lienert C, Hanni P, et al
    Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis.
    Mult Scler. 2018 Apr 1:1352458518768433. doi: 10.1177/1352458518768433.
    PubMed     Abstract available


  631. SAUL A, Taylor B, Simpson S Jr, Ponsonby AL, et al
    Polymorphism in the serotonin transporter gene polymorphisms ( 5-HTTLPR) modifies the association between significant life events and depression in people with multiple sclerosis.
    Mult Scler. 2018 Apr 1:1352458518770021. doi: 10.1177/1352458518770021.
    PubMed     Abstract available


  632. LLUFRIU S, Rocca MA, Pagani E, Riccitelli GC, et al
    Hippocampal-related memory network in multiple sclerosis: A structural connectivity analysis.
    Mult Scler. 2018 Apr 1:1352458518771838. doi: 10.1177/1352458518771838.
    PubMed     Abstract available


  633. CREARY LE, Mallempati KC, Gangavarapu S, Caillier SJ, et al
    Deconstruction of HLA-DRB1*04:01:01 and HLA-DRB1*15:01:01 class II haplotypes using next-generation sequencing in European-Americans with multiple sclerosis.
    Mult Scler. 2018 Apr 1:1352458518770019. doi: 10.1177/1352458518770019.
    PubMed     Abstract available


  634. MCCLURG D, Bugge C, Elders A, Irshad T, et al
    Factors affecting continuation of clean intermittent catheterisation in people with multiple sclerosis: Results of the COSMOS mixed-methods study.
    Mult Scler. 2018 Apr 1:1352458518768722. doi: 10.1177/1352458518768722.
    PubMed     Abstract available


  635. WAGLEY S, Bokori-Brown M, Morcrette H, Malaspina A, et al
    Evidence of Clostridium perfringens epsilon toxin associated with multiple sclerosis.
    Mult Scler. 2018 Apr 1:1352458518767327. doi: 10.1177/1352458518767327.
    PubMed     Abstract available


  636. GIOVANNONI G, Soelberg Sorensen P, Cook S, Rammohan KW, et al
    Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study.
    Mult Scler. 2018 Apr 1:1352458518771875. doi: 10.1177/1352458518771875.
    PubMed     Abstract available


  637. GIORDANA MT, Cavalla P, Uccelli A, Laroni A, et al
    Overexpression of sphingosine-1-phosphate receptors on reactive astrocytes drives neuropathology of multiple sclerosis rebound after fingolimod discontinuation.
    Mult Scler. 2018 Apr 1:1352458518763095. doi: 10.1177/1352458518763095.
    PubMed     Abstract available


  638. GIACOMINI PS
    Rebound disease in multiple sclerosis.
    Mult Scler. 2018 Apr 1:1352458518772913. doi: 10.1177/1352458518772913.
    PubMed    


  639. HARMEL P, Schlunk F, Harms L
    Fulminant rebound of relapsing-remitting multiple sclerosis after discontinuation of dimethyl fumarate: A case report.
    Mult Scler. 2018 Apr 1:1352458517741191. doi: 10.1177/1352458517741191.
    PubMed     Abstract available


    March 2018
  640. KOENIG KA, Rao SM, Lowe MJ, Lin J, et al
    The role of the thalamus and hippocampus in episodic memory performance in patients with multiple sclerosis.
    Mult Scler. 2018 Mar 1:1352458518760716. doi: 10.1177/1352458518760716.
    PubMed     Abstract available


  641. GOBEL K, Ruck T, Meuth SG
    Cytokine signaling in multiple sclerosis: Lost in translation.
    Mult Scler. 2018 Mar 1:1352458518763094. doi: 10.1177/1352458518763094.
    PubMed     Abstract available


  642. LEE JY, De Jager PL
    What is the epigenome and is it involved in multiple sclerosis?
    Mult Scler. 2018;24:268-269.
    PubMed    


  643. SILLER N, Kuhle J, Muthuraman M, Barro C, et al
    Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis.
    Mult Scler. 2018 Mar 1:1352458518765666. doi: 10.1177/1352458518765666.
    PubMed     Abstract available


  644. SOWA P, Harbo HF, White NS, Celius EG, et al
    Restriction spectrum imaging of white matter and its relation to neurological disability in multiple sclerosis.
    Mult Scler. 2018 Mar 1:1352458518765671. doi: 10.1177/1352458518765671.
    PubMed     Abstract available


  645. CORTI L, Ayrignac X, Carra Dalliere C, Charif M, et al
    Late activity rebound in non-active multiple sclerosis: A rare event.
    Mult Scler. 2018 Mar 1:1352458518765670. doi: 10.1177/1352458518765670.
    PubMed    


  646. CASTELLI L, Prosperini L, Pozzilli C
    Balance worsening associated with nabiximols in multiple sclerosis.
    Mult Scler. 2018 Mar 1:1352458518765649. doi: 10.1177/1352458518765649.
    PubMed     Abstract available


  647. GRAETZ C, Groger A, Luessi F, Salmen A, et al
    Association of smoking but not HLA-DRB1*15:01, APOE or body mass index with brain atrophy in early multiple sclerosis.
    Mult Scler. 2018 Mar 1:1352458518763541. doi: 10.1177/1352458518763541.
    PubMed     Abstract available


  648. HUA LH, Fan TH, Conway D, Thompson N, et al
    Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60.
    Mult Scler. 2018 Mar 1:1352458518765656. doi: 10.1177/1352458518765656.
    PubMed     Abstract available


  649. LANZILLO R, Moccia M, Criscuolo C, Cennamo G, et al
    Optical coherence tomography angiography detects retinal vascular alterations in different phases of multiple sclerosis.
    Mult Scler. 2018 Mar 1:1352458518768060. doi: 10.1177/1352458518768060.
    PubMed    


  650. VAN GEEST Q, Boeschoten RE, Keijzer MJ, Steenwijk MD, et al
    Fronto-limbic disconnection in patients with multiple sclerosis and depression.
    Mult Scler. 2018 Mar 1:1352458518767051. doi: 10.1177/1352458518767051.
    PubMed     Abstract available


  651. TOLEDANO M, Weinshenker BG, Kaufmann TJ, Parisi JE, et al
    Demographics and clinical characteristics of episodic hypothermia in multiple sclerosis.
    Mult Scler. 2018 Mar 1:1352458518767045. doi: 10.1177/1352458518767045.
    PubMed     Abstract available


  652. LEIBOVITCH EC, Lin CM, Billioux BJ, Graves J, et al
    Prevalence of salivary human herpesviruses in pediatric multiple sclerosis cases and controls.
    Mult Scler. 2018 Mar 1:1352458518765654. doi: 10.1177/1352458518765654.
    PubMed     Abstract available


  653. KIRA JI
    Reply to letter to the editor: Dimethyl fumarate for patients with neuromyelitis optica spectrum disorder by Pitarokoili and Gold.
    Mult Scler. 2018;24:366-367.
    PubMed    


  654. YAMOUT BI, Zeineddine MM
    Letter to the editor.
    Mult Scler. 2018;24:363.
    PubMed    


  655. PITAROKOILI K, Gold R
    Dimethyl fumarate for patients with neuromyelitis optica spectrum disorder.
    Mult Scler. 2018;24:364-365.
    PubMed    


    February 2018
  656. JAEGER S, Paul F, Scheel M, Brandt A, et al
    Multiple sclerosis-related fatigue: Altered resting-state functional connectivity of the ventral striatum and dorsolateral prefrontal cortex.
    Mult Scler. 2018 Feb 1:1352458518758911. doi: 10.1177/1352458518758911.
    PubMed     Abstract available


  657. DE STEFANO N, Giorgio A, Tintore M, Pia Amato M, et al
    Radiologically isolated syndrome or subclinical multiple sclerosis: MAGNIMS consensus recommendations.
    Mult Scler. 2018;24:214-221.
    PubMed    


  658. ROOSTAEI T, Sadaghiani S, Mashhadi R, Falahatian M, et al
    Convergent effects of a functional C3 variant on brain atrophy, demyelination, and cognitive impairment in multiple sclerosis.
    Mult Scler. 2018 Feb 1:1352458518760715. doi: 10.1177/1352458518760715.
    PubMed     Abstract available


  659. CAVALERA C, Rovaris M, Mendozzi L, Pugnetti L, et al
    Online meditation training for people with multiple sclerosis: A randomized controlled trial.
    Mult Scler. 2018 Feb 1:1352458518761187. doi: 10.1177/1352458518761187.
    PubMed     Abstract available


  660. CAMARA-LEMARROY CR, Castillo J, Sastre-Garriga J, Tintore M, et al
    Severe hypertriglyceridemia associated with teriflunomide in a patient with multiple sclerosis: A case report.
    Mult Scler. 2018 Feb 1:1352458518761185. doi: 10.1177/1352458518761185.
    PubMed     Abstract available


  661. PIEHL F, Hillert J
    Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis - Yes.
    Mult Scler. 2018 Feb 1:1352458518757930. doi: 10.1177/1352458518757930.
    PubMed    


  662. CREE BA
    Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis - Commentary.
    Mult Scler. 2018 Feb 1:1352458518760717. doi: 10.1177/1352458518760717.
    PubMed    


  663. WALLIN MT
    Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis - No.
    Mult Scler. 2018 Feb 1:1352458518757931. doi: 10.1177/1352458518757931.
    PubMed    


  664. BARKHOF F
    The optic nerve should be included as one of the typical CNS regions for establishing dissemination in space when diagnosing MS - Commentary.
    Mult Scler. 2018;24:125-126.
    PubMed    


  665. PORTER B
    Commentary on "Localized pigmentation disorder after subcutaneous pegylated interferon beta 1a injection" by Coghe et al.
    Mult Scler. 2018;24:233-235.
    PubMed    


    January 2018
  666. HILVEN K, Vandebergh M, Smets I, Mallants K, et al
    Genetic basis for relapse rate in multiple sclerosis: Association with LRP2 genetic variation.
    Mult Scler. 2018 Jan 1:1352458517749894. doi: 10.1177/1352458517749894.
    PubMed     Abstract available


  667. FEUCHT N, Maier M, Lepennetier G, Pettenkofer M, et al
    Optical coherence tomography angiography indicates associations of the retinal vascular network and disease activity in multiple sclerosis.
    Mult Scler. 2018 Jan 1:1352458517750009. doi: 10.1177/1352458517750009.
    PubMed     Abstract available


  668. DI STADIO A, Ralli M
    Inner ear involvement in multiple sclerosis: An underestimated condition?
    Mult Scler. 2018 Jan 1:1352458518750010. doi: 10.1177/1352458518750010.
    PubMed    


  669. DAMOTTE V, Lizee A, Tremblay M, Agrawal A, et al
    Harnessing electronic medical records to advance research on multiple sclerosis.
    Mult Scler. 2018 Jan 1:1352458517747407. doi: 10.1177/1352458517747407.
    PubMed     Abstract available


  670. DE STEFANO N, Giorgio A
    Response to 'Does cladribine have an impact on brain atrophy in people with relapsing remitting multiple sclerosis?' by Schiffmann et al.
    Mult Scler. 2018 Jan 1:1352458517748476. doi: 10.1177/1352458517748476.
    PubMed    


  671. SCHIFFMANN I, Scheiderbauer J, Riemann-Lorenz K, Heesen C, et al
    Does cladribine have an impact on brain atrophy in people with relapsing remitting multiple sclerosis?
    Mult Scler. 2018 Jan 1:1352458517749895. doi: 10.1177/1352458517749895.
    PubMed    


  672. SEGAL BM, Cohen JA, Antel J
    Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2017: Environmental factors, genetics, and epigenetics in MS susceptibility and clinical course.
    Mult Scler. 2018;24:4-5.
    PubMed     Abstract available


  673. TREMLETT H, Waubant E
    Gut microbiome and pediatric multiple sclerosis.
    Mult Scler. 2018;24:64-68.
    PubMed     Abstract available


  674. CASTRO K, Casaccia P
    Epigenetic modifications in brain and immune cells of multiple sclerosis patients.
    Mult Scler. 2018;24:69-74.
    PubMed     Abstract available


  675. TANKOU SK, Regev K, Healy BC, Cox LM, et al
    Investigation of probiotics in multiple sclerosis.
    Mult Scler. 2018;24:58-63.
    PubMed     Abstract available


  676. VOSKUHL RR, Sawalha AH, Itoh Y
    Sex chromosome contributions to sex differences in multiple sclerosis susceptibility and progression.
    Mult Scler. 2018;24:22-31.
    PubMed     Abstract available


  677. HAASE S, Haghikia A, Gold R, Linker RA, et al
    Dietary fatty acids and susceptibility to multiple sclerosis.
    Mult Scler. 2018;24:12-16.
    PubMed     Abstract available


  678. HARROUD A, Richards JB
    Mendelian randomization in multiple sclerosis: A causal role for vitamin D and obesity?
    Mult Scler. 2018;24:80-85.
    PubMed     Abstract available


  679. DOLEI A
    The aliens inside us: HERV-W endogenous retroviruses and multiple sclerosis.
    Mult Scler. 2018;24:42-47.
    PubMed     Abstract available


  680. CANTO E, Oksenberg JR
    Multiple sclerosis genetics.
    Mult Scler. 2018;24:75-79.
    PubMed     Abstract available


  681. WAUBANT E
    Effect of puberty on multiple sclerosis risk and course.
    Mult Scler. 2018;24:32-35.
    PubMed     Abstract available


  682. HODEL J, Bapst B, Outteryck O, Verclytte S, et al
    Magnetic resonance imaging changes following natalizumab discontinuation in multiple sclerosis patients with progressive multifocal leukoencephalopathy.
    Mult Scler. 2018 Jan 1:1352458517750765. doi: 10.1177/1352458517750765.
    PubMed     Abstract available


  683. BOVE R, Healy BC, Musallam A, Soltany P, et al
    Fatty acid binding protein-4 is associated with disability in multiple sclerosis patients.
    Mult Scler. 2018 Jan 1:1352458517750768. doi: 10.1177/1352458517750768.
    PubMed     Abstract available


  684. RIMKUS CM, Schoonheim MM, Steenwijk MD, Vrenken H, et al
    Gray matter networks and cognitive impairment in multiple sclerosis.
    Mult Scler. 2018 Jan 1:1352458517751650. doi: 10.1177/1352458517751650.
    PubMed     Abstract available


  685. COHEN JA, Hunter SF, Brown TR, Gudesblatt M, et al
    Safety and efficacy of ADS-5102 (amantadine) extended release capsules to improve walking in multiple sclerosis: A randomized, placebo-controlled, phase 2 trial.
    Mult Scler. 2018 Jan 1:1352458518754716. doi: 10.1177/1352458518754716.
    PubMed     Abstract available


  686. BARONCINI D, Zaffaroni M, Moiola L, Lorefice L, et al
    Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study.
    Mult Scler. 2018 Jan 1:1352458518754364. doi: 10.1177/1352458518754364.
    PubMed     Abstract available


  687. FORD HL, Wicks CR, Stroud A, Tennant A, et al
    Psychological determinants of job retention in multiple sclerosis.
    Mult Scler. 2018 Jan 1:1352458518754362. doi: 10.1177/1352458518754362.
    PubMed     Abstract available


  688. ROY S, Drake A, Fuchs T, Dwyer MG, et al
    Longitudinal personality change associated with cognitive decline in multiple sclerosis.
    Mult Scler. 2018 Jan 1:1352458517753720. doi: 10.1177/1352458517753720.
    PubMed     Abstract available


  689. HAUPTS MR, Spill-Askeridis P, Humpert M, Seidel D, et al
    Acute exacerbations after decades of non-active chronic multiple sclerosis.
    Mult Scler. 2018 Jan 1:1352458518754365. doi: 10.1177/1352458518754365.
    PubMed    


  690. DI IOIA M, Farina D, di Tommaso V, Travaglini D, et al
    Simultaneous early-onset severe autoimmune hemolytic anemia and albuminuria during alemtuzumab treatment for multiple sclerosis.
    Mult Scler. 2018 Jan 1:1352458517743093. doi: 10.1177/1352458517743093.
    PubMed     Abstract available


  691. MEUNIER B, Rico A, Seguier J, Boutiere C, et al
    Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab.
    Mult Scler. 2018 Jan 1:1352458517729766. doi: 10.1177/1352458517729766.
    PubMed     Abstract available


  692. MONTALBAN X, Gold R, Thompson AJ, Otero-Romero S, et al
    ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis.
    Mult Scler. 2018 Jan 1:1352458517751049. doi: 10.1177/1352458517751049.
    PubMed     Abstract available


  693. LAVERY AM, Collins BN, Waldman AT, Hart CN, et al
    The contribution of secondhand tobacco smoke exposure to pediatric multiple sclerosis risk.
    Mult Scler. 2018 Jan 1:1352458518757089. doi: 10.1177/1352458518757089.
    PubMed     Abstract available


    December 2017
  694. KROTH J, Ciolac D, Fleischer V, Koirala N, et al
    Increased cerebrospinal fluid albumin and immunoglobulin A fractions forecast cortical atrophy and longitudinal functional deterioration in relapsing-remitting multiple sclerosis.
    Mult Scler. 2017 Dec 1:1352458517748474. doi: 10.1177/1352458517748474.
    PubMed     Abstract available


  695. HUGOS CL, Chen Z, Chen Y, Turner AP, et al
    A multicenter randomized controlled trial of two group education programs for fatigue in multiple sclerosis: Short- and medium-term benefits.
    Mult Scler. 2017 Dec 1:1352458517745723. doi: 10.1177/1352458517745723.
    PubMed     Abstract available


  696. CALLESEN J, Richter C, Kristensen C, Sunesen I, et al
    Test-retest agreement and reliability of the Six Spot Step Test in persons with multiple sclerosis.
    Mult Scler. 2017 Dec 1:1352458517745725. doi: 10.1177/1352458517745725.
    PubMed     Abstract available


  697. PEETERS LM
    Fair data for next-generation management of multiple sclerosis.
    Mult Scler. 2017 Dec 1:1352458517748475. doi: 10.1177/1352458517748475.
    PubMed     Abstract available


    November 2017
  698. GRAN-RUAZ S, Mani A, O'Quinn S
    An overview of biosimilars and non-biologic complex drugs in Europe, the United States, and Canada and their relevance to multiple sclerosis.
    Mult Scler. 2017 Nov 1:1352458517739976. doi: 10.1177/1352458517739976.
    PubMed     Abstract available


  699. MANCARDI G, Sormani MP, Muraro PA, Boffa G, et al
    Intense immunosuppression followed by autologous haematopoietic stem cell transplantation as a therapeutic strategy in aggressive forms of multiple sclerosis.
    Mult Scler. 2017 Nov 1:1352458517742532. doi: 10.1177/1352458517742532.
    PubMed     Abstract available


  700. PIETROBONI AM, Dell'Arti L, Caprioli M, Scarioni M, et al
    The loss of macular ganglion cells begins from the early stages of disease and correlates with brain atrophy in multiple sclerosis patients.
    Mult Scler. 2017 Nov 1:1352458517740214. doi: 10.1177/1352458517740214.
    PubMed     Abstract available


  701. MALHOTRA S, Sorosina M, Rio J, Peroni S, et al
    NLRP3 polymorphisms and response to interferon-beta in multiple sclerosis patients.
    Mult Scler. 2017 Nov 1:1352458517739137. doi: 10.1177/1352458517739137.
    PubMed     Abstract available


  702. MALINOVA TS, Dijkstra CD, de Vries HE
    Serotonin: A mediator of the gut-brain axis in multiple sclerosis.
    Mult Scler. 2017 Nov 1:1352458517739975. doi: 10.1177/1352458517739975.
    PubMed     Abstract available


  703. ABBOUD H, Hill E, Siddiqui J, Serra A, et al
    Neuromodulation in multiple sclerosis.
    Mult Scler. 2017;23:1663-1676.
    PubMed     Abstract available


  704. FEYS P, Moumdjian L, Van Halewyck F, Wens I, et al
    Effects of an individual 12-week community-located "start-to-run" program on physical capacity, walking, fatigue, cognitive function, brain volumes, and structures in persons with multiple sclerosis.
    Mult Scler. 2017 Nov 1:1352458517740211. doi: 10.1177/1352458517740211.
    PubMed     Abstract available


  705. LOREFICE L, Fenu G, Sardu C, Frau J, et al
    Multiple sclerosis and HLA genotypes: A possible influence on brain atrophy.
    Mult Scler. 2017 Nov 1:1352458517739989. doi: 10.1177/1352458517739989.
    PubMed     Abstract available


  706. WINGES KM, Murchison CF, Bourdette DN, Spain RI, et al
    Longitudinal optical coherence tomography study of optic atrophy in secondary progressive multiple sclerosis: Results from a clinical trial cohort.
    Mult Scler. 2017 Nov 1:1352458517739136. doi: 10.1177/1352458517739136.
    PubMed     Abstract available


  707. UHER T, Vaneckova M, Krasensky J, Sobisek L, et al
    Pathological cut-offs of global and regional brain volume loss in multiple sclerosis.
    Mult Scler. 2017 Nov 1:1352458517742739. doi: 10.1177/1352458517742739.
    PubMed     Abstract available


  708. KAVALIUNAS A, Danylaite Karrenbauer V, Gyllensten H, Manouchehrinia A, et al
    Cognitive function is a major determinant of income among multiple sclerosis patients in Sweden acting independently from physical disability.
    Mult Scler. 2017 Nov 1:1352458517740212. doi: 10.1177/1352458517740212.
    PubMed     Abstract available


  709. AGIUS MA, Klodowska-Duda G, Maciejowski M, Potemkowski A, et al
    Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study.
    Mult Scler. 2017 Nov 1:1352458517740641. doi: 10.1177/1352458517740641.
    PubMed     Abstract available


  710. SPITERI S, Hassa T, Claros-Salinas D, Dettmers C, et al
    Neural correlates of effort-dependent and effort-independent cognitive fatigue components in patients with multiple sclerosis.
    Mult Scler. 2017 Nov 1:1352458517743090. doi: 10.1177/1352458517743090.
    PubMed     Abstract available


  711. RICCITELLI GC, Pagani E, Rodegher M, Colombo B, et al
    Imaging patterns of gray and white matter abnormalities associated with PASAT and SDMT performance in relapsing-remitting multiple sclerosis.
    Mult Scler. 2017 Nov 1:1352458517743091. doi: 10.1177/1352458517743091.
    PubMed     Abstract available


    October 2017
  712. MOSS-MORRIS R, Norton S
    Aerobic exercise, cognitive behavioural therapy and energy conservation management for multiple sclerosis (MS) fatigue: Are three trials better than one?
    Mult Scler. 2017;23:1436-1440.
    PubMed    


  713. ZETTERBERG H, Teunissen C
    Fluid biomarkers for disease activity in multiple sclerosis.
    Mult Scler. 2017 Oct 1:1352458517736151. doi: 10.1177/1352458517736151.
    PubMed    


  714. BOESEN F, Norgaard M, Trenel P, Rasmussen PV, et al
    Longer term effectiveness of inpatient multidisciplinary rehabilitation on health-related quality of life in MS patients: a pragmatic randomized controlled trial - The Danish MS Hospitals Rehabilitation Study.
    Mult Scler. 2017 Oct 1:1352458517735188. doi: 10.1177/1352458517735188.
    PubMed     Abstract available


  715. GIANFRANCESCO MA, Stridh P, Shao X, Rhead B, et al
    Genetic risk factors for pediatric-onset multiple sclerosis.
    Mult Scler. 2017 Oct 1:1352458517733551. doi: 10.1177/1352458517733551.
    PubMed     Abstract available


  716. VAN KEMPEN ZL, Rispens T, Killestein J
    Response to "Letter to the editor on the paper: The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing".
    Mult Scler. 2017 Oct 1:1352458517734073. doi: 10.1177/1352458517734073.
    PubMed    


  717. FOX RJ, Chataway J
    Advancing trial design in progressive multiple sclerosis.
    Mult Scler. 2017;23:1573-1578.
    PubMed     Abstract available


  718. MILLER DH, Thompson AJ
    Advancing trial design in progressive multiple sclerosis.
    Mult Scler. 2017;23:1571-1572.
    PubMed    


  719. MOCCIA M, de Stefano N, Barkhof F
    Imaging outcome measures for progressive multiple sclerosis trials.
    Mult Scler. 2017;23:1614-1626.
    PubMed     Abstract available


  720. PICHLER A, Khalil M, Langkammer C, Pinter D, et al
    The impact of vascular risk factors on brain volume and lesion load in patients with early multiple sclerosis.
    Mult Scler. 2017 Oct 1:1352458517736149. doi: 10.1177/1352458517736149.
    PubMed     Abstract available


  721. GLAZER CH, Tottenborg SS, Giwercman A, Brauner EV, et al
    Male factor infertility and risk of multiple sclerosis: A register-based cohort study.
    Mult Scler. 2017 Oct 1:1352458517734069. doi: 10.1177/1352458517734069.
    PubMed     Abstract available


  722. TINELLI M, Kanavos P, Efthymiadou O, Visintin E, et al
    Using IMPrESS to guide policy change in multiple sclerosis.
    Mult Scler. 2017 Oct 1:1352458517737388. doi: 10.1177/1352458517737388.
    PubMed     Abstract available


  723. DONADIEU M, Le Fur Y, Maarouf A, Gherib S, et al
    Metabolic counterparts of sodium accumulation in multiple sclerosis: A whole brain 23Na-MRI and fast 1H-MRSI study.
    Mult Scler. 2017 Oct 1:1352458517736146. doi: 10.1177/1352458517736146.
    PubMed     Abstract available


  724. FLEMING J, Hernandez G, Hartman L, Maksimovic J, et al
    Safety and efficacy of helminth treatment in relapsing-remitting multiple sclerosis: Results of the HINT 2 clinical trial.
    Mult Scler. 2017 Oct 1:1352458517736377. doi: 10.1177/1352458517736377.
    PubMed     Abstract available


  725. BSTEH G, Hegen H, Teuchner B, Amprosi M, et al
    Peripapillary retinal nerve fibre layer as measured by optical coherence tomography is a prognostic biomarker not only for physical but also for cognitive disability progression in multiple sclerosis.
    Mult Scler. 2017 Oct 1:1352458517740216. doi: 10.1177/1352458517740216.
    PubMed     Abstract available


  726. LEAVITT VM, Blanchard AR, Guo CY, Gelernt E, et al
    Aspirin is an effective pretreatment for exercise in multiple sclerosis: A double-blind randomized controlled pilot trial.
    Mult Scler. 2017 Oct 1:1352458517739138. doi: 10.1177/1352458517739138.
    PubMed     Abstract available


  727. DEKKER I, Sombekke MH, Witte BI, Geurts JJ, et al
    Asymptomatic spinal cord lesions do not predict the time to disability in patients with early multiple sclerosis.
    Mult Scler. 2017 Oct 1:1352458517736147. doi: 10.1177/1352458517736147.
    PubMed     Abstract available


    September 2017
  728. TOBYNE SM, Ochoa WB, Bireley JD, Smith VM, et al
    Cognitive impairment and the regional distribution of cerebellar lesions in multiple sclerosis.
    Mult Scler. 2017 Sep 1:1352458517730132. doi: 10.1177/1352458517730132.
    PubMed     Abstract available


  729. FAZIA T, Pastorino R, Foco L, Han L, et al
    Investigating multiple sclerosis genetic susceptibility on the founder population of east-central Sardinia via association and linkage analysis of immune-related loci.
    Mult Scler. 2017 Sep 1:1352458517732841. doi: 10.1177/1352458517732841.
    PubMed     Abstract available


  730. HUPPKE P, Huppke B, Ellenberger D, Rostasy K, et al
    Therapy of highly active pediatric multiple sclerosis.
    Mult Scler. 2017 Sep 1:1352458517732843. doi: 10.1177/1352458517732843.
    PubMed     Abstract available


  731. LANZILLO R, Cennamo G, Criscuolo C, Carotenuto A, et al
    Optical coherence tomography angiography retinal vascular network assessment in multiple sclerosis.
    Mult Scler. 2017 Sep 1:1352458517729463. doi: 10.1177/1352458517729463.
    PubMed     Abstract available


  732. COMBER L, Quinn G, McGuigan C, Galvin R, et al
    Medication usage and falls in people with multiple sclerosis.
    Mult Scler. 2017 Sep 1:1352458517731912. doi: 10.1177/1352458517731912.
    PubMed     Abstract available


  733. MEINL I, Havla J, Hohlfeld R, Kumpfel T, et al
    Recurrence of disease activity during pregnancy after cessation of fingolimod in multiple sclerosis.
    Mult Scler. 2017 Sep 1:1352458517731913. doi: 10.1177/1352458517731913.
    PubMed     Abstract available


  734. GIOVANNONI G, Wiendl H, Turner B, Umans K, et al
    Circulating lymphocyte levels and relationship with infection status in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta.
    Mult Scler. 2017 Sep 1:1352458517729464. doi: 10.1177/1352458517729464.
    PubMed     Abstract available


  735. KAPPOS L, Arnold DL, Bar-Or A, Camm AJ, et al
    Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis.
    Mult Scler. 2017 Sep 1:1352458517728343. doi: 10.1177/1352458517728343.
    PubMed     Abstract available


  736. BISECCO A, Nardo FD, Docimo R, Caiazzo G, et al
    Fatigue in multiple sclerosis: The contribution of resting-state functional connectivity reorganization.
    Mult Scler. 2017 Sep 1:1352458517730932. doi: 10.1177/1352458517730932.
    PubMed     Abstract available


  737. CHARVET LE, Dobbs B, Shaw MT, Bikson M, et al
    Remotely supervised transcranial direct current stimulation for the treatment of fatigue in multiple sclerosis: Results from a randomized, sham-controlled trial.
    Mult Scler. 2017 Sep 1:1352458517732842. doi: 10.1177/1352458517732842.
    PubMed     Abstract available


    August 2017
  738. BRUNDIN L, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Sweden.
    Mult Scler. 2017;23.
    PubMed     Abstract available


  739. BATTAGLIA M, Kobelt G, Ponzio M, Berg J, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Italy.
    Mult Scler. 2017;23.
    PubMed     Abstract available


  740. BERGER T, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Austria.
    Mult Scler. 2017;23.
    PubMed     Abstract available


  741. DUBOIS B, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Belgium.
    Mult Scler. 2017;23.
    PubMed     Abstract available


  742. OREJA-GUEVARA C, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Spain.
    Mult Scler. 2017;23.
    PubMed     Abstract available


  743. CALABRESE P, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Switzerland.
    Mult Scler. 2017;23.
    PubMed     Abstract available


  744. UITDEHAAG B, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for the Netherlands.
    Mult Scler. 2017;23.
    PubMed     Abstract available


  745. FLACHENECKER P, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Germany.
    Mult Scler. 2017;23.
    PubMed     Abstract available


  746. KOBELT G, Eriksson J, Phillips G, Berg J, et al
    The burden of multiple sclerosis 2015: Methods of data collection, assessment and analysis of costs, quality of life and symptoms.
    Mult Scler. 2017;23.
    PubMed     Abstract available


  747. PENTEK M, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Hungary.
    Mult Scler. 2017;23.
    PubMed     Abstract available


  748. BOYKO A, Kobelt G, Berg J, Boyko O, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Russia.
    Mult Scler. 2017;23.
    PubMed     Abstract available


  749. RASMUSSEN PV, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Denmark.
    Mult Scler. 2017;23.
    PubMed     Abstract available


  750. LEBRUN-FRENAY C, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for France.
    Mult Scler. 2017;23.
    PubMed     Abstract available


  751. THOMPSON A, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for the United Kingdom.
    Mult Scler. 2017;23.
    PubMed     Abstract available


  752. SELMAJ K, Kobelt G, Berg J, Orlewska E, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Poland.
    Mult Scler. 2017;23.
    PubMed     Abstract available


  753. SA MJ, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results for Portugal.
    Mult Scler. 2017;23.
    PubMed     Abstract available


  754. HAVRDOVA E, Kobelt G, Berg J, Capsa D, et al
    New insights into the burden and costs of multiple sclerosis in Europe: Results of the Czech Republic.
    Mult Scler. 2017;23.
    PubMed     Abstract available


  755. VERMOHLEN V, Schiller P, Schickendantz S, Drache M, et al
    Hippotherapy for patients with multiple sclerosis: A multicenter randomized controlled trial (MS-HIPPO).
    Mult Scler. 2017 Aug 1:1352458517721354. doi: 10.1177/1352458517721354.
    PubMed     Abstract available


  756. RUHRMANN S, Ewing E, Piket E, Kular L, et al
    Hypermethylation of MIR21 in CD4+ T cells from patients with relapsing-remitting multiple sclerosis associates with lower miRNA-21 levels and concomitant up-regulation of its target genes.
    Mult Scler. 2017 Aug 1:1352458517721356. doi: 10.1177/1352458517721356.
    PubMed     Abstract available


  757. LAROCCA NG, Hudson LD, Rudick R, Amtmann D, et al
    The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability.
    Mult Scler. 2017 Aug 1:1352458517723718. doi: 10.1177/1352458517723718.
    PubMed     Abstract available


  758. VAVASOUR IM, Huijskens SC, Li DK, Traboulsee AL, et al
    Global loss of myelin water over 5 years in multiple sclerosis normal-appearing white matter.
    Mult Scler. 2017 Aug 1:1352458517723717. doi: 10.1177/1352458517723717.
    PubMed     Abstract available


  759. BERGAMASCHI R, Cortese A, Pichiecchio A, Berzolari FG, et al
    Air pollution is associated to the multiple sclerosis inflammatory activity as measured by brain MRI.
    Mult Scler. 2017 Aug 1:1352458517726866. doi: 10.1177/1352458517726866.
    PubMed     Abstract available


  760. SEHR T, Proschmann U, Thomas K, Ziemssen T, et al
    Letter to the editor on the paper: "The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing".
    Mult Scler. 2017 Aug 1:1352458517726384. doi: 10.1177/1352458517726384.
    PubMed    


  761. LOUAPRE C, Govindarajan ST, Gianni C, Madigan N, et al
    Heterogeneous pathological processes account for thalamic degeneration in multiple sclerosis: Insights from 7 T imaging.
    Mult Scler. 2017 Aug 1:1352458517726382. doi: 10.1177/1352458517726382.
    PubMed     Abstract available


  762. SELLEBJERG F, Bornsen L, Ammitzboll C, Nielsen JE, et al
    Defining active progressive multiple sclerosis.
    Mult Scler. 2017 Aug 1:1352458517726592. doi: 10.1177/1352458517726592.
    PubMed     Abstract available


  763. ZIMMER P, Bloch W, Schenk A, Oberste M, et al
    High-intensity interval exercise improves cognitive performance and reduces matrix metalloproteinases-2 serum levels in persons with multiple sclerosis: A randomized controlled trial.
    Mult Scler. 2017 Aug 1:1352458517728342. doi: 10.1177/1352458517728342.
    PubMed     Abstract available


  764. LEURS CE, van Kempen ZL, Dekker I, Balk LJ, et al
    Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients.
    Mult Scler. 2017 Aug 1:1352458517726381. doi: 10.1177/1352458517726381.
    PubMed     Abstract available


  765. SOLOMON AJ, Watts R, Ontaneda D, Absinta M, et al
    Diagnostic performance of central vein sign for multiple sclerosis with a simplified three-lesion algorithm.
    Mult Scler. 2017 Aug 1:1352458517726383. doi: 10.1177/1352458517726383.
    PubMed     Abstract available


  766. AFOLABI D, Albor C, Zalewski L, Altmann DR, et al
    Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis.
    Mult Scler. 2017 Aug 1:1352458517726380. doi: 10.1177/1352458517726380.
    PubMed     Abstract available


  767. FAISSNER S, Mahjoub Y, Mishra M, Haupeltshofer S, et al
    Unexpected additive effects of minocycline and hydroxychloroquine in models of multiple sclerosis: Prospective combination treatment for progressive disease?
    Mult Scler. 2017 Aug 1:1352458517728811. doi: 10.1177/1352458517728811.
    PubMed     Abstract available


  768. KALINCIK T, Jokubaitis V, Spelman T, Horakova D, et al
    Cladribine versus fingolimod, natalizumab and interferon beta for multiple sclerosis.
    Mult Scler. 2017 Aug 1:1352458517728812. doi: 10.1177/1352458517728812.
    PubMed     Abstract available


  769. BOVE R, Chitnis T, Cree BA, Tintore M, et al
    SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts.
    Mult Scler. 2017 Aug 1:1352458517726657. doi: 10.1177/1352458517726657.
    PubMed     Abstract available


  770. GIOVANNONI G, Soelberg Sorensen P, Cook S, Rammohan K, et al
    Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study.
    Mult Scler. 2017 Aug 1:1352458517727603. doi: 10.1177/1352458517727603.
    PubMed     Abstract available


    July 2017
  771. MIGLIORE S, Curcio G, Couyoumdjian A, Ghazaryan A, et al
    Executive functioning in relapsing-remitting multiple sclerosis patients without cognitive impairment: A task-switching protocol.
    Mult Scler. 2017 Jul 1:1352458517719149. doi: 10.1177/1352458517719149.
    PubMed     Abstract available


  772. KJOLHEDE T, Siemonsen S, Wenzel D, Stellmann JP, et al
    Can resistance training impact MRI outcomes in relapsing-remitting multiple sclerosis?
    Mult Scler. 2017 Jul 1:1352458517722645. doi: 10.1177/1352458517722645.
    PubMed     Abstract available


  773. TANAKA M, Kinoshita M, Tanaka K
    Intermittent drug holidays in fingolimod therapy for multiple sclerosis.
    Mult Scler. 2017 Jul 1:1352458517722647. doi: 10.1177/1352458517722647.
    PubMed    


  774. RODRIGUEZ-LEAL FA, Haase R, Thomas K, Eisele JC, et al
    Fampridine response in MS patients with gait impairment in a real-world setting: Need for new response criteria?
    Mult Scler. 2017 Jul 1:1352458517720043. doi: 10.1177/1352458517720043.
    PubMed     Abstract available


  775. STAMPANONI BASSI M, Leocani L, Comi G, Iezzi E, et al
    Can pharmacological manipulation of LTP favor the effects of motor rehabilitation in multiple sclerosis?
    Mult Scler. 2017 Jul 1:1352458517721358. doi: 10.1177/1352458517721358.
    PubMed     Abstract available


  776. ROLF L, Muris AH, Mathias A, Du Pasquier R, et al
    Exploring the effect of vitamin D3 supplementation on the anti-EBV antibody response in relapsing-remitting multiple sclerosis.
    Mult Scler. 2017 Jul 1:1352458517722646. doi: 10.1177/1352458517722646.
    PubMed     Abstract available


  777. BALDASSARI LE, Salter AR, Longbrake EE, Cross AH, et al
    Streamlined EDSS for use in multiple sclerosis clinical practice: Development and cross-sectional comparison to EDSS.
    Mult Scler. 2017 Jul 1:1352458517721357. doi: 10.1177/1352458517721357.
    PubMed     Abstract available


  778. DUNN N, Juto A, Ryner M, Manouchehrinia A, et al
    Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies.
    Mult Scler. 2017 Jul 1:1352458517720044. doi: 10.1177/1352458517720044.
    PubMed     Abstract available


  779. CANCELLI A, Cottone C, Giordani A, Migliore S, et al
    Personalized, bilateral whole-body somatosensory cortex stimulation to relieve fatigue in multiple sclerosis.
    Mult Scler. 2017 Jul 1:1352458517720528. doi: 10.1177/1352458517720528.
    PubMed     Abstract available


    June 2017
  780. CHOI IY, Lee P, Adany P, Hughes AJ, et al
    In vivo evidence of oxidative stress in brains of patients with progressive multiple sclerosis.
    Mult Scler. 2017 Jun 1:1352458517711568. doi: 10.1177/1352458517711568.
    PubMed     Abstract available


  781. SATTARNEZHAD N, Farrow S, Kimbrough D, Glanz B, et al
    Agreement analysis comparing iPad LCVA and Sloan testing in multiple sclerosis patients.
    Mult Scler. 2017 Jun 1:1352458517713667. doi: 10.1177/1352458517713667.
    PubMed     Abstract available


  782. LEE H, Nakamura K, Narayanan S, Brown R, et al
    Impact of immunoablation and autologous hematopoietic stem cell transplantation on gray and white matter atrophy in multiple sclerosis.
    Mult Scler. 2017 Jun 1:1352458517715811. doi: 10.1177/1352458517715811.
    PubMed     Abstract available


  783. BOESEN MS, Magyari M, Koch-Henriksen N, Thygesen LC, et al
    Pediatric-onset multiple sclerosis and other acquired demyelinating syndromes of the central nervous system in Denmark during 1977-2015: A nationwide population-based incidence study.
    Mult Scler. 2017 Jun 1:1352458517713669. doi: 10.1177/1352458517713669.
    PubMed     Abstract available


  784. PAKPOOR J, Seminatore B, Graves JS, Schreiner T, et al
    Dietary factors and pediatric multiple sclerosis: A case-control study.
    Mult Scler. 2017 Jun 1:1352458517713343. doi: 10.1177/1352458517713343.
    PubMed     Abstract available


  785. SALMEN A
    Clinical commentary on "Varicella-zoster meningovasculitis in a multiple sclerosis patient treated with natalizumab".
    Mult Scler. 2017 Jun 1:1352458517717810. doi: 10.1177/1352458517717810.
    PubMed    


  786. MULERO P, Auger C, Parolin L, Fonseca E, et al
    Varicella-zoster meningovasculitis in a multiple sclerosis patient treated with natalizumab.
    Mult Scler. 2017 Jun 1:1352458517711569. doi: 10.1177/1352458517711569.
    PubMed     Abstract available


  787. FOLEY RW, Tagg NT, Schindler MK, Fenton KM, et al
    Recurrent natalizumab-related aseptic meningitis in a patient with multiple sclerosis.
    Mult Scler. 2017 Jun 1:1352458517702533. doi: 10.1177/1352458517702533.
    PubMed     Abstract available


  788. DOBRYAKOVA E, Hulst HE, Spirou A, Chiaravalloti ND, et al
    Fronto-striatal network activation leads to less fatigue in multiple sclerosis.
    Mult Scler. 2017 Jun 1:1352458517717087. doi: 10.1177/1352458517717087.
    PubMed     Abstract available


  789. RANGANATHAN U, Kaunzner U, Foster S, Vartanian T, et al
    Thrombocytopenia at the time of alemtuzumab infusion in relapsing-remitting multiple sclerosis.
    Mult Scler. 2017 Jun 1:1352458517719152. doi: 10.1177/1352458517719152.
    PubMed    


  790. YAP SM, McNicholas N, Hutchinson M, McGuigan C, et al
    Immediate thrombocytopenia at time of alemtuzumab infusion for multiple sclerosis - Not always self-limiting, fully reversible or predictable.
    Mult Scler. 2017 Jun 1:1352458517719151. doi: 10.1177/1352458517719151.
    PubMed    


  791. WEYGANDT M, Wakonig K, Behrens J, Meyer-Arndt L, et al
    Brain activity, regional gray matter loss, and decision-making in multiple sclerosis.
    Mult Scler. 2017 Jun 1:1352458517717089. doi: 10.1177/1352458517717089.
    PubMed     Abstract available


  792. HIDALGO DE LA CRUZ M, d'Ambrosio A, Valsasina P, Pagani E, et al
    Abnormal functional connectivity of thalamic sub-regions contributes to fatigue in multiple sclerosis.
    Mult Scler. 2017 Jun 1:1352458517717807. doi: 10.1177/1352458517717807.
    PubMed     Abstract available


  793. RUANO L, Branco M, Portaccio E, Goretti B, et al
    Patients with paediatric-onset multiple sclerosis are at higher risk of cognitive impairment in adulthood: An Italian collaborative study.
    Mult Scler. 2017 Jun 1:1352458517717341. doi: 10.1177/1352458517717341.
    PubMed     Abstract available


  794. BOZ C, Terzi M, Zengin Karahan S, Sen S, et al
    Safety of IV pulse methylprednisolone therapy during breastfeeding in patients with multiple sclerosis.
    Mult Scler. 2017 Jun 1:1352458517717806. doi: 10.1177/1352458517717806.
    PubMed     Abstract available


    May 2017
  795. VAN KEMPEN ZL, Leurs CE, Witte BI, de Vries A, et al
    The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing.
    Mult Scler. 2017 May 1:1352458517708464. doi: 10.1177/1352458517708464.
    PubMed     Abstract available


  796. GOVEROVER Y, Chiaravalloti N, Genova H, DeLuca J, et al
    A randomized controlled trial to treat impaired learning and memory in multiple sclerosis: The self-GEN trial.
    Mult Scler. 2017 May 1:1352458517709955. doi: 10.1177/1352458517709955.
    PubMed     Abstract available


  797. BENEDICT RH, Cohan S, Lynch SG, Riester K, et al
    Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study.
    Mult Scler. 2017 May 1:1352458517707345. doi: 10.1177/1352458517707345.
    PubMed     Abstract available


  798. FREILICH J, Manouchehrinia A, Trusheim M, Baird LG, et al
    Characterization of annual disease progression of multiple sclerosis patients: A population-based study.
    Mult Scler. 2017 May 1:1352458517706252. doi: 10.1177/1352458517706252.
    PubMed     Abstract available


  799. ZEYDAN B, Lowe VJ, Schwarz CG, Przybelski SA, et al
    Pittsburgh compound-B PET white matter imaging and cognitive function in late multiple sclerosis.
    Mult Scler. 2017 May 1:1352458517707346. doi: 10.1177/1352458517707346.
    PubMed     Abstract available


  800. SHINODA K, Matsushita T, Nakamura Y, Masaki K, et al
    HLA-DRB1*04:05 allele is associated with intracortical lesions on three-dimensional double inversion recovery images in Japanese patients with multiple sclerosis.
    Mult Scler. 2017 May 1:1352458517707067. doi: 10.1177/1352458517707067.
    PubMed     Abstract available


  801. SALTER A, Thomas NP, Tyry T, Cutter GR, et al
    A contemporary profile of primary progressive multiple sclerosis participants from the NARCOMS Registry.
    Mult Scler. 2017 May 1:1352458517711274. doi: 10.1177/1352458517711274.
    PubMed     Abstract available


  802. SUMOWSKI JF, Leavitt VM, Rocca MA, Inglese M, et al
    Mesial temporal lobe and subcortical grey matter volumes differentially predict memory across stages of multiple sclerosis.
    Mult Scler. 2017 May 1:1352458517708873. doi: 10.1177/1352458517708873.
    PubMed     Abstract available


  803. CAWLEY N, Tur C, Prados F, Plantone D, et al
    Spinal cord atrophy as a primary outcome measure in phase II trials of progressive multiple sclerosis.
    Mult Scler. 2017 May 1:1352458517709954. doi: 10.1177/1352458517709954.
    PubMed     Abstract available


  804. BALK LJ, Coric D, Nij Bijvank JA, Killestein J, et al
    Retinal atrophy in relation to visual functioning and vision-related quality of life in patients with multiple sclerosis.
    Mult Scler. 2017 May 1:1352458517708463. doi: 10.1177/1352458517708463.
    PubMed     Abstract available


  805. PRINEAS JW, Parratt JDE
    Multiple sclerosis: Serum anti-CNS autoantibodies.
    Mult Scler. 2017 May 1:1352458517706037. doi: 10.1177/1352458517706037.
    PubMed     Abstract available


  806. PALOTAI M, Mike A, Cavallari M, Strammer E, et al
    Changes to the septo-fornical area might play a role in the pathogenesis of anxiety in multiple sclerosis.
    Mult Scler. 2017 May 1:1352458517711273. doi: 10.1177/1352458517711273.
    PubMed     Abstract available


  807. MARINO M, Frisullo G, Di Sante G, Samengo DM, et al
    Low reliability of anti-KIR4.183-120 peptide auto-antibodies in multiple sclerosis patients.
    Mult Scler. 2017 May 1:1352458517711275. doi: 10.1177/1352458517711275.
    PubMed     Abstract available


  808. REDONDO J, Sarkar P, Kemp K, Virgo PF, et al
    Reduced cellularity of bone marrow in multiple sclerosis with decreased MSC expansion potential and premature ageing in vitro.
    Mult Scler. 2017 May 1:1352458517711276. doi: 10.1177/1352458517711276.
    PubMed     Abstract available


  809. BIBERACHER V, Schmidt P, Selter RC, Pernpeinter V, et al
    Fatigue in multiple sclerosis: Associations with clinical, MRI and CSF parameters.
    Mult Scler. 2017 May 1:1352458517712078. doi: 10.1177/1352458517712078.
    PubMed     Abstract available


  810. SMOOT K, Spinelli KJ, Stuchiner T, Lucas L, et al
    Three-year clinical outcomes of relapsing multiple sclerosis patients treated with dimethyl fumarate in a United States community health center.
    Mult Scler. 2017 May 1:1352458517709956. doi: 10.1177/1352458517709956.
    PubMed     Abstract available


  811. TORTORELLA C, Direnzo V, Ruggieri M, Zoccolella S, et al
    Cerebrospinal fluid neurofilament light levels mark grey matter volume in clinically isolated syndrome suggestive of multiple sclerosis.
    Mult Scler. 2017 May 1:1352458517711774. doi: 10.1177/1352458517711774.
    PubMed     Abstract available


  812. VAN DER VUURST DE VRIES RM, van den Dorpel JJ, Mescheriakova JY, Runia TF, et al
    Fatigue after a first attack of suspected multiple sclerosis.
    Mult Scler. 2017 May 1:1352458517709348. doi: 10.1177/1352458517709348.
    PubMed     Abstract available


  813. VAN DEN AKKER LE, Beckerman H, Collette EH, Twisk JW, et al
    Cognitive behavioral therapy positively affects fatigue in patients with multiple sclerosis: Results of a randomized controlled trial.
    Mult Scler. 2017 May 1:1352458517709361. doi: 10.1177/1352458517709361.
    PubMed     Abstract available


  814. HEINE M, Verschuren O, Hoogervorst EL, van Munster E, et al
    Does aerobic training alleviate fatigue and improve societal participation in patients with multiple sclerosis? A randomized controlled trial.
    Mult Scler. 2017 May 1:1352458517696596. doi: 10.1177/1352458517696596.
    PubMed     Abstract available


  815. BLIKMAN LJ, van Meeteren J, Twisk JW, de Laat FA, et al
    Effectiveness of energy conservation management on fatigue and participation in multiple sclerosis: A randomized controlled trial.
    Mult Scler. 2017 May 1:1352458517702751. doi: 10.1177/1352458517702751.
    PubMed     Abstract available


  816. KAPPOS L, Butzkueven H, Wiendl H, Spelman T, et al
    Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study.
    Mult Scler. 2017 May 1:1352458517709619. doi: 10.1177/1352458517709619.
    PubMed     Abstract available


  817. SORMANI MP
    Why non-inferiority is more challenging than superiority?
    Mult Scler. 2017;23:790-791.
    PubMed     Abstract available


  818. HOEPNER R, Kolb EM, Dahlhaus S, Hellwig K, et al
    Predictors of severity and functional outcome in natalizumab-associated progressive multifocal leukoencephalopathy.
    Mult Scler. 2017;23:830-835.
    PubMed     Abstract available


  819. NETRAVATHI M, Saini J, Mahadevan A, Hari-Krishna B, et al
    Is pruritus an indicator of aquaporin-positive neuromyelitis optica?
    Mult Scler. 2017;23:810-817.
    PubMed     Abstract available


  820. PITTERI M, Romualdi C, Magliozzi R, Monaco S, et al
    Cognitive impairment predicts disability progression and cortical thinning in MS: An 8-year study.
    Mult Scler. 2017;23:848-854.
    PubMed     Abstract available


    April 2017
  821. AL-LOUZI O, Button J, Newsome SD, Calabresi PA, et al
    Retrograde trans-synaptic visual pathway degeneration in multiple sclerosis: A case series.
    Mult Scler. 2017 Apr 1:1352458516679035. doi: 10.1177/1352458516679035.
    PubMed     Abstract available


  822. SIGNORI A, Izquierdo G, Lugaresi A, Hupperts R, et al
    Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis.
    Mult Scler. 2017 Apr 1:1352458517703800. doi: 10.1177/1352458517703800.
    PubMed     Abstract available


  823. SOLARI A, Giordano A, Patti F, Grasso MG, et al
    Randomized controlled trial of a home-based palliative approach for people with severe multiple sclerosis.
    Mult Scler. 2017 Apr 1:1352458517704078. doi: 10.1177/1352458517704078.
    PubMed     Abstract available


  824. COHEN JA, Imrey PB, Planchon SM, Bermel RA, et al
    Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis.
    Mult Scler. 2017 Apr 1:1352458517703802. doi: 10.1177/1352458517703802.
    PubMed     Abstract available


  825. GIOVANNONI G, Tomic D, Bright JR, Havrdova E, et al
    "No evident disease activity": The use of combined assessments in the management of patients with multiple sclerosis.
    Mult Scler. 2017 Apr 1:1352458517703193. doi: 10.1177/1352458517703193.
    PubMed     Abstract available


  826. MORANDI E, Tarlinton RE, Tanasescu R, Gran B, et al
    Human endogenous retroviruses and multiple sclerosis: Causation, association, or after-effect?
    Mult Scler. 2017 Apr 1:1352458517704711. doi: 10.1177/1352458517704711.
    PubMed     Abstract available


  827. KLAUSER AM, Wiebenga OT, Eijlers AJ, Schoonheim MM, et al
    Metabolites predict lesion formation and severity in relapsing-remitting multiple sclerosis.
    Mult Scler. 2017 Apr 1:1352458517702534. doi: 10.1177/1352458517702534.
    PubMed     Abstract available


  828. AMATO MP
    The diagnostic dilemma of multiple sclerosis presenting with isolated cognitive and behavioral disorders.
    Mult Scler. 2017 Apr 1:1352458517705002. doi: 10.1177/1352458517705002.
    PubMed     Abstract available


  829. ZAMBON AA, Cecchetti G, Caso F, Santangelo R, et al
    Primary progressive multiple sclerosis presenting with severe predominant cognitive impairment and psychiatric symptoms: A challenging case.
    Mult Scler. 2017 Apr 1:1352458517702550. doi: 10.1177/1352458517702550.
    PubMed     Abstract available


  830. CIAMPI E, Uribe-San-Martin R, Godoy-Santin J, Cruz JP, et al
    Secondary paroxysmal dyskinesia in multiple sclerosis: Clinical-radiological features and treatment. Case report of seven patients.
    Mult Scler. 2017 Apr 1:1352458517702968. doi: 10.1177/1352458517702968.
    PubMed     Abstract available


  831. POP R, Kipfer S
    Paroxysmal kinesigenic dyskinesia-like phenotype in multiple sclerosis.
    Mult Scler. 2017 Apr 1:1352458517702535. doi: 10.1177/1352458517702535.
    PubMed     Abstract available


  832. PAREES I
    Clinical commentary on "Paroxysmal kinesigenic dyskinesia-like phenotype in multiple sclerosis" and "Secondary paroxysmal dyskinesia in multiple sclerosis: Clinical-radiological features and treatment. Case report of seven patients".
    Mult Scler. 2017 Apr 1:1352458517702555. doi: 10.1177/1352458517702555.
    PubMed     Abstract available


  833. BODINI B, Branzoli F, Poirion E, Garcia-Lorenzo D, et al
    Dysregulation of energy metabolism in multiple sclerosis measured in vivo with diffusion-weighted spectroscopy.
    Mult Scler. 2017 Apr 1:1352458517698249. doi: 10.1177/1352458517698249.
    PubMed     Abstract available


  834. KOLBER P, Droby A, Roebroeck A, Goebel R, et al
    A "kissing lesion": In-vivo 7T evidence of meningeal inflammation in early multiple sclerosis.
    Mult Scler. 2017 Apr 1:1352458516683267. doi: 10.1177/1352458516683267.
    PubMed     Abstract available


  835. KILSDONK ID, Schoonheim M, Wattjes MP
    In-vivo imaging of meningeal inflammation in multiple sclerosis: Presence of evidence or evidence of presence?
    Mult Scler. 2017 Apr 1:1352458517704924. doi: 10.1177/1352458517704924.
    PubMed    


  836. TOUSSAINT-DUYSTER LC, Wong YYM, Van der Cammen-van Zijp MH, Van Pelt-Gravesteijn D, et al
    Fatigue and physical functioning in children with multiple sclerosis and acute disseminated encephalomyelitis.
    Mult Scler. 2017 Apr 1:1352458517706038. doi: 10.1177/1352458517706038.
    PubMed     Abstract available


  837. HAGENS MH, Killestein J, Yaqub MM, van Dongen GA, et al
    Cerebral rituximab uptake in multiple sclerosis: A 89Zr-immunoPET pilot study.
    Mult Scler. 2017 Apr 1:1352458517704507. doi: 10.1177/1352458517704507.
    PubMed     Abstract available


  838. SORMANI MP
    Indirect comparisons of treatment effects: Network meta-analyses.
    Mult Scler. 2017;23:510-512.
    PubMed     Abstract available


  839. BOUDOT DE LA MOTTE M, Louapre C, Bertrand A, Reach P, et al
    Extensive white matter lesions after 2 years of fingolimod: Progressive multifocal leukoencephalopathy or MS relapse?
    Mult Scler. 2017;23:614-616.
    PubMed     Abstract available


  840. AIRAS L, Rissanen E, Rinne J
    Imaging of microglial activation in MS using PET: Research use and potential future clinical application.
    Mult Scler. 2017;23:496-504.
    PubMed     Abstract available


  841. HUM S, Lapierre Y, Scott SC, Duquette P, et al
    Trajectory of MS disease course for men and women over three eras.
    Mult Scler. 2017;23:534-545.
    PubMed     Abstract available


  842. D'SOUZA M, Yaldizli O, John R, Vogt DR, et al
    Neurostatus e-Scoring improves consistency of Expanded Disability Status Scale assessments: A proof of concept study.
    Mult Scler. 2017;23:597-603.
    PubMed     Abstract available


  843. VERMERSCH P, Hobart J, Dive-Pouletty C, Bozzi S, et al
    Measuring treatment satisfaction in MS: Is the Treatment Satisfaction Questionnaire for Medication fit for purpose?
    Mult Scler. 2017;23:604-613.
    PubMed     Abstract available


  844. CIAMPI E, Pareto D, Sastre-Garriga J, Vidal-Jordana A, et al
    Grey matter atrophy is associated with disability increase in natalizumab-treated patients.
    Mult Scler. 2017;23:556-566.
    PubMed     Abstract available


  845. BROWNLEE WJ, Altmann DR, Alves Da Mota P, Swanton JK, et al
    Association of asymptomatic spinal cord lesions and atrophy with disability 5 years after a clinically isolated syndrome.
    Mult Scler. 2017;23:665-674.
    PubMed     Abstract available


  846. SORMANI MP, Kappos L, Radue EW, Cohen J, et al
    Defining brain volume cutoffs to identify clinically relevant atrophy in RRMS.
    Mult Scler. 2017;23:656-664.
    PubMed     Abstract available


  847. COETZEE T, Thompson A
    When are we going to take modifiable risk factors more seriously in multiple sclerosis?
    Mult Scler. 2017;23:494-495.
    PubMed    


    March 2017
  848. FEINSTEIN A, Pavisian B
    Multiple sclerosis and suicide.
    Mult Scler. 2017 Mar 1:1352458517702553. doi: 10.1177/1352458517702553.
    PubMed     Abstract available


  849. ASGARI N, Jarius S, Laustrup H, Skejoe HP, et al
    Aquaporin-4-autoimmunity in patients with systemic lupus erythematosus: A predominantly population-based study.
    Mult Scler. 2017 Mar 1:1352458517699791. doi: 10.1177/1352458517699791.
    PubMed     Abstract available


  850. CHARVET LE, Shaw M, Frontario A, Langdon D, et al
    Cognitive impairment in pediatric-onset multiple sclerosis is detected by the Brief International Cognitive Assessment for Multiple Sclerosis and computerized cognitive testing.
    Mult Scler. 2017 Mar 1:1352458517701588. doi: 10.1177/1352458517701588.
    PubMed     Abstract available


  851. HOUTCHENS MK, Zapata LB, Curtis KM, Whiteman MK, et al
    Contraception for women with multiple sclerosis: Guidance for healthcare providers.
    Mult Scler. 2017 Mar 1:1352458517701314. doi: 10.1177/1352458517701314.
    PubMed     Abstract available


  852. RUGGIERI S, Fanelli F, Castelli L, Petsas N, et al
    Lesion symptom map of cognitive-postural interference in multiple sclerosis.
    Mult Scler. 2017 Mar 1:1352458517701313. doi: 10.1177/1352458517701313.
    PubMed     Abstract available


  853. TOURBAH A, Sedel F
    Reply to the letter: Biotinidase deficiency masquerading as multiple sclerosis?
    Mult Scler. 2017 Mar 1:1352458517702554. doi: 10.1177/1352458517702554.
    PubMed    


  854. WOLF B
    Biotinidase deficiency masquerading as multiple sclerosis?
    Mult Scler. 2017 Mar 1:1352458517702551. doi: 10.1177/1352458517702551.
    PubMed    


  855. GYLLENSTEN H, Wiberg M, Alexanderson K, Friberg E, et al
    Comparing costs of illness of multiple sclerosis in three different years: A population-based study.
    Mult Scler. 2017 Mar 1:1352458517702549. doi: 10.1177/1352458517702549.
    PubMed     Abstract available


  856. INEICHEN BV, Schneider MP, Hlavica M, Hagenbuch N, et al
    High EDSS can predict risk for upper urinary tract damage in patients with multiple sclerosis.
    Mult Scler. 2017 Mar 1:1352458517703801. doi: 10.1177/1352458517703801.
    PubMed     Abstract available


  857. SORMANI MP
    Prognostic factors versus markers of response to treatment versus surrogate endpoints: Three different concepts.
    Mult Scler. 2017;23:378-381.
    PubMed     Abstract available


  858. HUH SY, Kim SH, Hyun JW, Jeong IH, et al
    Short segment myelitis as a first manifestation of neuromyelitis optica spectrum disorders.
    Mult Scler. 2017;23:413-419.
    PubMed     Abstract available


  859. GRAVES JS, Chohan H, Cedars B, Arnow S, et al
    Sex differences and subclinical retinal injury in pediatric-onset MS.
    Mult Scler. 2017;23:447-455.
    PubMed     Abstract available


  860. ARRAMBIDE G
    Commentary on "Successful pregnancy after natalizumab-associated progressive multifocal leukoencephalopathy in a patient with multiple sclerosis".
    Mult Scler. 2017;23:486-487.
    PubMed    


  861. RIO J, Rovira A, Tintore M, Otero-Romero S, et al
    Disability progression markers over 6-12 years in interferon-beta-treated multiple sclerosis patients.
    Mult Scler. 2017 Mar 1:1352458517698052. doi: 10.1177/1352458517698052.
    PubMed     Abstract available


  862. CORTESE M, Riise T, Bjornevik K, Myhr KM, et al
    Body size and physical exercise, and the risk of multiple sclerosis.
    Mult Scler. 2017 Mar 1:1352458517699289. doi: 10.1177/1352458517699289.
    PubMed     Abstract available


  863. BOGIE JF, Boelen E, Louagie E, Delputte P, et al
    CD169 is a marker for highly pathogenic phagocytes in multiple sclerosis.
    Mult Scler. 2017 Mar 1:1352458517698759. doi: 10.1177/1352458517698759.
    PubMed     Abstract available


  864. LEURS CE, Podlesniy P, Trullas R, Balk L, et al
    Cerebrospinal fluid mtDNA concentration is elevated in multiple sclerosis disease and responds to treatment.
    Mult Scler. 2017 Mar 1:1352458517699874. doi: 10.1177/1352458517699874.
    PubMed     Abstract available


  865. ROCCA MA, Valsasina P, Leavitt VM, Rodegher M, et al
    Functional network connectivity abnormalities in multiple sclerosis: Correlations with disability and cognitive impairment.
    Mult Scler. 2017 Mar 1:1352458517699875. doi: 10.1177/1352458517699875.
    PubMed     Abstract available


  866. RANGANATHAN U, Kaunzner U, Foster S, Vartanian T, et al
    Immediate transient thrombocytopenia at the time of alemtuzumab infusion in multiple sclerosis.
    Mult Scler. 2017 Mar 1:1352458517699876. doi: 10.1177/1352458517699876.
    PubMed     Abstract available


    February 2017
  867. BACCHETTA F, Mathias A, Schluep M, Du Pasquier R, et al
    Progressive multifocal leukoencephalopathy in two natalizumab-treated stepsisters: An intriguing coincidence.
    Mult Scler. 2017;23:300-303.
    PubMed     Abstract available


  868. HAMID SH, Elsone L, Mutch K, Solomon T, et al
    The impact of 2015 neuromyelitis optica spectrum disorders criteria on diagnostic rates.
    Mult Scler. 2017;23:228-233.
    PubMed     Abstract available


  869. SORMANI MP, Bruzzi P
    Estimating a treatment effect: Choosing between relative and absolute measures.
    Mult Scler. 2017;23:197-200.
    PubMed     Abstract available


  870. SORMANI MP, Muraro PA, Saccardi R, Mancardi G, et al
    NEDA status in highly active MS can be more easily obtained with autologous hematopoietic stem cell transplantation than other drugs.
    Mult Scler. 2017;23:201-204.
    PubMed     Abstract available


  871. HULST HE, Thompson AJ, Geurts JJ
    The measure tells the tale: Clinical outcome measures in multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517690825. doi: 10.1177/1352458517690825.
    PubMed    


  872. ROVIRA A
    Peripheral nervous system involvement in multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517693469. doi: 10.1177/1352458517693469.
    PubMed    


  873. CAMERON MH, McMillan G
    Methylphenidate is likely less effective than placebo for improving imbalance, walking, and fatigue in people with multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517692421. doi: 10.1177/1352458517692421.
    PubMed    


  874. CORIC D, Balk LJ, Verrijp M, Eijlers A, et al
    Cognitive impairment in patients with multiple sclerosis is associated with atrophy of the inner retinal layers.
    Mult Scler. 2017 Feb 1:1352458517694090. doi: 10.1177/1352458517694090.
    PubMed     Abstract available


  875. GIACOMINI E, Rizzo F, Etna MP, Cruciani M, et al
    Thymosin-alpha1 expands deficient IL-10-producing regulatory B cell subsets in relapsing-remitting multiple sclerosis patients.
    Mult Scler. 2017 Feb 1:1352458517695892. doi: 10.1177/1352458517695892.
    PubMed     Abstract available


  876. MAILLEUX J, Vanmierlo T, Bogie JF, Wouters E, et al
    Active liver X receptor signaling in phagocytes in multiple sclerosis lesions.
    Mult Scler. 2017 Feb 1:1352458517696595. doi: 10.1177/1352458517696595.
    PubMed     Abstract available


  877. ROY S, Drake AS, Eizaguirre MB, Zivadinov R, et al
    Trait neuroticism, extraversion, and conscientiousness in multiple sclerosis: Link to cognitive impairment?
    Mult Scler. 2017 Feb 1:1352458517695467. doi: 10.1177/1352458517695467.
    PubMed     Abstract available


  878. SCHWARTZ CE, Grover SA, Powell VE, Noguera A, et al
    Risk factors for non-adherence to disease-modifying therapy in pediatric multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517695469. doi: 10.1177/1352458517695469.
    PubMed     Abstract available


  879. CACAO G, Santos E, Martins Silva A
    Concurrent autoimmune hepatitis in multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517692885. doi: 10.1177/1352458517692885.
    PubMed     Abstract available


  880. ZECCA C, Merlini A, Disanto G, Rodegher M, et al
    Half-dose fingolimod for treating relapsing-remitting multiple sclerosis: Observational study.
    Mult Scler. 2017 Feb 1:1352458517694089. doi: 10.1177/1352458517694089.
    PubMed     Abstract available


  881. WESNES K, Myhr KM, Riise T, Cortese M, et al
    Physical activity is associated with a decreased multiple sclerosis risk: The EnvIMS study.
    Mult Scler. 2017 Feb 1:1352458517694088. doi: 10.1177/1352458517694088.
    PubMed     Abstract available


  882. PATEL VP, Walker LA, Feinstein A
    Revisiting cognitive reserve and cognition in multiple sclerosis: A closer look at depression.
    Mult Scler. 2017 Feb 1:1352458517692887. doi: 10.1177/1352458517692887.
    PubMed     Abstract available


  883. SONNENBERG A, Ajdacic-Gross V
    Similar birth-cohort patterns in Crohn's disease and multiple sclerosis.
    Mult Scler. 2017 Feb 1:1352458517691620. doi: 10.1177/1352458517691620.
    PubMed     Abstract available


  884. GALAZKA G, Mycko MP, Selmaj I, Raine CS, et al
    Multiple sclerosis: Serum-derived exosomes express myelin proteins.
    Mult Scler. 2017 Feb 1:1352458517696597. doi: 10.1177/1352458517696597.
    PubMed     Abstract available


    January 2017
  885. AMATO MP, Derfuss T, Hemmer B, Liblau R, et al
    Environmental modifiable risk factors for multiple sclerosis: Report from the 2016 ECTRIMS focused workshop.
    Mult Scler. 2017 Jan 6:1352458516686847. doi: 10.1177/1352458516686847.
    PubMed     Abstract available


  886. DECARD BF, Thone J, Haghikia A, Bornke C, et al
    Listeria rhombencephalitis mimicking a demyelinating event in an immunocompetent young patient.
    Mult Scler. 2017;23:123-125.
    PubMed     Abstract available


  887. GIRARD B, Bonnemains C, Schmitt E, Raffo E, et al
    Biotinidase deficiency mimicking neuromyelitis optica beginning at the age of 4: A treatable disease.
    Mult Scler. 2017;23:119-122.
    PubMed     Abstract available


  888. LAROCHELLE C, Metz I, Lecuyer MA, Terouz S, et al
    Immunological and pathological characterization of fatal rebound MS activity following natalizumab withdrawal.
    Mult Scler. 2017;23:72-81.
    PubMed     Abstract available


  889. BURTON JM, Eliasziw M, Trufyn J, Tung C, et al
    A prospective cohort study of vitamin D in optic neuritis recovery.
    Mult Scler. 2017;23:82-93.
    PubMed     Abstract available


  890. HAAS J, Schneider K, Schwarz A, Korporal-Kuhnke M, et al
    Th17 cells: A prognostic marker for MS rebound after natalizumab cessation?
    Mult Scler. 2017;23:114-118.
    PubMed     Abstract available


  891. KALINCIK T, Sormani MP
    Reporting treatment outcomes in observational data: A fine balance.
    Mult Scler. 2017;23:21-22.
    PubMed     Abstract available


  892. SORMANI MP
    Subgroup analysis in MS trials.
    Mult Scler. 2017;23:34-35.
    PubMed     Abstract available


  893. DE STEFANO N, Giorgio A, Battaglini M, De Leucio A, et al
    Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets.
    Mult Scler. 2017 Jan 1:1352458517690269. doi: 10.1177/1352458517690269.
    PubMed     Abstract available


  894. MOTL RW, Mowry EM, Ehde DM, LaRocca NG, et al
    Wellness and multiple sclerosis: The National MS Society establishes a Wellness Research Working Group and research priorities.
    Mult Scler. 2017 Jan 1:1352458516687404. doi: 10.1177/1352458516687404.
    PubMed     Abstract available


    December 2016
  895. GHEZZI A
    Randomized clinical trials (RCTs) in pediatric multiple sclerosis: Are they really necessary?
    Mult Scler. 2016 Dec 1:1352458516684025. doi: 10.1177/1352458516684025.
    PubMed    


    September 2016
  896. HENGSTMAN GJ
    Controversies in MS: All relapsing multiple sclerosis patients should be managed at a specialist clinic - Combine the best of two worlds!
    Mult Scler. 2016 Sep 21. pii: 1352458516670737.
    PubMed    


    October 2015
  897. WILLIS MD, Harding KE, Pickersgill TP, Wardle M, et al
    Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort.
    Mult Scler. 2015 Oct 29. pii: 1352458515614092.
    PubMed     Abstract available


  898. UDDIN MN, Lebel RM, Seres P, Blevins G, et al
    Spin echo transverse relaxation and atrophy in multiple sclerosis deep gray matter: A two-year longitudinal study.
    Mult Scler. 2015 Oct 26. pii: 1352458515614091.
    PubMed     Abstract available


  899. AHLBRECHT J, Martino F, Pul R, Skripuletz T, et al
    Deregulation of microRNA-181c in cerebrospinal fluid of patients with clinically isolated syndrome is associated with early conversion to relapsing-remitting multiple sclerosis.
    Mult Scler. 2015 Oct 22. pii: 1352458515613641.
    PubMed     Abstract available


  900. ROCCA MA, Meani A, Riccitelli GC, Colombo B, et al
    Abnormal adaptation over time of motor network recruitment in multiple sclerosis patients with fatigue.
    Mult Scler. 2015 Oct 22. pii: 1352458515614407.
    PubMed     Abstract available


  901. HEITMANN H, Biberacher V, Tiemann L, Buck D, et al
    Prevalence of neuropathic pain in early multiple sclerosis.
    Mult Scler. 2015 Oct 19. pii: 1352458515613643.
    PubMed     Abstract available


  902. LANZILLO R, Quarantelli M, Pozzilli C, Trojano M, et al
    No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon beta1a therapy in relapsing-remitting multiple sclerosis (the ARIANNA study).
    Mult Scler. 2015 Oct 14. pii: 1352458515611222.
    PubMed     Abstract available


  903. KARAKY M, Alcina A, Fedetz M, Barrionuevo C, et al
    The multiple sclerosis-associated regulatory variant rs10877013 affects expression of CYP27B1 and VDR under inflammatory or vitamin D stimuli.
    Mult Scler. 2015 Oct 14. pii: 1352458515610208.
    PubMed     Abstract available


  904. SANDBERG L, Bistrom M, Salzer J, Vagberg M, et al
    Vitamin D and axonal injury in multiple sclerosis.
    Mult Scler. 2015 Oct 13. pii: 1352458515606986.
    PubMed     Abstract available


  905. ZECCA C, Disanto G, Sormani MP, Riccitelli GC, et al
    Relevance of asymptomatic spinal MRI lesions in patients with multiple sclerosis.
    Mult Scler. 2015 Oct 12. pii: 1352458515599246.
    PubMed     Abstract available


  906. HEDSTROM AK, Olsson T, Alfredsson L
    Smoking is a major preventable risk factor for multiple sclerosis.
    Mult Scler. 2015 Oct 12. pii: 1352458515609794.
    PubMed     Abstract available


  907. LONGBRAKE EE, Ramsbottom MJ, Cantoni C, Ghezzi L, et al
    Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients.
    Mult Scler. 2015 Oct 12. pii: 1352458515608961.
    PubMed     Abstract available


  908. AKHTAR S, Alroughani R, Ahmed SF, Al-Hashel JY, et al
    Prognostic indicators of secondary progression in a paediatric-onset multiple sclerosis cohort in Kuwait.
    Mult Scler. 2015 Oct 9. pii: 1352458515608960.
    PubMed     Abstract available


  909. SIGNORIELLO E, Lanzillo R, Brescia Morra V, Di Iorio G, et al
    Lymphocytosis as a response biomarker of natalizumab therapeutic efficacy in multiple sclerosis.
    Mult Scler. 2015 Oct 9. pii: 1352458515604381.
    PubMed     Abstract available


  910. EISELE P, Konstandin S, Griebe M, Szabo K, et al
    Heterogeneity of acute multiple sclerosis lesions on sodium (23Na) MRI.
    Mult Scler. 2015 Oct 9. pii: 1352458515609430.
    PubMed     Abstract available


  911. RICCELLI R, Passamonti L, Cerasa A, Nigro S, et al
    Individual differences in depression are associated with abnormal function of the limbic system in multiple sclerosis patients.
    Mult Scler. 2015 Oct 9. pii: 1352458515606987.
    PubMed     Abstract available


  912. DEGN M, Modvig S, Dyring-Andersen B, Bonefeld CM, et al
    Increased prevalence of lymphoid tissue inducer cells in the cerebrospinal fluid of patients with early multiple sclerosis.
    Mult Scler. 2015 Oct 9. pii: 1352458515609795.
    PubMed     Abstract available


  913. MACDONELL R, Nagels G, Laplaud DA, Pozzilli C, et al
    Improved patient-reported health impact of multiple sclerosis: The ENABLE study of PR-fampridine.
    Mult Scler. 2015 Oct 7. pii: 1352458515606809.
    PubMed     Abstract available


  914. BOVE R, Healy BC, Musallam A, Glanz BI, et al
    Exploration of changes in disability after menopause in a longitudinal multiple sclerosis cohort.
    Mult Scler. 2015 Oct 7. pii: 1352458515606211.
    PubMed     Abstract available


  915. VERCELLINO M, Fenoglio C, Galimberti D, Mattioda A, et al
    Progranulin genetic polymorphisms influence progression of disability and relapse recovery in multiple sclerosis.
    Mult Scler. 2015 Oct 7. pii: 1352458515610646.
    PubMed     Abstract available


  916. TILLEMA JM, Hulst HE, Rocca MA, Vrenken H, et al
    Regional cortical thinning in multiple sclerosis and its relation with cognitive impairment: A multicenter study.
    Mult Scler. 2015 Oct 2. pii: 1352458515607650.
    PubMed     Abstract available


  917. RATZER R, Iversen P, Bornsen L, Dyrby TB, et al
    Monthly oral methylprednisolone pulse treatment in progressive multiple sclerosis.
    Mult Scler. 2015 Oct 2. pii: 1352458515605908.
    PubMed     Abstract available


  918. KEARNEY H, Miszkiel KA, Yiannakas MC, Altmann DR, et al
    Grey matter involvement by focal cervical spinal cord lesions is associated with progressive multiple sclerosis.
    Mult Scler. 2015 Oct 2. pii: 1352458515604905.
    PubMed     Abstract available


    September 2015
  919. GUTTMANN CR, Rousset M, Roch JA, Hannoun S, et al
    Multiple sclerosis lesion formation and early evolution revisited: A weekly high-resolution magnetic resonance imaging study.
    Mult Scler. 2015 Sep 11. pii: 1352458515600247.
    PubMed     Abstract available


  920. MARTINEZ-RODRIGUEZ JE, Cobo-Calvo A, Villar LM, Munteis E, et al
    Adaptive natural killer cell response to cytomegalovirus and disability progression in multiple sclerosis.
    Mult Scler. 2015 Sep 11. pii: 1352458515601215.
    PubMed     Abstract available


  921. UHER T, Horakova D, Tyblova M, Zeman D, et al
    Increased albumin quotient (QAlb) in patients after first clinical event suggestive of multiple sclerosis is associated with development of brain atrophy and greater disability 48 months later.
    Mult Scler. 2015 Sep 11. pii: 1352458515601903.
    PubMed     Abstract available


  922. BINZER S, Stenager E, Binzer M, Kyvik KO, et al
    Genetic analysis of the isolated Faroe Islands reveals SORCS3 as a potential multiple sclerosis risk gene.
    Mult Scler. 2015 Sep 11. pii: 1352458515602338.
    PubMed     Abstract available


  923. SIMULA S, Laitinen T, Laitinen TM, Tarkiainen T, et al
    Effect of fingolimod on cardiac autonomic regulation in patients with multiple sclerosis.
    Mult Scler. 2015 Sep 11. pii: 1352458515604384.
    PubMed     Abstract available


    August 2015
  924. GONSETTE R, Debouverie M, Sindic C, Ferre JC, et al
    Pixantrone: a B-cell-depleting immunosuppressant for multiple sclerosis patients with active disease.
    Mult Scler. 2015 Aug 18. pii: 1352458515601902.
    PubMed     Abstract available


  925. BHARGAVA P, Steele SU, Waubant E, Revirajan NR, et al
    Multiple sclerosis patients have a diminished serologic response to vitamin D supplementation compared to healthy controls.
    Mult Scler. 2015 Aug 18. pii: 1352458515600248.
    PubMed     Abstract available


  926. TACCONI P, Peltz MT, Lorefice L, Marrosu MG, et al
    Facial synkinesis as a first symptom of multiple sclerosis.
    Mult Scler. 2015 Aug 5. pii: 1352458515584415.
    PubMed     Abstract available


  927. MILLER DM, Bethoux F, Victorson D, Nowinski CJ, et al
    Validating Neuro-QoL short forms and targeted scales with people who have multiple sclerosis.
    Mult Scler. 2015 Aug 3. pii: 1352458515599450.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Autoimmune Disorders is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: